




- (51) **International Patent Classification:**
G01N 33/68 (2006.01)
- (21) **International Application Number:**
PCT/US2017/016798
- (22) **International Filing Date:**
7 February 2017 (07.02.2017)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/292,582 8 February 2016 (08.02.2016) US
62/362,019 13 July 2016 (13.07.2016) US
- (71) **Applicant:** SOMALOGIC, INC. [US/US]; 2945 Wilderness Place, Boulder, Colorado 80301 (US).
- (72) **Inventor:** FIELD, Stuart; 2945 Wilderness Place, Boulder, Colorado 80301 (US).
- (74) **Agents:** SCARR, Rebecca et al.; 500 W. Silver Spring Drive, Suite K-200, Glendale, Wisconsin 53217 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))



WO 2017/139254 A1

(54) **Title:** NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NONALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS AND USES THEREOF

(57) **Abstract:** Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (NAFLD), and more specifically one or more of the following associated conditions of steatosis, lobular inflammation, hepatocyte ballooning and fibrosis, are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatohepatitis (NASH) are also provided.

**NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NONALCOHOLIC
STEATOHEPATITIS (NASH) BIOMARKERS AND USES THEREOF****CROSS-REFERENCE TO RELATED APPLICATIONS**

[0001] This application claims the benefit of priority of US Provisional Application No. 62/292,582, filed February 8, 2016, and US Provisional Application No. 62/362,019, filed July 13, 2016, each of which is incorporated by reference herein in its entirety for any purpose.

FIELD OF THE INVENTION

[0002] The present application relates generally to the detection of biomarkers and the characterization of nonalcoholic fatty liver disease (NAFLD), for example, to identify subjects with steatosis and nonalcoholic steatohepatitis (NASH). In various embodiments, the invention relates to one or more biomarkers, methods, devices, reagents, systems, and kits for characterizing NAFLD and NASH in an individual.

BACKGROUND

[0003] The following description provides a summary of information and is not an admission that any of the information provided or publications referenced herein is prior art to the present application.

[0004] Nonalcoholic fatty liver disease (NAFLD) is defined as the presence of hepatic steatosis, with or without inflammation and fibrosis, in the absence of alcohol history. NAFLD is subdivided into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). In NAFL, hepatic steatosis is present without evidence of significant inflammation, whereas in NASH, hepatic steatosis is associated with hepatic inflammation that may be histologically indistinguishable from alcoholic steatohepatitis.

[0005] NAFLD has become an epidemic worldwide and is the leading cause of liver disease in North America, as a result of the rapidly increasing prevalence of obesity. However, accurate population-based data on the incidence of NAFL and NASH are sparse, in part because the diagnosis requires histopathologic documentation. Major risk factors for NAFLD are central obesity, type 2 diabetes mellitus, high levels of triglyceride (fat) in the blood, and high blood pressure. In the U.S., NAFLD is present in 20-40% of the population and NASH is present in about 25% of the obese population. Ten to twenty-nine percent of the NASH patients develop cirrhosis and 4-27% of those develop hepatic cancer.

[0006] Most people with NASH have no symptoms. Some may have right upper quadrant pain, hepatomegaly, or nonspecific symptoms such as abdominal discomfort, weakness, fatigue or malaise. A doctor or nurse may suspect the presence of NASH from the

results of routine blood tests. In NAFLD, liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are often high.

[0007] The current gold standard to confirm NASH is a histological evaluation of liver biopsy, which is expensive, invasive, and can cause pain, hemorrhage, or even death.

[0008] A simple blood test that would identify and distinguish the various stages of both NAFLD and NASH (and thereby reduce the need for liver biopsy) would be highly desirable.

SUMMARY

[0009] In some embodiments, methods of determining whether a subject has nonalcoholic fatty liver disease (NAFLD) are provided. In some embodiments, methods of identifying subjects with steatosis are provided. In some embodiments, methods of determining the severity of steatosis are provided.

[0010] In some embodiments, methods of determining whether a subject has nonalcoholic steatohepatitis (NASH) are provided. In some embodiments, methods of identifying subjects with NASH are provided. In some embodiments, methods of distinguishing subjects with NASH from subjects with steatosis are provided. In some embodiments, methods of determining the severity of NASH are provided.

[0011] In some embodiments, the method herein is for determining whether a subject has non-alcoholic fatty liver disease (NAFLD), comprising forming a biomarker panel having N biomarker proteins from the biomarker proteins listed in Table 15 and/or Table 16, and detecting the level of each of the N biomarker proteins of the panel in a sample from the subject, wherein N is at least 5. In some embodiments, N is 5 to 10, or N is 6 to 10, or N is 7 to 10, or N is 8 to 10, or N is 9 to 10, or N is at least 6, or N is at least 7, or N is at least 8, or N is at least 9. In some embodiments, N is 5, or N is 6, or N is 7, or N is 8, or N is 9, or N is 10.

[0012] In some embodiments, a method of determining whether a subject has non-alcoholic fatty liver disease (NAFLD) is provided, comprising detecting the level of ITGA1/ITGB1 in a sample from the subject, wherein a level of ITGA1/ITGB1 that is higher than a control level indicates that the subject has NAFLD. In some embodiments, a method of determining whether a subject has non-alcoholic fatty liver disease (NAFLD) is provided, comprising detecting the level of HSP90AA1/HSP90AB1 in a sample from the subject, wherein a level of HSP90AA1/HSP90AB1 that is higher than a control level indicates that the subject has NAFLD. In some embodiments, a method of determining whether a subject has non-alcoholic fatty liver disease (NAFLD) is provided, comprising detecting the levels of ITGA1/ITGB1 and HSP90AA1/HSP90AB1 in a sample from the subject, wherein a level of ITGA1/ITGB1 and/or a level of HSP90AA1/HSP90AB1 that is higher than a control level indicates that the subject has NAFLD. In some embodiments, the method further comprising

detecting the level of at least one, at least two, at least three, at least four, at least five, at least six, or at least seven biomarkers selected from ACY1, C7, COLEC11, CSF1R, DCN, KYNU, POR and THBS2, in a sample from the subject, wherein a level of at least one biomarker selected from ACY1, C7, COLEC11, CSF1R, DCN, KYNU, POR and THBS2 that is higher than a control level of the respective biomarker, indicates that the subject has NAFLD. In some embodiments, the method comprises detecting the levels of ITGA1/ITGB1, HSP90AA1/HSP90AB1, ACY1, COLEC11, and THBS2. In some embodiments, the method comprises determining the AST level in the subject, wherein an elevated AST level indicates the subject has NAFLD.

[0013] In some embodiments, the method herein is for determining whether a subject has non-alcoholic fatty liver disease (NAFLD), comprising detecting the level of at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or eleven biomarkers selected from ACY1, C7, COLEC11, CSF1R, DCN, HSP90AA1/HSP90AB1, ITGA1/ITGB1, KYNU, POR, FCGR3B, LGALS3BP, SERPINC1, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and THBS2, in a sample from the subject, wherein a level of at least one biomarker selected from ACY1, C7, COLEC11, CSF1R, DCN, HSP90AA1/HSP90AB1, ITGA1/ITGB1, KYNU, POR, FCGR3B, LGALS3BP, SERPINC1, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and THBS2 that is higher than a control level of the respective biomarker, indicates that the subject has NAFLD. In some embodiments, the method comprises detecting the level of HSP90AA1/HSP90AB1 or ITGA1/ITGB1, or both HSP90AA1/HSP90AB1 and ITGA1/ITGB1.

[0014] In any of the embodiments described herein, the method comprises determining whether a subject has steatosis, lobular inflammation, hepatocyte ballooning, and/or fibrosis.

[0015] In some embodiments, the method herein is for determining whether a subject has steatosis, comprising providing a biomarker panel comprising at least one, at least two, at least three, at least four, at least five, at least six, or seven biomarkers selected from ACY1, KYNU, ITGA1/ITGB1, POR, HSP90AA1/HSP90AB1, THBS2, and CSF1R; detecting the level of the biomarkers in a sample from the subject to give biomarker values that correspond to the biomarkers in the biomarker panel in order to determine whether the subject has steatosis or determine the likelihood that the subject has steatosis.

[0016] In some embodiments, the method herein is for determining whether a subject has steatosis, comprising detecting at least one, at least two, at least three, at least four, at least five, at least six, or seven biomarkers selected from ACY1, KYNU, ITGA1/ITGB1, POR, HSP90AA1/HSP90AB1, THBS2, and CSF1R, in a sample from the subject in order to

determine whether the subject has steatosis or determine the likelihood that the subject has steatosis.

[0017] In some embodiments, the biomarker panel comprises ACY1, KNYU and at least one, at least two, at least three, at least four, or five additional biomarker selected from ITGA1/ITGB1, POR, HSP90AA1/HSP90AB1, THBS2, and CSF1R.

[0018] In some embodiments, the method comprises detecting ACY1, KNYU and at least one, at least two, at least three, at least four, or five additional biomarker selected from ITGA1/ITGB1, POR, HSP90AA1/HSP90AB1, THBS2, and CSF1R. In some embodiments, the method comprises detecting at least one biomarker selected from ITGA1/ITGB1, HSP90AA1/HSP90AB1, and CSF1R. In some embodiments, the method comprises detecting at least one, at least two, at least three, at least four, at least five, or six biomarkers selected from ACY1, ITGA1/ITGB1, HSP90AA1/HSP90AB1, POR, THBS2, and KYNNU.

[0019] In some embodiments, the method herein is for determining whether a subject has lobular inflammation, comprising providing a biomarker panel comprising at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or eight biomarkers selected from ACY1, THBS2, COLEC11, ITGA1/ITGB1, CSF1R, KYNNU, FCGR3B, and POR; detecting the level of the biomarkers in a sample from the subject to give biomarker values that correspond to the biomarkers in the biomarker panel in order to determine whether the subject has lobular inflammation or determine the likelihood that the subject has lobular inflammation.

[0020] In some embodiments, the method herein is for determining whether a subject has lobular inflammation, comprising detecting at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or eight biomarkers selected from ACY1, THBS2, COLEC11, ITGA1/ITGB1, CSF1R, KYNNU, FCGR3B, and POR, in a sample from the subject in order to determine whether the subject has lobular inflammation or determine the likelihood that the subject has lobular inflammation.

[0021] In some embodiments, the biomarker panel comprises ACY1, THBS2, COLEC11 and at least one, at least two, at least three, at least four, or five additional biomarker selected from ITGA1/ITGB1, CSF1R, KYNNU, FCGR3B, and POR.

[0022] In some embodiments, the method comprises detecting ACY1, THBS2, COLEC11 and at least one, at least two, at least three, at least four, or five additional biomarker selected from ITGA1/ITGB1, CSF1R, KYNNU, FCGR3B, and POR. In some embodiments, the method comprises detecting ITGA1/ITGB1.

[0023] In some embodiments, the method herein is for determining whether a subject has hepatocyte ballooning, comprising providing a biomarker panel comprising at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or eight biomarkers

selected from ACY1, COLEC11, THBS2, ITGA1/ITGB1, C7, POR, LGALS3BP, and HSP90AA1/HSP90AB1; detecting the level of the biomarkers in a sample from the subject to give biomarker values that correspond to the biomarkers in the biomarker panel in order to determine whether the subject has hepatocyte ballooning or determine the likelihood that the subject has hepatocyte ballooning.

[0024] In some embodiments, the method herein is for determining whether a subject has hepatocyte ballooning, comprising detecting at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or eight biomarkers selected from ACY1, COLEC11, THBS2, ITGA1/ITGB1, C7, POR, LGALS3BP, and HSP90AA1/HSP90AB1, in a sample from the subject in order to determine whether the subject has hepatocyte ballooning or determine the likelihood that the subject has hepatocyte ballooning.

[0025] In some embodiments, biomarker panel comprises ACY1, COLEC11, THBS2 and at least one or two additional biomarkers selected from ITGA1/ITGB1 and HSP90AA1/HSP90AB1.

[0026] In some embodiments, the method comprises detecting ACY1, COLEC11, THBS2 and at least one or two additional biomarkers selected from ITGA1/ITGB1 and HSP90AA1/HSP90AB1.

[0027] In some embodiments, the method herein is for determining whether a subject has fibrosis, comprising providing a biomarker panel comprising at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, or fourteen biomarkers selected from C7, COLEC11, THBS2, ITGA1/ITGB1, HSP90AA1/HSP90AB1, ACY1, CSF1R, KYNU, POR, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and DCN; detecting the level of the biomarkers in a sample from the subject to give biomarker values that correspond to the biomarkers in the biomarker panel in order to determine whether the subject has fibrosis or determine the likelihood that the subject has fibrosis.

[0028] In some embodiments, the method herein is for determining whether a subject has fibrosis, comprising detecting at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, or fourteen biomarkers selected from C7, COLEC11, THBS2, ITGA1/ITGB1, HSP90AA1/HSP90AB1, ACY1, CSF1R, KYNU, POR, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and DCN, in a sample from the subject in order to determine whether the subject has fibrosis or determine the likelihood that the subject has fibrosis.

[0029] In some embodiments, the biomarker panel comprises C7, COLEC11, THBS2 and at least one, at least two, or three additional biomarkers selected from ITGA1/ITGB1, HSP90AA1/HSP90AB1 and DCN.

[0030] In some embodiments, the method comprises detecting C7, COLEC11, THBS2 and at least one, at least two, or three additional biomarkers selected from ITGA1/ITGB1, HSP90AA1/HSP90AB1 and DCN.

[0031] In any of the embodiments described herein, the subject is at risk of developing steatosis, lobular inflammation, hepatocyte ballooning and/or fibrosis.

[0032] In any of the embodiments described herein, the subject may be at risk of developing NAFLD. In any of the embodiments described herein, the subject may be at risk of developing steatosis. In any of the embodiments described herein, the subject may be at risk of developing NASH. In any of the embodiments described herein, the subject may have an NAFLD comorbidity selected from obesity, abdominal obesity, metabolic syndrome, cardiovascular disease, and diabetes. In any of the embodiments described herein, the subject may be obese.

[0033] In any of the embodiments described herein, at least one biomarker may be a protein biomarker. In any of the embodiments described herein, each biomarker may be a protein biomarker. In some embodiments, a method comprises contacting biomarkers of the sample from the subject with a set of biomarker capture reagents, wherein each biomarker capture reagent of the set of biomarker capture reagents specifically binds to a different biomarker being detected. In some embodiments, each biomarker capture reagent is an antibody or an aptamer. In some embodiments, each biomarker capture reagent is an aptamer. In some embodiments, at least one aptamer is a slow off-rate aptamer. In some embodiments, at least one slow off-rate aptamer comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least 10 nucleotides with modifications. In some embodiments, each slow off-rate aptamer binds to its target protein with an off rate ($t_{1/2}$) of ≥ 30 minutes, ≥ 60 minutes, ≥ 90 minutes, ≥ 120 minutes, ≥ 150 minutes, ≥ 180 minutes, ≥ 210 minutes, or ≥ 240 minutes.

[0034] In any of the embodiments described herein, the sample may be a blood sample. In any of the embodiments described herein, the sample may be selected from a serum sample and a plasma sample.

[0035] In any of the embodiments described herein, if the subject has NAFLD or NASH, the subject may be recommended a regimen selected from weight loss, blood sugar control, and alcohol avoidance. In any of the embodiments described herein, if the subject has NAFLD or NASH, the subject may be recommended for gastric bypass surgery. In any of the embodiments

described herein, if the subject has NAFLD or NASH, the subject may be prescribed at least one therapeutic agent selected from pioglitazone, vitamin E, and metformin.

[0036] In some embodiments, a method described herein is for the purpose of determining a medical insurance premium or life insurance premium. In some embodiments, a method further comprises determining a medical insurance premium or life insurance premium. In some embodiments, a method described herein further comprises using information resulting from the method to predict and/or manage the utilization of medical resources.

[0037] In some embodiments, kits are provided. In some embodiments, a kit comprises at least five, at least six, at least seven, at least eight, at least nine, at least ten, or eleven aptamers that specifically bind to a target protein selected from ACY1, C7, COLEC11, CSF1R, DCN, HSP90AA1/HSP90AB1, ITGA1/ITGB1, KYNU, POR, FCGR3B, LGALS3BP, SERPINC1, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and THBS2.

[0038] In some embodiments, a kit comprises at least one, at least two, at least three, at least four, at least five, at least six, or seven aptamers that specifically bind to a target protein selected from ACY1, KYNU, ITGA1/ITGB1, POR, HSP90AA1/HSP90AB1, THBS2, and CSF1R.

[0039] In some embodiments, a kit comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or eight aptamers that selected from specifically bind to a target protein selected from ACY1, THBS2, COLEC11, ITGA1/ITGB1, CSF1R, KYNU, FCGR3B, and POR.

[0040] In some embodiments, a kit is provided, wherein the kit comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or eight aptamers that selected from specifically bind to a target protein selected from ACY1, COLEC11, THBS2, ITGA1/ITGB1, C7, POR, LGALS3BP, and HSP90AA1/HSP90AB1.

In some embodiments, a kit comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, or fourteen aptamers that selected from specifically bind to a target protein selected from C7, COLEC11, THBS2, ITGA1/ITGB1, HSP90AA1/HSP90AB1, ACY1, CSF1R, KYNU, POR, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and DCN. In any of the embodiments herein, each aptamer binds to a different target protein.

[0041] In any of the embodiments described herein, at least one aptamer may be a slow off-rate aptamer. In any of the embodiments described herein, each aptamer may be a slow off-rate aptamer. In some embodiments, at least one slow off-rate aptamer comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least 10 nucleotides with hydrophobic modifications.

[0042] In some embodiments, each slow off-rate aptamer binds to its target protein with an off rate ($t_{1/2}$) of ≥ 30 minutes, ≥ 60 minutes, ≥ 90 minutes, ≥ 120 minutes, ≥ 150 minutes, ≥ 180 minutes, ≥ 210 minutes, or ≥ 240 minutes.

[0043] In some embodiments, compositions are provided. In some such embodiments, a composition comprises proteins of a sample from a subject and at least five, at least six, at least seven, at least eight, at least nine, at least ten, or eleven aptamers that specifically bind to a target protein selected from ACY1, C7, COLEC11, CSF1R, DCN, HSP90AA1/HSP90AB1, ITGA1/ITGB1, KYNU, POR, FCGR3B, LGALS3BP, SERPINC1, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and THBS2.

[0044] In some embodiments, a composition comprises proteins of a sample from a subject and at least one, at least two, at least three, at least four, at least five, at least six, or seven aptamers that specifically bind to a target protein selected from ACY1, KYNU, ITGA1/ITGB1, POR, HSP90AA1/HSP90AB1, THBS2, and CSF1R.

[0045] In some embodiments, a composition is provided that comprises proteins of a sample from a subject and at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or eight aptamers that selected from specifically bind to a target protein selected from ACY1, THBS2, COLEC11, ITGA1/ITGB1, CSF1R, KYNU, FCGR3B, and POR.

[0046] In some embodiments, each aptamer binds to a different target protein.

[0047] In some embodiments, a composition is provided that comprises proteins of a sample from a subject and at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or eight aptamers that selected from specifically bind to a target protein selected from ACY1, COLEC11, THBS2, ITGA1/ITGB1, C7, POR, LGALS3BP, and HSP90AA1/HSP90AB1.

[0048] In some embodiments, a composition is provided that comprises proteins of a sample from a subject and at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, or fourteen aptamers that selected from specifically bind to a target protein selected from C7, COLEC11, THBS2, ITGA1/ITGB1, HSP90AA1/HSP90AB1, ACY1, CSF1R, KYNU, POR, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and DCN.

[0049] In some embodiments, each aptamer specifically binds to a different target protein.

[0050] In any of the embodiments described herein, the sample may be a blood sample. In any of the embodiments described herein, the sample may be selected from a serum sample and a plasma sample.

[0051] In any of the embodiments described herein, at least one aptamer may be a slow off-rate aptamer. In any of the embodiments described herein, each aptamer may be a slow off-rate aptamer. In some embodiments, at least one slow off-rate aptamer comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least 10 nucleotides with hydrophobic modifications. In some embodiments, each slow off-rate aptamer binds to its target protein with an off rate ($t_{1/2}$) of ≥ 30 minutes, ≥ 60 minutes, ≥ 90 minutes, ≥ 120 minutes, ≥ 150 minutes, ≥ 180 minutes, ≥ 210 minutes, or ≥ 240 minutes.

[0052] In any of the embodiments described herein, each biomarker may be a protein biomarker. In any of the embodiments described herein, the method may comprise contacting biomarkers of the sample from the subject with a set of biomarker capture reagents, wherein each biomarker capture reagent of the set of biomarker capture reagents specifically binds to a biomarker being detected. In some embodiments, each biomarker capture reagent of the set of biomarker capture reagents specifically binds to a different biomarker being detected. In any of the embodiments described herein, each biomarker capture reagent may be an antibody or an aptamer. In any of the embodiments described herein, each biomarker capture reagent may be an aptamer. In any of the embodiments described herein, at least one aptamer may be a slow off-rate aptamer. In any of the embodiments described herein, at least one slow off-rate aptamer may comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least 10 nucleotides with modifications. In some embodiments, the modifications are hydrophobic modifications. In some embodiments, the modifications are hydrophobic base modifications. In some embodiments, one or more of the modifications may be selected from the modifications shown in Figure 11. In some embodiments, each slow off-rate aptamer binds to its target protein with an off rate ($t_{1/2}$) of ≥ 30 minutes, ≥ 60 minutes, ≥ 90 minutes, ≥ 120 minutes, ≥ 150 minutes, ≥ 180 minutes, ≥ 210 minutes, or ≥ 240 minutes.

[0053] In any of the embodiments described herein, the sample may be a blood sample. In some embodiments, the blood sample is selected from a serum sample and a plasma sample.

[0054] In any of the embodiments, described herein, the sample in a composition may be a blood sample. In some embodiments, the blood sample is selected from a serum sample and a plasma sample.

[0055] In any of the embodiments described herein, a kit or composition may comprise at least one aptamer that is a slow off-rate aptamer. In any of the embodiments described herein, each aptamer of a kit or composition may be a slow off-rate aptamer. In some embodiments, at least one slow off-rate aptamer comprises at least one, at least two, at least three, at least four, at

least five, at least six, at least seven, at least eight, at least nine, or at least 10 nucleotides with modifications. In some embodiments, at least one nucleotide with a modification is a nucleotide with a hydrophobic base modification. In some embodiments, each nucleotide with a modification is a nucleotide with a hydrophobic base modification. In some embodiments, each hydrophobic base modification is independently selected from the modification in Figure 11. In some embodiments, each slow off-rate aptamer in a kit binds to its target protein with an off rate ($t_{1/2}$) of ≥ 30 minutes, ≥ 60 minutes, ≥ 90 minutes, ≥ 120 minutes, ≥ 150 minutes, ≥ 180 minutes, ≥ 210 minutes, or ≥ 240 minutes.

BRIEF DESCRIPTION OF THE DRAWINGS

- [0056] FIG. 1 shows stability selection paths of the steatosis classifier, as described in Example 2.
- [0057] FIG. 2 shows a ROC curve of a nine biomarker classifier for steatosis, as described in Example 2.
- [0058] FIG. 3 shows the vote by class for the nine-marker random forest classifier for steatosis, as described in Example 2.
- [0059] FIG. 4 shows the cumulative distribution functions for each of the biomarkers in the nine-marker classifier for steatosis, as described in Example 2.
- [0060] FIG. 5 shows stability selection paths of the NASH (fibrosis) classifier, as described in Example 2.
- [0061] FIG. 6 shows a ROC curve of a four biomarker classifier for NASH (fibrosis), as described in Example 2.
- [0062] FIG. 7 shows box plots for the four-marker classifier for NASH (fibrosis) in each of the subject groups, as described in Example 2.
- [0063] FIG. 8 shows the cumulative distribution functions for each of the biomarkers in the four-marker classifier for NASH (fibrosis), as described in Example 2.
- [0064] FIG. 9 illustrates a nonlimiting exemplary computer system for use with various computer-implemented methods described herein.
- [0065] FIG. 10 illustrates a nonlimiting exemplary aptamer assay that can be used to detect one or more biomarkers in a biological sample.
- [0066] FIG. 11 shows certain exemplary modified pyrimidines that may be incorporated into aptamers, such as slow off-rate aptamers.
- [0067] FIG. 12 shows box plots for the 8-marker classifier for steatosis in each of the subject groups, as described in Example 5.
- [0068] FIG. 13 shows box plots for the 8-marker classifier for fibrosis in each of the subject groups, as described in Example 5.

- [0069] FIG. 14 shows the cumulative distribution functions for each of the biomarkers in the four-marker classifier for NASH (fibrosis), as described in Example 5.
- [0070] FIG. 15 shows box plots for the 8-marker classifier for steatosis for the blinded samples after unblinding, according to their actual sample group, as described in Example 6.
- [0071] FIG. 16 shows ROC curves for the 8-marker steatosis classifier performance for the discovery set and for the blinded validation set, as described in Example 6.
- [0072] FIG. 17 shows box plots for the 8-marker classifier for fibrosis for the blinded samples after unblinding, according to their actual sample group, as described in Example 6.
- [0073] FIG. 18 shows ROC curves for the 8-marker fibrosis classifier performance for the discovery set and for two blinded validation sets, as described in Example 6.
- [0074] FIG. 19A and B show sensitivity and specificity distributions of 2500 bootstrap iterations of the 20% hold-out verification set, using (A) the 8-marker steatosis classifier, and (B) the 8-marker fibrosis classifier, as described in Example 6.
- [0075] FIG. 20 shows box plots for the 8-marker steatosis classifier in each of the pediatric samples according to their actual sample group, as described in Example 7.
- [0076] FIG. 21 shows the distribution of histological and NAS scores from the baseline liver biopsy, as described in Example 8.
- [0077] FIG. 22 shows box plots for the top 6 biomarkers for steatosis, as described in Example 8.
- [0078] FIG. 23 shows box plots for the top 6 biomarkers for lobular inflammation, as described in Example 8.
- [0079] FIG. 24 shows box plots for the top 6 biomarkers for hepatocyte ballooning, as described in Example 8.
- [0080] FIG. 25 shows box plots for the top 6 biomarkers for fibrosis, as described in Example 8.
- [0081] FIG. 26 shows box plots for the top 6 biomarkers for NAS score, as described in Example 8.
- [0082] FIG. 27 shows box plots for the top 6 biomarkers for NASH diagnosis, as described in Example 8.
- [0083] FIG. 28 shows a Venn diagram of significant protein biomarkers by histological category and NASH diagnosis.
- [0084] FIG. 29 shows feature selection for steatosis.
- [0085] FIG. 30 shows feature selection for lobular inflammation.
- [0086] FIG. 31 shows feature selection for hepatocyte ballooning.
- [0087] FIG. 32 shows feature selection for fibrosis.

[0088] FIGs. 33A and 33B show probability density functions (scaled by sample size) of the training data used to fit the naïve Bayes model for Protein 1 (33A) and Protein 2 (33B). Curves are colored by class and the protein measurements for Sample 1 ($\vec{x} = 3.79301, 2.59934$) are represented by the dashed vertical line. This graphically indicates that Sample 1 is more likely to have come from the control distribution.

[0089] FIGs. 34A and 34B show bivariate plots of training data used to fit the two protein marker naïve Bayes model. Dotted lines are the class specific means of the model parameters, points are indicated by class (solid circles are control, dotted circles are disease), and the non-linear Bayes decision boundary reflecting the $p = 0.5$ cutoff is represented by the curve. The green “x” represents the coordinates of Samples 1-5.

DETAILED DESCRIPTION

[0090] While the invention will be described in conjunction with certain representative embodiments, it will be understood that the invention is defined by the claims, and is not limited to those embodiments.

[0091] One skilled in the art will recognize many methods and materials similar or equivalent to those described herein may be used in the practice of the present invention. The present invention is in no way limited to the methods and materials described.

[0092] Unless defined otherwise, technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice of the invention, certain methods, devices, and materials are described herein.

[0093] All publications, published patent documents, and patent applications cited herein are hereby incorporated by reference to the same extent as though each individual publication, published patent document, or patent application was specifically and individually indicated as being incorporated by reference.

[0094] As used in this application, including the appended claims, the singular forms “a,” “an,” and “the” include the plural, unless the context clearly dictates otherwise, and may be used interchangeably with “at least one” and “one or more.” Thus, reference to “an aptamer” includes mixtures of aptamers, reference to “a probe” includes mixtures of probes, and the like.

[0095] As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “contains,” “containing,” and any variations thereof, are intended to cover a non-exclusive inclusion, such that a process, method, product-by-process, or composition of matter that

comprises, includes, or contains an element or list of elements may include other elements not expressly listed.

[0096] The present application includes biomarkers, methods, devices, reagents, systems, and kits for determining whether a subject has NAFLD. The present application also includes biomarkers, methods, devices, reagents, systems, and kits for determining whether a subject has NASH. In some embodiments, biomarkers, methods, devices, reagents, systems, and kits are provided for determining whether a subject with NAFLD has NASH.

[0097] As used herein, the term “ITGA1/ITGB1” is used to refer to ITGA1 and/or ITGB1 and/or the complex of ITGA1 and ITGB1. Thus, if a method comprises detecting the biomarker “ITGA1/ITGB1,” the method may comprise detecting ITGA1, ITGB1, both ITGA1 and ITGB1, and/or the complex of ITGA1 and ITGB1. A biomarker capture reagent that specifically binds ITGA1/ITGB1 may bind ITGA1 and/or ITGB1 and/or both ITGA1 and ITGB1 and/or the complex of ITGA1 and ITGB1.

[0098] As used herein, the term “HSP90AA1/HSP90AB1” is used to refer to HSP90AA1 and/or HSP90AB1. Thus, if a method comprises detecting the biomarker “HSP90AA1/HSP90AB1,” the method may comprise detecting HSP90AA1, HSP90AB1, or both HSP90AA1 and HSP90AB1. A biomarker capture reagent that specifically binds HSP90AA1/HSP90AB1 may bind HSP90AA1 and/or HSP90AB1 and/or both HSP90AA1 and HSP90AB1.

[0099] In some embodiments, one or more biomarkers are provided for use either alone or in various combinations to determine whether a subject has NAFLD. As described in detail below, exemplary embodiments include the biomarkers provided in Table 15 and Table 16, with or without one or more biomarkers provided in Tables 3, 4, 6, 7, 8, and/or 9.

[00100] The biomarkers were identified using a multiplex aptamer-based assay. Table 3 lists nine biomarkers that are useful for distinguishing samples obtained from normal obese individuals from samples from individuals with NAFLD. Table 4 lists four biomarkers that are useful for distinguishing samples obtained from individuals with steatosis from samples from individuals with NASH stages 2, 3, and 4. Table 8 lists eight biomarkers that are useful for distinguishing samples obtained from normal obese individuals from samples from individuals with NAFLD. Table 9 lists eight biomarkers that are useful for distinguishing samples obtained from individuals with steatosis from samples from individuals with NASH stages 2, 3, and 4. Tables 6 and 7 list additional biomarkers that may be used in any combination with one another and/or with the biomarkers from Tables 3, 4, 8, and/or 9. In some embodiments, a subset of biomarkers from Tables 3, 4, 6, 7, 8, and 9 are combined into a panel shown in Table 5.

[00101] Table 15 and Table 16 list biomarkers that are useful for characterizing histologic grading of NASH. In some embodiments, one or more biomarkers from Table 15 and/or Table 16 are provided for use either alone or in various combinations to determine whether a subject has steatosis or determine the likelihood that the subject has NASH. In some embodiments, one or more biomarkers from Table 15 and/or Table 16 are useful for determining whether a subject has steatosis, lobular inflammation, hepatocyte ballooning, and/or fibrosis. In some embodiments, one or more biomarkers from Table 15 and/or Table 16 are useful for determining the likelihood the subject has steatosis, lobular inflammation, hepatocyte ballooning, and/or fibrosis. In some embodiments, one or more of the biomarkers listed in Table 15 and/or Table 16 are useful either alone or in various combinations to determine whether a subject has NASH of any stage. In some embodiments, one or more of the biomarkers listed in Table 15 and/or Table 16 may be combined with one more biomarkers selected from Tables 3, 4, 6, 7, 8, and/or 9 to form a panel.

[00102] In some embodiments, one or more of the biomarkers listed in Table 15 and Table 16 are useful to identify subjects at risk of developing NASH. In some embodiments, one or more of the biomarkers listed in Table 15 and/or Table 16 are useful to identify subjects at risk of developing steatosis, lobular inflammation, hepatocyte ballooning, and/or fibrosis. In some embodiments, one or more biomarkers are provided for use either alone or in various combinations to determine whether a subject has steatosis. In some embodiments, the subject is obese. One or more of the biomarkers in Table 15 and/or Table 16 may be used in combination with one or more biomarkers from Table 3 and/or Table 4 and/or Table 6 and/or Table 7 and/or Table 8 and/or Table 9 in a method described herein.

[00103] In some embodiments, one or more biomarkers are provided for use either alone or in various combinations to determine whether a subject has NASH of any stage. In some embodiments, one or more biomarkers are provided for use either alone or in various combinations to determine whether a subject has stage 2, 3, or 4 NASH. In some embodiments, the subject is already known to have steatosis. As described in detail below, exemplary embodiments include the biomarkers provided in Table 15 and/or Table 16, which were identified using a multiplex aptamer-based assay. In some embodiments, the number and identity of biomarkers in a panel are selected based on the sensitivity and specificity for the particular combination of biomarker values. The terms “sensitivity” and “specificity” are used herein with respect to the ability to correctly classify an individual, based on one or more biomarker levels detected in a biological sample, as having the disease or not having the disease. In some embodiments, the terms “sensitivity” and “specificity” may be used herein with respect to the ability to correctly classify an individual, based on one or more biomarker levels detected

in a biological sample, as having steatosis or not having steatosis. In such embodiments, “sensitivity” indicates the performance of the biomarker(s) with respect to correctly classifying individuals with steatosis. “Specificity” indicates the performance of the biomarker(s) with respect to correctly classifying individuals who do not have steatosis. For example, 85% specificity and 90% sensitivity for a panel of biomarkers used to test a set of control samples (such as samples from healthy individuals or subjects known not to have steatosis) and test samples (such as samples from individuals with steatosis) indicates that 85% of the control samples were correctly classified as control samples by the panel, and 90% of the test samples were correctly classified as test samples by the panel.

[00104] In some embodiments, the terms “sensitivity” and “specificity” may be used herein with respect to the ability to correctly classify an individual, based on one or more biomarker levels detected in a biological sample, as having NASH (or stage 2, 3, or 4 NASH) or having steatosis. “Sensitivity” indicates the performance of the biomarker(s) with respect to correctly classifying individuals with NASH (or stage 2, 3, or 4 NASH). “Specificity” indicates the performance of the biomarker(s) with respect to correctly classifying individuals who do not have NASH (or do not have stage 2, 3, or 4 NASH). For example, 85% specificity and 90% sensitivity for a panel of biomarkers used to test a set of control samples (such as samples from individuals with steatosis) and test samples (such as samples from individuals with NASH, or stage 2, 3, or 4 NASH) indicates that 85% of the control samples were correctly classified as control samples by the panel, and 90% of the test samples were correctly classified as test samples by the panel.

[00105] In some embodiments, overall performance of a panel of one or more biomarkers is represented by the area-under-the-curve (AUC) value. The AUC value is derived from receiver operating characteristic (ROC) curve, which are exemplified herein. The ROC curve is the plot of the true positive rate (sensitivity) of a test against the false positive rate (1-specificity) of the test. The term “area under the curve” or “AUC” refers to the area under the curve of a receiver operating characteristic (ROC) curve, both of which are well known in the art. AUC measures are useful for comparing the accuracy of a classifier across the complete data range. Classifiers with a greater AUC have a greater capacity to classify unknowns correctly between two groups of interest (e.g., normal individuals and individuals with NAFLD, or individuals with steatosis and individuals with NASH). ROC curves are useful for plotting the performance of a particular feature (e.g., any of the biomarkers described herein and/or any item of additional biomedical information) in distinguishing between two populations. Typically, the feature data across the entire population are sorted in ascending order based on the value of a single feature. Then, for each value for that feature, the true positive and false positive rates for the data are

calculated. The true positive rate is determined by counting the number of cases above the value for that feature and then dividing by the total number of cases. The false positive rate is determined by counting the number of controls above the value for that feature and then dividing by the total number of controls. Although this definition refers to scenarios in which a feature is elevated in cases compared to controls, this definition also applies to scenarios in which a feature is lower in cases compared to the controls (in such a scenario, samples below the value for that feature would be counted). ROC curves can be generated for a single feature as well as for other single outputs, for example, a combination of two or more features can be mathematically combined (e.g., added, subtracted, multiplied, etc.) to provide a single sum value, and this single sum value can be plotted in a ROC curve. Additionally, any combination of multiple features, in which the combination derives a single output value, can be plotted in a ROC curve.

[00106] In some embodiments, a method comprises detecting the level of at least one biomarker listed in Table 15 and/or Table 16, with or without at least one biomarker listed in Table 3, 4, 6, 7, 8, and/or 9 in a sample from a subject for determining whether a subject has NAFLD. In some such embodiments, the method comprises contacting the sample or a portion of the sample from the subject with at least one capture reagent, wherein each capture reagent specifically binds a biomarker whose levels are being detected. In some embodiments, the method comprises contacting the sample, or proteins from the sample, with at least one aptamer, wherein each aptamer specifically binds a biomarker whose levels are being detected.

[00107] In some embodiments, a method comprises determining whether a subject has non-alcoholic fatty liver disease (NAFLD), comprising forming a biomarker panel having N biomarker proteins from the biomarker proteins listed in Table 15 and/or Table 16, and detecting the level of each of the N biomarker proteins of the panel in a sample from the subject, wherein N is at least 5. In some embodiments, N is 5 to 10, or N is 6 to 10, or N is 7 to 10, or N is 8 to 10, or N is 9 to 10, or N is at least 6, or N is at least 7, or N is at least 8, or N is at least 9, or N is 5, or N is 6, or N is 7, or N is 8, or N is 9, or N is 10. In some embodiments, a method comprises detecting the level of at least five, at least six, at least seven, at least eight, at least nine, or ten selected from ACY1, C7, COLEC11, CSF1R, DCN, HSP90AA1/HSP90AB1, ITGA1/ITGB1, KYNU, POR, FCGR3B, LGALS3BP, SERPINC1, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and THBS2 to determine whether a subject has NAFLD.

[00108] In some embodiments, a method comprises detecting the level of ITGA1/ITGB1 in a sample from the subject, wherein a level of ITGA1/ITGB1 that is higher than a control level indicates that the subject has NAFLD.

[00109] In some embodiments, a method comprises detecting the level of HSP90AA1/HSP90AB1 in a sample from the subject, wherein a level of HSP90AA1/HSP90AB1 that is higher than a control level indicates that the subject has NAFLD.

[00110] In some embodiments, a method comprises detecting the levels of ITGA1/ITGB1 and HSP90AA1/HSP90AB1 in a sample from the subject, wherein a level of ITGA1/ITGB1 and/or a level of HSP90AA1/HSP90AB1 that is higher than a control level indicates that the subject has NAFLD.

[00111] In some embodiments, the method further comprises detecting the level of at least one, at least two, at least three, at least four, at least five, at least six, or at least seven biomarkers selected from ACY1, C7, COLEC11, CSF1R, DCN, KYNU, POR and THBS2, in a sample from the subject, wherein a level of at least one biomarker selected from ACY1, C7, COLEC11, CSF1R, DCN, KYNU, POR and THBS2 that is higher than a control level of the respective biomarker, indicates that the subject has NAFLD. In some embodiments, the method comprises detecting the levels of ITGA1/ITGB1, HSP90AA1/HSP90AB1, ACY1, COLEC11, and THBS2. In some embodiments, a method comprises determining the AST level in the subject, wherein an elevated AST level indicates the subject has NAFLD.

[00112] In another embodiment, a method comprises detecting the level of at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or ten biomarkers selected from ACY1, C7, COLEC11, CSF1R, DCN, HSP90AA1/HSP90AB1, ITGA1/ITGB1, KYNU, POR, FCGR3B, LGALS3BP, SERPINC1, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and THBS2, in a sample from the subject, wherein a level of at least one biomarker selected from ACY1, C7, COLEC11, CSF1R, DCN, HSP90AA1/HSP90AB1, ITGA1/ITGB1, KYNU, POR, FCGR3B, LGALS3BP, SERPINC1, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and THBS2 that is higher than a control level of the respective biomarker, indicates that the subject has NAFLD. In some embodiments, a method comprises the method comprises detecting the level of HSP90AA1/HSP90AB1 or ITGA1/ITGB1, or both HSP90AA1/HSP90AB1 and ITGA1/ITGB1.

[00113] In some embodiments, the method comprises determining whether a subject has steatosis, lobular inflammation, hepatocyte ballooning, and/or fibrosis. In some embodiments, the steatosis is mild, moderate, or severe steatosis. In some embodiments, the method comprises determining whether a subject has non-alcoholic steatohepatitis (NASH). In some embodiments, the method comprises determining whether the subject has NASH, such as stage 1, 2, 3, or 4 NASH. In some embodiments, the subject is at risk of developing NAFLD. In some embodiments, the subject is at risk of developing NASH. In some embodiments, the subject is at risk of developing steatosis, lobular inflammation, hepatocyte ballooning and/or fibrosis. In

some embodiments, the subject is an obese subject. In some embodiments, the method comprises determining whether the subject has steatosis, and/or determining whether the steatosis is mild, moderate or severe.

[00114] In some embodiments, a method of detecting steatosis is provided, comprising providing a biomarker panel comprising at least one, at least two, at least three, at least four, at least five, or six biomarkers selected from ACY1, KYNU, ITGA1/ITGB1, POR, HSP90AA1/HSP90AB1, THBS2, and CSF1R; detecting the level of the biomarkers in a sample from the subject to give biomarker values that correspond to the biomarkers in the biomarker panel in order to determine whether the subject has steatosis or determine the likelihood that the subject has steatosis.

[00115] In some embodiments, the method comprises detecting the level of at least one, at least two, at least three, at least four, at least five, or six biomarkers selected from ACY1, KYNU, ITGA1/ITGB1, POR, HSP90AA1/HSP90AB1, THBS2, and CSF1R, in a sample from the subject in order to determine whether the subject has steatosis or determine the likelihood that the subject has steatosis. In some embodiments, the biomarker panel comprises ACY1, KNYU and at least one, at least two, at least three or four additional marker selected from ITGA1/ITGB1, POR, HSP90AA1/HSP90AB1 and CSF1R. In some embodiments, the method comprises detecting ACY1, KNYU and at least one, at least two, at least three or four additional marker selected from ITGA1/ITGB1, POR, HSP90AA1/HSP90AB1 and CSF1R. In some embodiments, the method comprises detecting at least one biomarker selected from ITGA1/ITGB1, HSP90AA1/HSP90AB1, and CSF1R.

[00116] In some embodiments, a method for determining whether subject has lobular inflammation is provided, comprises providing a biomarker panel comprising at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or eight biomarkers selected from ACY1, THBS2, COLEC11, ITGA1/ITGB1, CSF1R, KYNU, FCGR3B, and POR; detecting the level of the biomarkers in a sample from the subject to give biomarker values that correspond to the biomarkers in the biomarker panel in order to determine whether the subject has lobular inflammation or determine the likelihood that the subject has lobular inflammation. In some embodiments, the method comprises detecting a biomarker panel comprising at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or eight biomarkers selected from ACY1, THBS2, COLEC11, ITGA1/ITGB1, CSF1R, KYNU, FCGR3B, and POR, in a sample from the subject in order to determine whether the subject has lobular inflammation or determine the likelihood that the subject has lobular inflammation. In some embodiments, the biomarker panel comprises ACY1, THBS2, COLEC11 and at least one or two additional biomarker selected from ITGA1/ITGB1 and POR. In some embodiments, the

method comprises detecting ACY1, THBS2, COLEC11 and at least one or two additional biomarker selected from ITGA1/ITGB1 and POR. In some embodiments, the method comprises detecting ITGA1/ITGB1.

[00117] In some embodiments, a method for determining whether subject has hepatocyte ballooning is provided, comprising providing a biomarker panel comprising at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or eight biomarkers selected from ACY1, COLEC11, THBS2, ITGA1/ITGB1, C7, POR, LGALS3BP, and HSP90AA1/HSP90AB1; detecting the level of the biomarkers in a sample from the subject to give biomarker values that correspond to the biomarkers in the biomarker panel in order to determine whether the subject has hepatocyte ballooning or determine the likelihood that the subject has hepatocyte ballooning. In some embodiments, the method comprises detecting a biomarker panel comprising at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or eight biomarkers selected from ACY1, COLEC11, THBS2, ITGA1/ITGB1, C7, POR, LGALS3BP, and HSP90AA1/HSP90AB1, in a sample from the subject in order to determine whether the subject has hepatocyte ballooning or determine the likelihood that the subject has hepatocyte ballooning. In some embodiments, the biomarker panel comprises ACY1, COLEC11, THBS2 and at least one or two additional biomarker selected from ITGA1/ITGB1 and HSP90AA1/HSP90AB1. In some embodiments, the method comprises detecting ACY1, COLEC11, THBS2 and at least one or two additional biomarker selected from ITGA1/ITGB1 and HSP90AA1/HSP90AB1.

[00118] In some embodiments, a method for determining whether subject has fibrosis is provided, comprising providing a biomarker panel comprising at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, or fourteen biomarkers selected from C7, COLEC11, THBS2, ITGA1/ITGB1, HSP90AA1/HSP90AB1, ACY1, CSF1R, KYNU, POR, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and DCN; detecting the level of the biomarkers in a sample from the subject to give biomarker values that correspond to the biomarkers in the biomarker panel in order to determine whether the subject has fibrosis or determine the likelihood that the subject has fibrosis. In some embodiments, the biomarker panel comprises detecting at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, or fourteen biomarkers selected from C7, COLEC11, THBS2, ITGA1/ITGB1, HSP90AA1/HSP90AB1, ACY1, CSF1R, KYNU, POR, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and DCN, in a sample from the subject in order to determine whether the subject has fibrosis or determine the likelihood that the subject has fibrosis. In some

embodiments, the method comprises detecting a biomarker panel comprising C7, COLEC11, THBS2 and at least one, at least two or three additional biomarkers selected from ITGA1/ITGB1, HSP90AA1/HSP90AB1 and DCN. In some embodiments, the method comprises detecting C7, COLEC11, THBS2 and at least one, at least two or three additional biomarker selected from ITGA1/ITGB1, HSP90AA1/HSP90AB1 and DCN.

[00119] In some embodiments, a method comprises detecting the level of at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten biomarkers selected from the biomarkers in Table 15 and Table 16. In some embodiments, a level of a biomarker in Table 15 or Table 16 that is higher than a control level of the respective biomarker indicates that the subject has NAFLD.

[00120] The biomarkers identified herein provide a number of choices for subsets or panels of biomarkers that can be used to effectively identify NAFLD. The biomarkers identified herein provide a number of choices for subsets or panels of biomarkers that can be used to effectively identify steatosis, lobular inflammation, hepatocyte ballooning, and/or fibrosis. The biomarkers identified herein provide a number of choices for subsets or panels of biomarkers that can be used to effectively identify NASH. The biomarkers identified herein provide a number of choices for subsets or panels of biomarkers that can be used to effectively identify NASH of stage 1, 2, 3, or 4. Selection of the appropriate number of such biomarkers may depend on the specific combination of biomarkers chosen. In addition, in any of the methods described herein, except where explicitly indicated, a panel of biomarkers may comprise additional biomarkers not shown in Table 3, 4, 6, 7, 8, 9, or 15.

[00121] In some embodiments, a method comprises detecting the level of at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten biomarkers selected from ACY1, C7, COLEC11, CSF1R, DCN, HSP90AA1/HSP90AB1, ITGA1/ITGB1, KYNU, POR, FCGR3B, LGALS3BP, SERPINC1, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and THBS2 in a sample from the subject, wherein a level of at least one biomarker indicates that the subject has NAFLD.

[00122] In some embodiments, a method comprises detecting the level of at least one biomarker listed in Table 3, 4, 6, 7, 8, 9, and/or 15 in a sample from a subject for determining whether a subject has NASH, or stage 2, 3, or 4 NASH. In some such embodiments, the method comprises contacting the sample or a portion of the sample from the subject with at least one capture reagent, wherein each capture reagent specifically binds a biomarker whose levels are being detected. In some embodiments, the method comprises contacting the sample, or proteins from the sample, with at least one aptamer, wherein each aptamer specifically binds a biomarker whose levels are being detected.

[00123] The biomarkers identified herein provide a number of choices for subsets or panels of biomarkers that can be used to effectively identify NASH, or stage 2, 3, or 4 NASH. Selection of the appropriate number of such biomarkers may depend on the specific combination of biomarkers chosen. In addition, in any of the methods described herein, except where explicitly indicated, a panel of biomarkers may comprise additional biomarkers not shown in Table 3, 4, 6, 7, 8, 9, or 15.

[00124] As used herein, “nonalcoholic fatty liver disease” or “NAFLD” refers to a condition in which fat is deposited in the liver (hepatic steatosis), with or without inflammation and fibrosis, in the absence of excessive alcohol use.

[00125] As used herein, “steatosis” and “non-alcoholic steatosis” are used interchangeably, and include mild, moderate, and severe steatosis, without inflammation or fibrosis, in the absence of excessive alcohol use. Table 1 shows exemplary classification of mild, moderate, and severe steatosis.

[00126] As used herein, “nonalcoholic steatohepatitis” or “NASH” refers to NAFLD in which there is inflammation and/or fibrosis in the liver. NASH may be divided into four stages. Exemplary methods of determining the stage of NASH are described, for example, in Kleiner et al., 2005, *Hepatology*, 41(6):1313-1321, and Brunt et al., 2007, *Modern Pathol.*, 20: S40-S48. Table 1 shows exemplary classification of stage 1, 2, 3, and 4 NASH.

[00127] As used herein, “obese” with reference to a subject refers to a subject with a BMI of 30 or greater.

[00128] “Biological sample”, “sample”, and “test sample” are used interchangeably herein to refer to any material, biological fluid, tissue, or cell obtained or otherwise derived from an individual. This includes blood (including whole blood, leukocytes, peripheral blood mononuclear cells, buffy coat, plasma, and serum), sputum, tears, mucus, nasal washes, nasal aspirate, urine, saliva, peritoneal washings, ascites, cystic fluid, glandular fluid, lymph fluid, bronchial aspirate, synovial fluid, joint aspirate, organ secretions, cells, a cellular extract, and cerebrospinal fluid. This also includes experimentally separated fractions of all of the preceding. For example, a blood sample can be fractionated into serum, plasma, or into fractions containing particular types of blood cells, such as red blood cells or white blood cells (leukocytes). In some embodiments, a sample can be a combination of samples from an individual, such as a combination of a tissue and fluid sample. The term “biological sample” also includes materials containing homogenized solid material, such as from a stool sample, a tissue sample, or a tissue biopsy, for example. The term “biological sample” also includes materials derived from a tissue culture or a cell culture. Any suitable methods for obtaining a biological sample can be employed; exemplary methods include, e.g., phlebotomy, swab (e.g.,

buccal swab), and a fine needle aspirate biopsy procedure. Exemplary tissues susceptible to fine needle aspiration include lymph node, lung, thyroid, breast, pancreas, and liver. Samples can also be collected, e.g., by micro dissection (e.g., laser capture micro dissection (LCM) or laser micro dissection (LMD)), bladder wash, smear (e.g., a PAP smear), or ductal lavage. A “biological sample” obtained or derived from an individual includes any such sample that has been processed in any suitable manner after being obtained from the individual.

[00129] Further, in some embodiments, a biological sample may be derived by taking biological samples from a number of individuals and pooling them, or pooling an aliquot of each individual’s biological sample. The pooled sample may be treated as described herein for a sample from a single individual, and, for example, if a poor prognosis is established in the pooled sample, then each individual biological sample can be re-tested to determine which individual(s) have steatosis and/or NASH.

[00130] “Target”, “target molecule”, and “analyte” are used interchangeably herein to refer to any molecule of interest that may be present in a biological sample. A “molecule of interest” includes any minor variation of a particular molecule, such as, in the case of a protein, for example, minor variations in amino acid sequence, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component, which does not substantially alter the identity of the molecule. A “target molecule”, “target”, or “analyte” refers to a set of copies of one type or species of molecule or multi-molecular structure. “Target molecules”, “targets”, and “analytes” refer to more than one type or species of molecule or multi-molecular structure. Exemplary target molecules include proteins, polypeptides, nucleic acids, carbohydrates, lipids, polysaccharides, glycoproteins, hormones, receptors, antigens, antibodies, affibodies, antibody mimics, viruses, pathogens, toxic substances, substrates, metabolites, transition state analogs, cofactors, inhibitors, drugs, dyes, nutrients, growth factors, cells, tissues, and any fragment or portion of any of the foregoing. In some embodiments, a target molecule is a protein, in which case the target molecule may be referred to as a “target protein.”

[00131] As used herein, a “capture agent” or “capture reagent” refers to a molecule that is capable of binding specifically to a biomarker. A “target protein capture reagent” refers to a molecule that is capable of binding specifically to a target protein. Nonlimiting exemplary capture reagents include aptamers, antibodies, adnectins, ankyrins, other antibody mimetics and other protein scaffolds, autoantibodies, chimeras, small molecules, nucleic acids, lectins, ligand-binding receptors, imprinted polymers, avimers, peptidomimetics, hormone receptors, cytokine receptors, synthetic receptors, and modifications and fragments of any of the aforementioned

capture reagents. In some embodiments, a capture reagent is selected from an aptamer and an antibody.

[00132] The term “antibody” refers to full-length antibodies of any species and fragments and derivatives of such antibodies, including Fab fragments, F(ab')₂ fragments, single chain antibodies, Fv fragments, and single chain Fv fragments. The term “antibody” also refers to synthetically-derived antibodies, such as phage display-derived antibodies and fragments, affybodies, nanobodies, etc.

[00133] As used herein, “marker” and “biomarker” are used interchangeably to refer to a target molecule that indicates or is a sign of a normal or abnormal process in an individual or of a disease or other condition in an individual. More specifically, a “marker” or “biomarker” is an anatomic, physiologic, biochemical, or molecular parameter associated with the presence of a specific physiological state or process, whether normal or abnormal, and, if abnormal, whether chronic or acute. Biomarkers are detectable and measurable by a variety of methods including laboratory assays and medical imaging. In some embodiments, a biomarker is a target protein.

[00134] As used herein, “biomarker level” and “level” refer to a measurement that is made using any analytical method for detecting the biomarker in a biological sample and that indicates the presence, absence, absolute amount or concentration, relative amount or concentration, titer, a level, an expression level, a ratio of measured levels, or the like, of, for, or corresponding to the biomarker in the biological sample. The exact nature of the “level” depends on the specific design and components of the particular analytical method employed to detect the biomarker.

[00135] A “control level” of a target molecule refers to the level of the target molecule in the same sample type from an individual that does not have the disease or condition, or from an individual that is not suspected of having the disease or condition. A “control level” of a target molecule need not be determined each time the present methods are carried out, and may be a previously determined level that is used as a reference or threshold to determine whether the level in a particular sample is higher or lower than a normal level. In some embodiments, a control level in a method described herein is the level that has been observed in one or more subjects without NAFLD. In some embodiments, a control level in a method described herein is the level that has been observed in one or more subjects with NAFLD, but not NASH. In some embodiments, a control level in a method described herein is the average or mean level, optionally plus or minus a statistical variation, that has been observed in a plurality of normal subjects, or subjects with NAFLD but not NASH.

[00136] As used herein, “individual” and “subject” are used interchangeably to refer to a test subject or patient. The individual can be a mammal or a non-mammal. In various

embodiments, the individual is a mammal. A mammalian individual can be a human or non-human. In various embodiments, the individual is a human. A healthy or normal individual is an individual in which the disease or condition of interest (such as NASH) is not detectable by conventional diagnostic methods.

[00137] “Diagnose”, “diagnosing”, “diagnosis”, and variations thereof refer to the detection, determination, or recognition of a health status or condition of an individual on the basis of one or more signs, symptoms, data, or other information pertaining to that individual. The health status of an individual can be diagnosed as healthy / normal (i.e., a diagnosis of the absence of a disease or condition) or diagnosed as ill / abnormal (i.e., a diagnosis of the presence, or an assessment of the characteristics, of a disease or condition). The terms “diagnose”, “diagnosing”, “diagnosis”, etc., encompass, with respect to a particular disease or condition, the initial detection of the disease; the characterization or classification of the disease; the detection of the progression, remission, or recurrence of the disease; and the detection of disease response after the administration of a treatment or therapy to the individual. The diagnosis of NAFLD includes distinguishing individuals who have NAFLD from individuals who do not. The diagnosis of NASH includes distinguishing individuals who have NASH from individuals who have steatosis in the liver, but not NASH, and from individuals with no liver disease.

[00138] “Prognose”, “prognosing”, “prognosis”, and variations thereof refer to the prediction of a future course of a disease or condition in an individual who has the disease or condition (e.g., predicting patient survival), and such terms encompass the evaluation of disease response after the administration of a treatment or therapy to the individual.

[00139] “Evaluate”, “evaluating”, “evaluation”, and variations thereof encompass both “diagnose” and “prognose” and also encompass determinations or predictions about the future course of a disease or condition in an individual who does not have the disease as well as determinations or predictions regarding the likelihood that a disease or condition will recur in an individual who apparently has been cured of the disease. The term “evaluate” also encompasses assessing an individual’s response to a therapy, such as, for example, predicting whether an individual is likely to respond favorably to a therapeutic agent or is unlikely to respond to a therapeutic agent (or will experience toxic or other undesirable side effects, for example), selecting a therapeutic agent for administration to an individual, or monitoring or determining an individual’s response to a therapy that has been administered to the individual. Thus, “evaluating” NAFLD can include, for example, any of the following: prognosing the future course of NAFLD in an individual; predicting whether NAFLD will progress to NASH; predicting whether a particular stage of NASH will progress to a higher stage of NASH; etc.

[00140] As used herein, “detecting” or “determining” with respect to a biomarker level includes the use of both the instrument used to observe and record a signal corresponding to a biomarker level and the material/s required to generate that signal. In various embodiments, the level is detected using any suitable method, including fluorescence, chemiluminescence, surface plasmon resonance, surface acoustic waves, mass spectrometry, infrared spectroscopy, Raman spectroscopy, atomic force microscopy, scanning tunneling microscopy, electrochemical detection methods, nuclear magnetic resonance, quantum dots, and the like.

[00141] As used herein, a “subject with NAFLD” refers to a subject that has been diagnosed with NAFLD. In some embodiments, NAFLD is suspected during a routine checkup, monitoring of metabolic syndrome and obesity, or monitoring for possible side effects of drugs (e.g., cholesterol lowering agents or steroids). In some instance, liver enzymes such AST and ALT are high. In some embodiments, a subject is diagnosed following abdominal or thoracic imaging, liver ultrasound, or magnetic resonance imaging. In some embodiments, other conditions such as excess alcohol consumption, hepatitis C, and Wilson’s disease have been ruled out prior to an NAFLD diagnosis. In some embodiments, a subject has been diagnosed following a liver biopsy.

[00142] As used herein, a “subject with steatosis” and a “subject with non-alcoholic steatosis” are used interchangeably, and refer to a subject that has been diagnosed with steatosis. In some embodiments, steatosis is diagnosed by a method described above for NAFLD in general.

[00143] As used herein, a “subject with NASH” refers to a subject that has been diagnosed with NASH. In some embodiments, NASH is diagnosed by a method described above for NAFLD in general. In some embodiments, advanced fibrosis is diagnosed in a patient with NAFLD, for example, according to Gambino R, et.al. *Annals of Medicine* 2011;43(8):617-49.

[00144] As used herein, a “subject at risk of developing NAFLD” refers to a subject with one or more NAFLD comorbidities, such as obesity, abdominal obesity, metabolic syndrome, cardiovascular disease, and diabetes.

[00145] As used herein, a “subject at risk of developing steatosis” refers to a subject that has not been diagnosed as having steatosis, but who has one or more NAFLD comorbidities, such as obesity, abdominal obesity, metabolic syndrome, cardiovascular disease, and diabetes.

[00146] As used herein, a “subject at risk of developing NASH” refers to a subject with steatosis who continues to have one or more NAFLD comorbidities, such as obesity, abdominal obesity, metabolic syndrome, cardiovascular disease, and diabetes.

[00147] “Solid support” refers herein to any substrate having a surface to which molecules may be attached, directly or indirectly, through either covalent or non-covalent bonds. A “solid support” can have a variety of physical formats, which can include, for example, a membrane; a chip (e.g., a protein chip); a slide (e.g., a glass slide or coverslip); a column; a hollow, solid, semi-solid, pore- or cavity- containing particle, such as, for example, a bead; a gel; a fiber, including a fiber optic material; a matrix; and a sample receptacle. Exemplary sample receptacles include sample wells, tubes, capillaries, vials, and any other vessel, groove or indentation capable of holding a sample. A sample receptacle can be contained on a multi-sample platform, such as a microtiter plate, slide, microfluidics device, and the like. A support can be composed of a natural or synthetic material, an organic or inorganic material. The composition of the solid support on which capture reagents are attached generally depends on the method of attachment (e.g., covalent attachment). Other exemplary receptacles include microdroplets and microfluidic controlled or bulk oil/aqueous emulsions within which assays and related manipulations can occur. Suitable solid supports include, for example, plastics, resins, polysaccharides, silica or silica-based materials, functionalized glass, modified silicon, carbon, metals, inorganic glasses, membranes, nylon, natural fibers (such as, for example, silk, wool and cotton), polymers, and the like. The material composing the solid support can include reactive groups such as, for example, carboxy, amino, or hydroxyl groups, which are used for attachment of the capture reagents. Polymeric solid supports can include, e.g., polystyrene, polyethylene glycol tetrphthalate, polyvinyl acetate, polyvinyl chloride, polyvinyl pyrrolidone, polyacrylonitrile, polymethyl methacrylate, polytetrafluoroethylene, butyl rubber, styrenebutadiene rubber, natural rubber, polyethylene, polypropylene, (poly)tetrafluoroethylene, (poly)vinylidene fluoride, polycarbonate, and polymethylpentene. Suitable solid support particles that can be used include, e.g., encoded particles, such as Luminex[®]-type encoded particles, magnetic particles, and glass particles.

Exemplary Uses of Biomarkers

[00148] In various exemplary embodiments, methods are provided for determining whether a subject has NAFLD. In various embodiments, a method is provided for determining whether a subject has NAFLD, comprising forming a biomarker panel having N biomarker proteins from the biomarker proteins listed in Table 15 and/or Table 16, and detecting the level of each of the N biomarker proteins of the panel in a sample from the subject, wherein N is at least 5. In various embodiments, a method is provided for determining whether a subject has NAFLD, comprising detecting the level of at least one biomarker listed in Table 15 and/or Table 16 in a sample from a subject for determining whether a subject has NAFLD.

[00149] In various embodiments, methods are provided for determining whether a subject has steatosis, which may be mild, moderate, or severe steatosis. In various embodiments, methods are provided for determining whether a subject has NASH, which may be stage 1, 2, 3, or 4 NASH, or which may be stage 2, 3, or 4 NASH. In some embodiments, methods are provided for determining whether a subject with steatosis has NASH, which may be stage 1, 2, 3, or 4 NASH, or which may be stage 2, 3, or 4 NASH. In some embodiments, methods are provided for characterizing the histologic staging of NASH. In some embodiments, methods are provided for determining whether a subject has steatosis, lobular inflammation, hepatocyte ballooning, and/or fibrosis. The methods comprise detecting one or more biomarker levels corresponding to one or more biomarkers that are present in the circulation of an individual, such as in serum or plasma, by any number of analytical methods, including any of the analytical methods described herein. These biomarkers are, for example, present at different levels in individuals with NAFLD as compared to normal individuals (wherein normal individuals may be obese individuals). In some embodiments, the biomarkers are present at different levels in individuals with NASH (such as stage 1, 2, 3, or 4 NASH, or stage 2, 3, or 4 NASH) as compared to normal individuals (wherein normal individuals may be obese individuals). In some embodiments, the biomarkers are present at different levels in individuals with NASH (such as stage 1, 2, 3, or 4 NASH, or stage 2, 3, or 4 NASH) as compared to subjects with steatosis, which may be mild, moderate, or severe steatosis.

[00150] In some embodiments, the biomarkers are present at different levels in individuals with steatosis compared to normal individuals (wherein normal individuals may be obese individuals). In some embodiments, the biomarkers are present at different levels in individuals with lobular inflammation compared to normal individuals (wherein normal individuals may be obese individuals). In some embodiments, the biomarkers are present at different levels in individuals with hepatocyte ballooning compared to normal individuals (wherein normal individuals may be obese individuals). In some embodiments, the biomarkers are present at different levels in individuals with fibrosis compared to normal individuals (wherein normal individuals may be obese individuals).

[00151] Detection of the differential levels of a biomarker in an individual can be used, for example, to permit the determination of whether an individual has NAFLD (which may be steatosis or NASH), or whether an individual with steatosis has developed NASH. In some embodiments, any of the biomarkers described herein may be used to monitor individuals (such as obese individuals) for development of NAFLD, or to monitor individuals with steatosis for development of NASH.

[00152] As an example of the manner in which any of the biomarkers described herein can be used to determine whether a subject has NAFLD, levels of one or more of the described biomarkers in an individual who has not been diagnosed with NAFLD, but has one or more NAFLD comorbidities, may indicate that the individual has developed NAFLD at an earlier stage than would be determined using an invasive test, such as liver biopsy. Because the present methods are non-invasive, they may be used to monitor individuals at risk of developing NAFLD (such as, for example, obese individuals). By detecting NAFLD at an earlier stage, medical intervention may be more effective. Such medical intervention may include, but is not limited to, weight loss, blood sugar control, and alcohol avoidance. In some embodiments, therapeutic agents may be used, such as pioglitazone, vitamin E, and/or metformin. *See, e.g.,* Sanyal et al., 2010, *NEJM*, 362: 1675-1685. In some instances, such early intervention may delay or prevent liver failure and the need for a liver transplant.

[00153] Similarly, as a further example of the manner in which the biomarkers described herein can be used to determine whether a subject that has steatosis is developing NASH, levels of one or more of the described biomarkers in an individual with steatosis may indicate that the individual is developing NASH. Because the present methods are non-invasive, individuals with steatosis may be monitored for development of NASH. By detecting NASH at an earlier stage, medical intervention may be more effective. Such medical intervention may include, but is not limited to, weight loss, blood sugar control, and alcohol avoidance. In some embodiments, therapeutic agents may be used, such as pioglitazone, vitamin E, and/or metformin. *See, e.g.,* Sanyal et al., 2010, *NEJM*, 362: 1675-1685. In some instances, such early intervention may delay or prevent liver failure and the need for a liver transplant.

[00154] In addition, in some embodiments, a differential expression level of one or more of the biomarkers in an individual over time may be indicative of the individual's response to a particular therapeutic regimen. In some embodiments, changes in expression of one or more of the biomarkers during follow-up monitoring may indicate that a particular therapy is effective or may suggest that the therapeutic regimen should be altered in some way, such as by more aggressively controlling blood sugar, more aggressively pursuing weight loss, etc. In some embodiments, a constant expression level of one or more of the biomarkers in an individual over time may be indicative that an individual's steatosis is not worsening, or is not developing into NASH.

[00155] In addition to testing biomarker levels as a stand-alone diagnostic test, biomarker levels can also be done in conjunction with determination of single nucleotide polymorphisms (SNPs) or other genetic lesions or variability that are indicative of increased risk of susceptibility of disease. (*See, e.g.,* Amos et al., *Nature Genetics* 40, 616-622 (2009)).

[00156] In addition to testing biomarker levels as a stand-alone diagnostic test, biomarker levels can also be done in conjunction with other NAFLD screening methods, such as detection of an enlarged liver, blood tests (for example, to detect elevations in certain liver enzymes, such as ALT and/or AST), abdominal ultrasound, and liver biopsy. In some instances, methods using the biomarkers described herein may facilitate the medical and economic justification for implementing more aggressive treatments for NAFLD or NASH, more frequent follow-up screening, etc. The biomarkers may also be used to begin treatment in individuals at risk of developing NAFLD, but who have not been diagnosed with steatosis, if the diagnostic test indicates they are likely to develop the disease.

[00157] In addition to testing biomarker levels in conjunction with other NAFLD diagnostic methods, information regarding the biomarkers can also be evaluated in conjunction with other types of data, particularly data that indicates an individual's risk for NAFLD. These various data can be assessed by automated methods, such as a computer program/software, which can be embodied in a computer or other apparatus/device.

Detection and Determination of Biomarkers and Biomarker Levels

[00158] A biomarker level for the biomarkers described herein can be detected using any of a variety of known analytical methods. In one embodiment, a biomarker level is detected using a capture reagent. In various embodiments, the capture reagent can be exposed to the biomarker in solution or can be exposed to the biomarker while the capture reagent is immobilized on a solid support. In other embodiments, the capture reagent contains a feature that is reactive with a secondary feature on a solid support. In these embodiments, the capture reagent can be exposed to the biomarker in solution, and then the feature on the capture reagent can be used in conjunction with the secondary feature on the solid support to immobilize the biomarker on the solid support. The capture reagent is selected based on the type of analysis to be conducted. Capture reagents include but are not limited to aptamers, antibodies, adnectins, ankyrins, other antibody mimetics and other protein scaffolds, autoantibodies, chimeras, small molecules, F(ab')₂ fragments, single chain antibody fragments, Fv fragments, single chain Fv fragments, nucleic acids, lectins, ligand-binding receptors, affybodies, nanobodies, imprinted polymers, avimers, peptidomimetics, hormone receptors, cytokine receptors, and synthetic receptors, and modifications and fragments of these.

[00159] In some embodiments, a biomarker level is detected using a biomarker/capture reagent complex.

[00160] In some embodiments, the biomarker level is derived from the biomarker/capture reagent complex and is detected indirectly, such as, for example, as a result of a reaction that is

subsequent to the biomarker/capture reagent interaction, but is dependent on the formation of the biomarker/capture reagent complex.

[00161] In some embodiments, the biomarker level is detected directly from the biomarker in a biological sample.

[00162] In some embodiments, biomarkers are detected using a multiplexed format that allows for the simultaneous detection of two or more biomarkers in a biological sample. In some embodiments of the multiplexed format, capture reagents are immobilized, directly or indirectly, covalently or non-covalently, in discrete locations on a solid support. In some embodiments, a multiplexed format uses discrete solid supports where each solid support has a unique capture reagent associated with that solid support, such as, for example quantum dots. In some embodiments, an individual device is used for the detection of each one of multiple biomarkers to be detected in a biological sample. Individual devices can be configured to permit each biomarker in the biological sample to be processed simultaneously. For example, a microtiter plate can be used such that each well in the plate is used to analyze one or more of multiple biomarkers to be detected in a biological sample.

[00163] In one or more of the foregoing embodiments, a fluorescent tag can be used to label a component of the biomarker/capture reagent complex to enable the detection of the biomarker level. In various embodiments, the fluorescent label can be conjugated to a capture reagent specific to any of the biomarkers described herein using known techniques, and the fluorescent label can then be used to detect the corresponding biomarker level. Suitable fluorescent labels include rare earth chelates, fluorescein and its derivatives, rhodamine and its derivatives, dansyl, allophycocyanin, PBXL-3, Qdot 605, Lissamine, phycoerythrin, Texas Red, and other such compounds.

[00164] In some embodiments, the fluorescent label is a fluorescent dye molecule. In some embodiments, the fluorescent dye molecule includes at least one substituted indolium ring system in which the substituent on the 3-carbon of the indolium ring contains a chemically reactive group or a conjugated substance. In some embodiments, the dye molecule includes an AlexaFluor molecule, such as, for example, AlexaFluor 488, AlexaFluor 532, AlexaFluor 647, AlexaFluor 680, or AlexaFluor 700. In some embodiments, the dye molecule includes a first type and a second type of dye molecule, such as, e.g., two different AlexaFluor molecules. In some embodiments, the dye molecule includes a first type and a second type of dye molecule, and the two dye molecules have different emission spectra.

[00165] Fluorescence can be measured with a variety of instrumentation compatible with a wide range of assay formats. For example, spectrofluorimeters have been designed to analyze microtiter plates, microscope slides, printed arrays, cuvettes, etc. See Principles of Fluorescence

Spectroscopy, by J.R. Lakowicz, Springer Science + Business Media, Inc., 2004. See Bioluminescence & Chemiluminescence: Progress & Current Applications; Philip E. Stanley and Larry J. Kricka editors, World Scientific Publishing Company, January 2002.

[00166] In one or more embodiments, a chemiluminescence tag can optionally be used to label a component of the biomarker/capture complex to enable the detection of a biomarker level. Suitable chemiluminescent materials include any of oxalyl chloride, Rodamin 6G, Ru(bipy)₃²⁺, TMAE (tetrakis(dimethylamino)ethylene), Pyrogallol (1,2,3-trihydroxybenzene), Lucigenin, peroxyoxalates, Aryl oxalates, Acridinium esters, dioxetanes, and others.

[00167] In some embodiments, the detection method includes an enzyme/substrate combination that generates a detectable signal that corresponds to the biomarker level. Generally, the enzyme catalyzes a chemical alteration of the chromogenic substrate which can be measured using various techniques, including spectrophotometry, fluorescence, and chemiluminescence. Suitable enzymes include, for example, luciferases, luciferin, malate dehydrogenase, urease, horseradish peroxidase (HRPO), alkaline phosphatase, beta-galactosidase, glucoamylase, lysozyme, glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, uricase, xanthine oxidase, lactoperoxidase, microperoxidase, and the like.

[00168] In some embodiments, the detection method can be a combination of fluorescence, chemiluminescence, radionuclide or enzyme/substrate combinations that generate a measurable signal. In some embodiments, multimodal signaling could have unique and advantageous characteristics in biomarker assay formats.

[00169] In some embodiments, the biomarker levels for the biomarkers described herein can be detected using any analytical methods including, singleplex aptamer assays, multiplexed aptamer assays, singleplex or multiplexed immunoassays, mRNA expression profiling, miRNA expression profiling, mass spectrometric analysis, histological/cytological methods, etc. as discussed below.

Determination of Biomarker Levels using Aptamer-Based Assays

[00170] Assays directed to the detection and quantification of physiologically significant molecules in biological samples and other samples are important tools in scientific research and in the health care field. One class of such assays involves the use of a microarray that includes one or more aptamers immobilized on a solid support. The aptamers are each capable of binding to a target molecule in a highly specific manner and with very high affinity. See, e.g., U.S. Patent No. 5,475,096 entitled "Nucleic Acid Ligands"; see also, e.g., U.S. Patent No. 6,242,246, U.S. Patent No. 6,458,543, and U.S. Patent No. 6,503,715, each of which is entitled "Nucleic

Acid Ligand Diagnostic Biochip”. Once the microarray is contacted with a sample, the aptamers bind to their respective target molecules present in the sample and thereby enable a determination of a biomarker level corresponding to a biomarker.

[00171] As used herein, an “aptamer” refers to a nucleic acid that has a specific binding affinity for a target molecule. It is recognized that affinity interactions are a matter of degree; however, in this context, the “specific binding affinity” of an aptamer for its target means that the aptamer binds to its target generally with a much higher degree of affinity than it binds to other components in a test sample. An “aptamer” is a set of copies of one type or species of nucleic acid molecule that has a particular nucleotide sequence. An aptamer can include any suitable number of nucleotides, including any number of chemically modified nucleotides. “Aptamers” refers to more than one such set of molecules. Different aptamers can have either the same or different numbers of nucleotides. Aptamers can be DNA or RNA or chemically modified nucleic acids and can be single stranded, double stranded, or contain double stranded regions, and can include higher ordered structures. An aptamer can also be a photoaptamer, where a photoreactive or chemically reactive functional group is included in the aptamer to allow it to be covalently linked to its corresponding target. Any of the aptamer methods disclosed herein can include the use of two or more aptamers that specifically bind the same target molecule. As further described below, an aptamer may include a tag. If an aptamer includes a tag, all copies of the aptamer need not have the same tag. Moreover, if different aptamers each include a tag, these different aptamers can have either the same tag or a different tag.

[00172] An aptamer can be identified using any known method, including the SELEX process. Once identified, an aptamer can be prepared or synthesized in accordance with any known method, including chemical synthetic methods and enzymatic synthetic methods.

[00173] The terms “SELEX” and “SELEX process” are used interchangeably herein to refer generally to a combination of (1) the selection of aptamers that interact with a target molecule in a desirable manner, for example binding with high affinity to a protein, with (2) the amplification of those selected nucleic acids. The SELEX process can be used to identify aptamers with high affinity to a specific target or biomarker.

[00174] SELEX generally includes preparing a candidate mixture of nucleic acids, binding of the candidate mixture to the desired target molecule to form an affinity complex, separating the affinity complexes from the unbound candidate nucleic acids, separating and isolating the nucleic acid from the affinity complex, purifying the nucleic acid, and identifying a specific aptamer sequence. The process may include multiple rounds to further refine the affinity of the selected aptamer. The process can include amplification steps at one or more

points in the process. See, *e.g.*, U.S. Patent No. 5,475,096, entitled “Nucleic Acid Ligands”. The SELEX process can be used to generate an aptamer that covalently binds its target as well as an aptamer that non-covalently binds its target. See, *e.g.*, U.S. Patent No. 5,705,337 entitled “Systematic Evolution of Nucleic Acid Ligands by Exponential Enrichment: Chemi-SELEX.”

[00175] The SELEX process can be used to identify high-affinity aptamers containing modified nucleotides that confer improved characteristics on the aptamer, such as, for example, improved *in vivo* stability or improved delivery characteristics. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions. SELEX process-identified aptamers containing modified nucleotides are described in U.S. Patent No. 5,660,985, entitled “High Affinity Nucleic Acid Ligands Containing Modified Nucleotides”, which describes oligonucleotides containing nucleotide derivatives chemically modified at the 5'- and 2'-positions of pyrimidines. U.S. Patent No. 5,580,737, see *supra*, describes highly specific aptamers containing one or more nucleotides modified with 2'-amino (2'-NH₂), 2'-fluoro (2'-F), and/or 2'-O-methyl (2'-OMe). See also, U.S. Patent Application Publication No. 2009/0098549, entitled “SELEX and PHOTOSELEX”, which describes nucleic acid libraries having expanded physical and chemical properties and their use in SELEX and photoSELEX.

[00176] SELEX can also be used to identify aptamers that have desirable off-rate characteristics. See U.S. Publication No. US 2009/0004667, entitled “Method for Generating Aptamers with Improved Off-Rates”, which describes improved SELEX methods for generating aptamers that can bind to target molecules. Methods for producing aptamers and photoaptamers having slower rates of dissociation from their respective target molecules are described. The methods involve contacting the candidate mixture with the target molecule, allowing the formation of nucleic acid-target complexes to occur, and performing a slow off-rate enrichment process wherein nucleic acid-target complexes with fast dissociation rates will dissociate and not reform, while complexes with slow dissociation rates will remain intact. Additionally, the methods include the use of modified nucleotides in the production of candidate nucleic acid mixtures to generate aptamers with improved off-rate performance. Nonlimiting exemplary modified nucleotides include, for example, the modified pyrimidines shown in Figure 11. In some embodiments, an aptamer comprises at least one nucleotide with a modification, such as a base modification. In some embodiments, an aptamer comprises at least one nucleotide with a hydrophobic modification, such as a hydrophobic base modification, allowing for hydrophobic contacts with a target protein. Such hydrophobic contacts, in some embodiments, contribute to greater affinity and/or slower off-rate binding by the aptamer. Nonlimiting exemplary nucleotides with hydrophobic modifications are shown in Figure 11. In some embodiments, an aptamer comprises at least two, at least three, at least four, at least five, at least six, at least

seven, at least eight, at least nine, or at least 10 nucleotides with hydrophobic modifications, where each hydrophobic modification may be the same or different from the others. In some embodiments, at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least 10 hydrophobic modifications in an aptamer may be independently selected from the hydrophobic modifications shown in Figure 11.

[00177] In some embodiments, a slow off-rate aptamer (including an aptamers comprising at least one nucleotide with a hydrophobic modification) has an off-rate ($t_{1/2}$) of ≥ 30 minutes, ≥ 60 minutes, ≥ 90 minutes, ≥ 120 minutes, ≥ 150 minutes, ≥ 180 minutes, ≥ 210 minutes, or ≥ 240 minutes.

[00178] In some embodiments, an assay employs aptamers that include photoreactive functional groups that enable the aptamers to covalently bind or “photocrosslink” their target molecules. See, e.g., U.S. Patent No. 6,544,776 entitled “Nucleic Acid Ligand Diagnostic Biochip”. These photoreactive aptamers are also referred to as photoaptamers. See, e.g., U.S. Patent No. 5,763,177, U.S. Patent No. 6,001,577, and U.S. Patent No. 6,291,184, each of which is entitled “Systematic Evolution of Nucleic Acid Ligands by Exponential Enrichment: Photoselection of Nucleic Acid Ligands and Solution SELEX”; see also, e.g., U.S. Patent No. 6,458,539, entitled “Photoselection of Nucleic Acid Ligands”. After the microarray is contacted with the sample and the photoaptamers have had an opportunity to bind to their target molecules, the photoaptamers are photoactivated, and the solid support is washed to remove any non-specifically bound molecules. Harsh wash conditions may be used, since target molecules that are bound to the photoaptamers are generally not removed, due to the covalent bonds created by the photoactivated functional group(s) on the photoaptamers. In this manner, the assay enables the detection of a biomarker level corresponding to a biomarker in the test sample.

[00179] In some assay formats, the aptamers are immobilized on the solid support prior to being contacted with the sample. Under certain circumstances, however, immobilization of the aptamers prior to contact with the sample may not provide an optimal assay. For example, pre-immobilization of the aptamers may result in inefficient mixing of the aptamers with the target molecules on the surface of the solid support, perhaps leading to lengthy reaction times and, therefore, extended incubation periods to permit efficient binding of the aptamers to their target molecules. Further, when photoaptamers are employed in the assay and depending upon the material utilized as a solid support, the solid support may tend to scatter or absorb the light used to effect the formation of covalent bonds between the photoaptamers and their target molecules. Moreover, depending upon the method employed, detection of target molecules bound to their aptamers can be subject to imprecision, since the surface of the solid support may also be exposed to and affected by any labeling agents that are used. Finally, immobilization of the

aptamers on the solid support generally involves an aptamer-preparation step (i.e., the immobilization) prior to exposure of the aptamers to the sample, and this preparation step may affect the activity or functionality of the aptamers.

[00180] Aptamer assays that permit an aptamer to capture its target in solution and then employ separation steps that are designed to remove specific components of the aptamer-target mixture prior to detection have also been described (*see* U.S. Publication No. 2009/0042206, entitled “Multiplexed Analyses of Test Samples”). The described aptamer assay methods enable the detection and quantification of a non-nucleic acid target (e.g., a protein target) in a test sample by detecting and quantifying a nucleic acid (i.e., an aptamer). The described methods create a nucleic acid surrogate (i.e., the aptamer) for detecting and quantifying a non-nucleic acid target, thus allowing the wide variety of nucleic acid technologies, including amplification, to be applied to a broader range of desired targets, including protein targets.

[00181] Aptamers can be constructed to facilitate the separation of the assay components from an aptamer biomarker complex (or photoaptamer biomarker covalent complex) and permit isolation of the aptamer for detection and/or quantification. In one embodiment, these constructs can include a cleavable or releasable element within the aptamer sequence. In other embodiments, additional functionality can be introduced into the aptamer, for example, a labeled or detectable component, a spacer component, or a specific binding tag or immobilization element. For example, the aptamer can include a tag connected to the aptamer via a cleavable moiety, a label, a spacer component separating the label, and the cleavable moiety. In one embodiment, a cleavable element is a photocleavable linker. The photocleavable linker can be attached to a biotin moiety and a spacer section, can include an NHS group for derivatization of amines, and can be used to introduce a biotin group to an aptamer, thereby allowing for the release of the aptamer later in an assay method.

[00182] Homogenous assays, done with all assay components in solution, do not require separation of sample and reagents prior to the detection of signal. These methods are rapid and easy to use. These methods generate signal based on a molecular capture or binding reagent that reacts with its specific target. In some embodiments of the methods described herein, the molecular capture reagents comprise an aptamer or an antibody or the like and the specific target may be a biomarker shown in Table 3, 4, 6, 7, 8 and/or 9.

[00183] In some embodiments, a method for signal generation takes advantage of anisotropy signal change due to the interaction of a fluorophore-labeled capture reagent with its specific biomarker target. When the labeled capture reacts with its target, the increased molecular weight causes the rotational motion of the fluorophore attached to the complex to become much slower changing the anisotropy value. By monitoring the anisotropy change,

binding events may be used to quantitatively measure the biomarkers in solutions. Other methods include fluorescence polarization assays, molecular beacon methods, time resolved fluorescence quenching, chemiluminescence, fluorescence resonance energy transfer, and the like.

[00184] An exemplary solution-based aptamer assay that can be used to detect a biomarker level in a biological sample includes the following: (a) preparing a mixture by contacting the biological sample with an aptamer that includes a first tag and has a specific affinity for the biomarker, wherein an aptamer affinity complex is formed when the biomarker is present in the sample; (b) exposing the mixture to a first solid support including a first capture element, and allowing the first tag to associate with the first capture element; (c) removing any components of the mixture not associated with the first solid support; (d) attaching a second tag to the biomarker component of the aptamer affinity complex; (e) releasing the aptamer affinity complex from the first solid support; (f) exposing the released aptamer affinity complex to a second solid support that includes a second capture element and allowing the second tag to associate with the second capture element; (g) removing any non-complexed aptamer from the mixture by partitioning the non-complexed aptamer from the aptamer affinity complex; (h) eluting the aptamer from the solid support; and (i) detecting the biomarker by detecting the aptamer component of the aptamer affinity complex.

[00185] A nonlimiting exemplary method of detecting biomarkers in a biological sample using aptamers is described in Example 7. See also Kraemer et al., *PLoS One* 6(10): e26332.

Determination of Biomarker Levels using Immunoassays

[00186] Immunoassay methods are based on the reaction of an antibody to its corresponding target or analyte and can detect the analyte in a sample depending on the specific assay format. To improve specificity and sensitivity of an assay method based on immuno-reactivity, monoclonal antibodies and fragments thereof are often used because of their specific epitope recognition. Polyclonal antibodies have also been successfully used in various immunoassays because of their increased affinity for the target as compared to monoclonal antibodies. Immunoassays have been designed for use with a wide range of biological sample matrices. Immunoassay formats have been designed to provide qualitative, semi-quantitative, and quantitative results.

[00187] Quantitative results are generated through the use of a standard curve created with known concentrations of the specific analyte to be detected. The response or signal from an unknown sample is plotted onto the standard curve, and a quantity or level corresponding to the target in the unknown sample is established.

[00188] Numerous immunoassay formats have been designed. ELISA or EIA can be quantitative for the detection of an analyte. This method relies on attachment of a label to either the analyte or the antibody and the label component includes, either directly or indirectly, an enzyme. ELISA tests may be formatted for direct, indirect, competitive, or sandwich detection of the analyte. Other methods rely on labels such as, for example, radioisotopes (I^{125}) or fluorescence. Additional techniques include, for example, agglutination, nephelometry, turbidimetry, Western blot, immunoprecipitation, immunocytochemistry, immunohistochemistry, flow cytometry, Luminex assay, and others (see *ImmunoAssay: A Practical Guide*, edited by Brian Law, published by Taylor & Francis, Ltd., 2005 edition).

[00189] Exemplary assay formats include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, fluorescent, chemiluminescence, and fluorescence resonance energy transfer (FRET) or time resolved-FRET (TR-FRET) immunoassays. Examples of procedures for detecting biomarkers include biomarker immunoprecipitation followed by quantitative methods that allow size and peptide level discrimination, such as gel electrophoresis, capillary electrophoresis, planar electrochromatography, and the like.

[00190] Methods of detecting and/or for quantifying a detectable label or signal generating material depend on the nature of the label. The products of reactions catalyzed by appropriate enzymes (where the detectable label is an enzyme; see above) can be, without limitation, fluorescent, luminescent, or radioactive or they may absorb visible or ultraviolet light. Examples of detectors suitable for detecting such detectable labels include, without limitation, x-ray film, radioactivity counters, scintillation counters, spectrophotometers, colorimeters, fluorometers, luminometers, and densitometers.

[00191] Any of the methods for detection can be performed in any format that allows for any suitable preparation, processing, and analysis of the reactions. This can be, for example, in multi-well assay plates (e.g., 96 wells or 386 wells) or using any suitable array or microarray. Stock solutions for various agents can be made manually or robotically, and all subsequent pipetting, diluting, mixing, distribution, washing, incubating, sample readout, data collection and analysis can be done robotically using commercially available analysis software, robotics, and detection instrumentation capable of detecting a detectable label.

Determination of Biomarker Levels using Gene Expression Profiling

[00192] Measuring mRNA in a biological sample may, in some embodiments, be used as a surrogate for detection of the level of the corresponding protein in the biological sample. Thus, in some embodiments, a biomarker or biomarker panel described herein can be detected by detecting the appropriate RNA.

[00193] In some embodiments, mRNA expression levels are measured by reverse transcription quantitative polymerase chain reaction (RT-PCR followed with qPCR). RT-PCR is used to create a cDNA from the mRNA. The cDNA may be used in a qPCR assay to produce fluorescence as the DNA amplification process progresses. By comparison to a standard curve, qPCR can produce an absolute measurement such as number of copies of mRNA per cell. Northern blots, microarrays, Invader assays, and RT-PCR combined with capillary electrophoresis have all been used to measure expression levels of mRNA in a sample. See *Gene Expression Profiling: Methods and Protocols*, Richard A. Shimkets, editor, Humana Press, 2004.

Detection of Biomarkers Using *In Vivo* Molecular Imaging Technologies

[00194] In some embodiments, a biomarker described herein may be used in molecular imaging tests. For example, an imaging agent can be coupled to a capture reagent, which can be used to detect the biomarker *in vivo*.

[00195] *In vivo* imaging technologies provide non-invasive methods for determining the state of a particular disease in the body of an individual. For example, entire portions of the body, or even the entire body, may be viewed as a three dimensional image, thereby providing valuable information concerning morphology and structures in the body. Such technologies may be combined with the detection of the biomarkers described herein to provide information concerning the biomarker *in vivo*.

[00196] The use of *in vivo* molecular imaging technologies is expanding due to various advances in technology. These advances include the development of new contrast agents or labels, such as radiolabels and/or fluorescent labels, which can provide strong signals within the body; and the development of powerful new imaging technology, which can detect and analyze these signals from outside the body, with sufficient sensitivity and accuracy to provide useful information. The contrast agent can be visualized in an appropriate imaging system, thereby providing an image of the portion or portions of the body in which the contrast agent is located. The contrast agent may be bound to or associated with a capture reagent, such as an aptamer or an antibody, for example, and/or with a peptide or protein, or an oligonucleotide (for example, for the detection of gene expression), or a complex containing any of these with one or more macromolecules and/or other particulate forms.

[00197] The contrast agent may also feature a radioactive atom that is useful in imaging. Suitable radioactive atoms include technetium-99m or iodine-123 for scintigraphic studies. Other readily detectable moieties include, for example, spin labels for magnetic resonance imaging (MRI) such as, for example, iodine-123 again, iodine-131, indium-111, fluorine-19,

carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron. Such labels are well known in the art and could easily be selected by one of ordinary skill in the art.

[00198] Standard imaging techniques include but are not limited to magnetic resonance imaging, computed tomography scanning, positron emission tomography (PET), single photon emission computed tomography (SPECT), and the like. For diagnostic *in vivo* imaging, the type of detection instrument available is a major factor in selecting a given contrast agent, such as a given radionuclide and the particular biomarker that it is used to target (protein, mRNA, and the like). The radionuclide chosen typically has a type of decay that is detectable by a given type of instrument. Also, when selecting a radionuclide for *in vivo* diagnosis, its half-life should be long enough to enable detection at the time of maximum uptake by the target tissue but short enough that deleterious radiation of the host is minimized.

[00199] Exemplary imaging techniques include but are not limited to PET and SPECT, which are imaging techniques in which a radionuclide is synthetically or locally administered to an individual. The subsequent uptake of the radiotracer is measured over time and used to obtain information about the targeted tissue and the biomarker. Because of the high-energy (gamma-ray) emissions of the specific isotopes employed and the sensitivity and sophistication of the instruments used to detect them, the two-dimensional distribution of radioactivity may be inferred from outside of the body.

[00200] Commonly used positron-emitting nuclides in PET include, for example, carbon-11, nitrogen-13, oxygen-15, and fluorine-18. Isotopes that decay by electron capture and/or gamma-emission are used in SPECT and include, for example iodine-123 and technetium-99m. An exemplary method for labeling amino acids with technetium-99m is the reduction of pertechnetate ion in the presence of a chelating precursor to form the labile technetium-99m-precursor complex, which, in turn, reacts with the metal binding group of a bifunctionally modified chemotactic peptide to form a technetium-99m-chemotactic peptide conjugate.

[00201] Antibodies are frequently used for such *in vivo* imaging diagnostic methods. The preparation and use of antibodies for *in vivo* diagnosis is well known in the art. Similarly, aptamers may be used for such *in vivo* imaging diagnostic methods. For example, an aptamer that was used to identify a particular biomarker described herein may be appropriately labeled and injected into an individual to detect the biomarker *in vivo*. The label used will be selected in accordance with the imaging modality to be used, as previously described. Aptamer-directed imaging agents could have unique and advantageous characteristics relating to tissue penetration, tissue distribution, kinetics, elimination, potency, and selectivity as compared to other imaging agents.

[00202] Such techniques may also optionally be performed with labeled oligonucleotides, for example, for detection of gene expression through imaging with antisense oligonucleotides. These methods are used for in situ hybridization, for example, with fluorescent molecules or radionuclides as the label. Other methods for detection of gene expression include, for example, detection of the activity of a reporter gene.

[00203] Another general type of imaging technology is optical imaging, in which fluorescent signals within the subject are detected by an optical device that is external to the subject. These signals may be due to actual fluorescence and/or to bioluminescence. Improvements in the sensitivity of optical detection devices have increased the usefulness of optical imaging for in vivo diagnostic assays.

[00204] For a review of other techniques, see N. Blow, *Nature Methods*, 6, 465-469, 2009.

Determination of Biomarkers using Histology/Cytology Methods

[00205] In some embodiments, the biomarkers described herein may be detected in a variety of tissue samples using histological or cytological methods. For example, endo- and trans-bronchial biopsies, fine needle aspirates, cutting needles, and core biopsies can be used for histology. Bronchial washing and brushing, pleural aspiration, and sputum, can be used for cytology. Any of the biomarkers identified herein can be used to stain a specimen as an indication of disease.

[00206] In some embodiments, one or more capture reagent/s specific to the corresponding biomarker/s are used in a cytological evaluation of a sample and may include one or more of the following: collecting a cell sample, fixing the cell sample, dehydrating, clearing, immobilizing the cell sample on a microscope slide, permeabilizing the cell sample, treating for analyte retrieval, staining, destaining, washing, blocking, and reacting with one or more capture reagent/s in a buffered solution. In another embodiment, the cell sample is produced from a cell block.

[00207] In some embodiments, one or more capture reagent/s specific to the corresponding biomarkers are used in a histological evaluation of a tissue sample and may include one or more of the following: collecting a tissue specimen, fixing the tissue sample, dehydrating, clearing, immobilizing the tissue sample on a microscope slide, permeabilizing the tissue sample, treating for analyte retrieval, staining, destaining, washing, blocking, rehydrating, and reacting with capture reagent/s in a buffered solution. In another embodiment, fixing and dehydrating are replaced with freezing.

[00208] In another embodiment, the one or more aptamer/s specific to the corresponding biomarker/s are reacted with the histological or cytological sample and can serve as the nucleic acid target in a nucleic acid amplification method. Suitable nucleic acid amplification methods include, for example, PCR, q-beta replicase, rolling circle amplification, strand displacement, helicase dependent amplification, loop mediated isothermal amplification, ligase chain reaction, and restriction and circularization aided rolling circle amplification.

[00209] In one embodiment, the one or more capture reagent/s specific to the corresponding biomarkers for use in the histological or cytological evaluation are mixed in a buffered solution that can include any of the following: blocking materials, competitors, detergents, stabilizers, carrier nucleic acid, polyanionic materials, etc.

[00210] A “cytology protocol” generally includes sample collection, sample fixation, sample immobilization, and staining. “Cell preparation” can include several processing steps after sample collection, including the use of one or more aptamers for the staining of the prepared cells.

Determination of Biomarker Levels using Mass Spectrometry Methods

[00211] A variety of configurations of mass spectrometers can be used to detect biomarker levels. Several types of mass spectrometers are available or can be produced with various configurations. In general, a mass spectrometer has the following major components: a sample inlet, an ion source, a mass analyzer, a detector, a vacuum system, and instrument-control system, and a data system. Difference in the sample inlet, ion source, and mass analyzer generally define the type of instrument and its capabilities. For example, an inlet can be a capillary-column liquid chromatography source or can be a direct probe or stage such as used in matrix-assisted laser desorption. Common ion sources are, for example, electrospray, including nanospray and microspray or matrix-assisted laser desorption. Common mass analyzers include a quadrupole mass filter, ion trap mass analyzer and time-of-flight mass analyzer. Additional mass spectrometry methods are well known in the art (see Burlingame et al. *Anal. Chem.* 70:647 R-716R (1998); Kinter and Sherman, New York (2000)).

[00212] Protein biomarkers and biomarker levels can be detected and measured by any of the following: electrospray ionization mass spectrometry (ESI-MS), ESI-MS/MS, ESI-MS/(MS)_n, matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS), surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS), desorption/ionization on silicon (DIOS), secondary ion mass spectrometry (SIMS), quadrupole time-of-flight (Q-TOF), tandem time-of-flight (TOF/TOF) technology, called ultraflex III TOF/TOF, atmospheric pressure chemical ionization mass

spectrometry (APCI-MS), APCI-MS/MS, APCI-(MS)^N, atmospheric pressure photoionization mass spectrometry (APPI-MS), APPI-MS/MS, and APPI-(MS)^N, quadrupole mass spectrometry, Fourier transform mass spectrometry (FTMS), quantitative mass spectrometry, and ion trap mass spectrometry.

[00213] Sample preparation strategies are used to label and enrich samples before mass spectroscopic characterization of protein biomarkers and determination biomarker levels. Labeling methods include but are not limited to isobaric tag for relative and absolute quantitation (iTRAQ) and stable isotope labeling with amino acids in cell culture (SILAC). Capture reagents used to selectively enrich samples for candidate biomarker proteins prior to mass spectroscopic analysis include but are not limited to aptamers, antibodies, nucleic acid probes, chimeras, small molecules, an F(ab')₂ fragment, a single chain antibody fragment, an Fv fragment, a single chain Fv fragment, a nucleic acid, a lectin, a ligand-binding receptor, affybodies, nanobodies, ankyrins, domain antibodies, alternative antibody scaffolds (e.g. diabodies etc) imprinted polymers, avimers, peptidomimetics, peptoids, peptide nucleic acids, threose nucleic acid, a hormone receptor, a cytokine receptor, and synthetic receptors, and modifications and fragments of these.

[00214] The foregoing assays enable the detection of biomarker levels that are useful in the methods described herein, where the methods comprise detecting, in a biological sample from an individual, at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, or at least nine biomarkers selected from the biomarkers in Tables 3, 4, 6, 7, 8, and 9. In various embodiments, the methods comprise detecting the levels of one or more biomarkers selected from any of the groups of biomarkers described herein, such as the panels shown in Table 5 and subsets of the biomarkers shown in Tables 3, 4, 6, 7, 8, and 9. Thus, while some of the described biomarkers may be useful alone for detecting NAFLD and/or NASH, methods are also described herein for the grouping of multiple biomarkers and subsets of the biomarkers to form panels of two or more biomarkers. In accordance with any of the methods described herein, biomarker levels can be detected and classified individually or they can be detected and classified collectively, as for example in a multiplex assay format.

Classification of Biomarkers and Calculation of Disease Scores

[00215] In some embodiments, a biomarker “signature” for a given diagnostic test contains a set of biomarkers, each biomarker having characteristic levels in the populations of interest. Characteristic levels, in some embodiments, may refer to the mean or average of the biomarker levels for the individuals in a particular group. In some embodiments, a diagnostic method described herein can be used to assign an unknown sample from an individual into one

of two groups, either NAFLD or normal. In some embodiments, a diagnostic method described herein can be used to assign an unknown sample from an individual into one of two groups, either NASH or NAFLD. In some embodiments, a diagnostic method described herein can be used to assign an unknown sample from an individual into one of three groups: normal, NAFLD without NASH, and NASH.

[00216] The assignment of a sample into one of two or more groups is known as classification, and the procedure used to accomplish this assignment is known as a classifier or a classification method. Classification methods may also be referred to as scoring methods. There are many classification methods that can be used to construct a diagnostic classifier from a set of biomarker levels. In some instances, classification methods are performed using supervised learning techniques in which a data set is collected using samples obtained from individuals within two (or more, for multiple classification states) distinct groups one wishes to distinguish. Since the class (group or population) to which each sample belongs is known in advance for each sample, the classification method can be trained to give the desired classification response. It is also possible to use unsupervised learning techniques to produce a diagnostic classifier.

[00217] Common approaches for developing diagnostic classifiers include decision trees; bagging + boosting + forests; rule inference based learning; Parzen Windows; linear models; logistic; neural network methods; unsupervised clustering; K-means; hierarchical ascending/descending; semi-supervised learning; prototype methods; nearest neighbor; kernel density estimation; support vector machines; hidden Markov models; Boltzmann Learning; and classifiers may be combined either simply or in ways which minimize particular objective functions. For a review, see, e.g., *Pattern Classification*, R.O. Duda, et al., editors, John Wiley & Sons, 2nd edition, 2001; see also, *The Elements of Statistical Learning - Data Mining, Inference, and Prediction*, T. Hastie, et al., editors, Springer Science+Business Media, LLC, 2nd edition, 2009.

[00218] To produce a classifier using supervised learning techniques, a set of samples called training data are obtained. In the context of diagnostic tests, training data includes samples from the distinct groups (classes) to which unknown samples will later be assigned. For example, samples collected from individuals in a control population and individuals in a particular disease population can constitute training data to develop a classifier that can classify unknown samples (or, more particularly, the individuals from whom the samples were obtained) as either having the disease or being free from the disease. The development of the classifier from the training data is known as training the classifier. Specific details on classifier training depend on the nature of the supervised learning technique. Training a naïve Bayesian classifier

is an example of such a supervised learning technique (see, e.g., Pattern Classification, R.O. Duda, et al., editors, John Wiley & Sons, 2nd edition, 2001; see also, The Elements of Statistical Learning - Data Mining, Inference, and Prediction, T. Hastie, et al., editors, Springer Science+Business Media, LLC, 2nd edition, 2009). Training of a naïve Bayesian classifier is described, e.g., in U.S. Publication Nos: 2012/0101002 and 2012/0077695.

[00219] Since typically there are many more potential biomarker levels than samples in a training set, care must be used to avoid over-fitting. Over-fitting occurs when a statistical model describes random error or noise instead of the underlying relationship. Over-fitting can be avoided in a variety of way, including, for example, by limiting the number of biomarkers used in developing the classifier, by assuming that the biomarker responses are independent of one another, by limiting the complexity of the underlying statistical model employed, and by ensuring that the underlying statistical model conforms to the data.

[00220] An illustrative example of the development of a diagnostic test using a set of biomarkers includes the application of a naïve Bayes classifier, a simple probabilistic classifier based on Bayes theorem with strict independent treatment of the biomarkers. Each biomarker is described by a class-dependent probability density function (pdf) for the measured RFU values or log RFU (relative fluorescence units) values in each class. The joint pdfs for the set of biomarkers in one class is assumed to be the product of the individual class-dependent pdfs for each biomarker. Training a naïve Bayes classifier in this context amounts to assigning parameters (“parameterization”) to characterize the class dependent pdfs. Any underlying model for the class-dependent pdfs may be used, but the model should generally conform to the data observed in the training set.

[00221] The performance of the naïve Bayes classifier is dependent upon the number and quality of the biomarkers used to construct and train the classifier. A single biomarker will perform in accordance with its KS-distance (Kolmogorov-Smirnov). The addition of subsequent biomarkers with good KS distances (>0.3 , for example) will, in general, improve the classification performance if the subsequently added biomarkers are independent of the first biomarker. Using the sensitivity plus specificity as a classifier score, many high scoring classifiers can be generated with a variation of a greedy algorithm. (A greedy algorithm is any algorithm that follows the problem solving metaheuristic of making the locally optimal choice at each stage with the hope of finding the global optimum.)

[00222] Another way to depict classifier performance is through a receiver operating characteristic (ROC), or simply ROC curve or ROC plot. The ROC is a graphical plot of the sensitivity, or true positive rate, vs. false positive rate ($1 - \text{specificity}$ or $1 - \text{true negative rate}$), for a binary classifier system as its discrimination threshold is varied. The ROC can also

be represented equivalently by plotting the fraction of true positives out of the positives (TPR = true positive rate) vs. the fraction of false positives out of the negatives (FPR = false positive rate). Also known as a Relative Operating Characteristic curve, because it is a comparison of two operating characteristics (TPR & FPR) as the criterion changes. The area under the ROC curve (AUC) is commonly used as a summary measure of diagnostic accuracy. It can take values from 0.0 to 1.0. The AUC has an important statistical property: the AUC of a classifier is equivalent to the probability that the classifier will rank a randomly chosen positive instance higher than a randomly chosen negative instance (Fawcett T, 2006. An introduction to ROC analysis. *Pattern Recognition Letters* .27: 861–874). This is equivalent to the Wilcoxon test of ranks (Hanley, J.A., McNeil, B.J., 1982. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology* 143, 29–36.).

[00223] Exemplary embodiments use any number of the biomarkers listed in Table 15 and/or Table 16, with or without one or more biomarkers from Tables 3, 4, 6, 7, 8, and/or 9, in various combinations to produce diagnostic tests for identifying individuals with NAFLD. The biomarkers listed in Tables 3, 4, 6, 7, 8, 9, 15, and 16 can be combined in many ways to produce classifiers. In some embodiments, panels of biomarkers are comprised of different sets of biomarkers depending on a specific diagnostic performance criterion that is selected. For example, certain combinations of biomarkers may produce tests that are more sensitive (or more specific) than other combinations. In some embodiments, a panel of biomarkers for identifying individuals with NAFLD is selected from the panels in Table 5.

[00224] Exemplary embodiments use any number of the biomarkers listed in Table 15 and/or Table 16, with or without one or more biomarkers from Tables 3, 4, 6, 7, 8, and/or 9, in various combinations to produce diagnostic tests for identifying individuals with steatosis. The biomarkers listed in Tables 3, 4, 6, 7, 8, 9, 15, and 16 can be combined in many ways to produce classifiers. In some embodiments, panels of biomarkers are comprised of different sets of biomarkers depending on a specific diagnostic performance criterion that is selected. For example, certain combinations of biomarkers may produce tests that are more sensitive (or more specific) than other combinations. In some embodiments, a panel of biomarkers for identifying individuals with steatosis is selected from the panels in Table 5. In some embodiments, a panel of biomarkers for identifying individuals with steatosis comprises the biomarkers in Table 3. In some embodiments, a panel of biomarkers for identifying individuals with steatosis comprises the biomarkers in Table 8. In some embodiments, a panel of biomarkers for identifying individuals with steatosis comprises at least five biomarkers from Table 15. In some embodiments, a panel of biomarkers for identifying individuals with steatosis comprises at least one, at least two, at least three, at least four, or five biomarkers from Table 16.

[00225] Exemplary embodiments use any number of the biomarkers listed in Table 15 and/or Table 16, with or without one or more additional biomarkers, in various combinations to produce diagnostic tests for identifying individuals with lobular inflammation. In some embodiments, panels of biomarkers are comprised of different sets of biomarkers depending on a specific diagnostic performance criterion that is selected. For example, certain combinations of biomarkers may produce tests that are more sensitive (or more specific) than other combinations. In some embodiments, a panel of biomarkers for identifying individuals with lobular inflammation comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or eight biomarkers selected from ACY1, THBS2, COLEC11, ITGA1/ITGB1, CSF1R, KYNU, FCGR3B, and POR. In some embodiments, a panel of biomarkers for identifying individuals with lobular inflammation comprises ACY1, THBS2, COLEC11 and at least one or two additional biomarker selected from ITGA1/ITGB1 and POR.

[00226] Exemplary embodiments use any number of the biomarkers listed in Table 15 and/or Table 16, with or without one or more additional biomarkers, in various combinations to produce diagnostic tests for identifying individuals with hepatocyte ballooning. In some embodiments, panels of biomarkers are comprised of different sets of biomarkers depending on a specific diagnostic performance criterion that is selected. For example, certain combinations of biomarkers may produce tests that are more sensitive (or more specific) than other combinations. In some embodiments, a panel of biomarkers for identifying individuals with hepatocyte ballooning comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or eight biomarkers selected from ACY1, COLEC11, THBS2, ITGA1/ITGB1, C7, POR, LGALS3BP, and HSP90AA1/HSP90AB1. In some embodiments, a panel of biomarkers for identifying individuals with hepatocyte ballooning comprises ACY1, COLEC11, THBS2 and at least one or two additional biomarker selected from ITGA1/ITGB1 and HSP90AA1/HSP90AB1.

[00227] Exemplary embodiments use any number of the biomarkers listed in Table 15 and/or Table 16, with or without one or more additional biomarkers, in various combinations to produce diagnostic tests for identifying individuals with fibrosis. In some embodiments, panels of biomarkers are comprised of different sets of biomarkers depending on a specific diagnostic performance criterion that is selected. For example, certain combinations of biomarkers may produce tests that are more sensitive (or more specific) than other combinations. In some embodiments, a panel of biomarkers for identifying individuals with fibrosis comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, or fourteen biomarkers selected from C7, COLEC11, THBS2, ITGA1/ITGB1, HSP90AA1/HSP90AB1, ACY1, CSF1R,

KYNU, POR, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and DCN. In some embodiments, a panel of biomarkers for identifying individuals with fibrosis comprises C7, COLEC11, THBS2 and at least one, at least two or three additional biomarker selected from ITGA1/ITGB1, HSP90AA1/HSP90AB1 and DCN.

[00228] Exemplary embodiments use any number of the biomarkers listed in Table 15 and/or Table 16, with or without one or more additional biomarkers, in various combinations to produce diagnostic tests for identifying individuals with NASH. The biomarkers listed in Tables 3, 4, 6, 7, 8, 9, 15, and 16 can be combined in many ways to produce classifiers. In some embodiments, panels of biomarkers are comprised of different sets of biomarkers depending on a specific diagnostic performance criterion that is selected. For example, certain combinations of biomarkers may produce tests that are more sensitive (or more specific) than other combinations. In some embodiments, a panel of biomarkers for identifying individuals with NASH comprises N biomarker proteins from the biomarker proteins listed in Table 15 and/or Table 16, wherein N is at least 5.

[00229] Exemplary embodiments use any number of the biomarkers listed in Table 15 and/or Table 16, with or without one or more additional biomarkers, in various combinations to produce diagnostic tests for identifying individuals with NAFLD, steatosis, and/or NASH. The biomarkers listed in Tables 3, 4, 6, 7, 8, 9, 15, and 16 can be combined in many ways to produce classifiers. In some embodiments, panels of biomarkers are comprised of different sets of biomarkers depending on a specific diagnostic performance criterion that is selected. For example, certain combinations of biomarkers may produce tests that are more sensitive (or more specific) than other combinations. In some embodiments, a panel of biomarkers for identifying individuals with NAFLD, steatosis, and/or NASH is selected from the panels in Table 5. In some embodiments, a panel of biomarkers for identifying individuals with NAFLD, steatosis, and/or NASH comprises N biomarker proteins from the biomarker proteins listed in Table 15 and/or Table 16, wherein N is at least 5.

[00230] In some embodiments, once a panel is defined to include a particular set of biomarkers from Table 15 and/or Table 16, with or without one or more additional biomarkers, and a classifier is constructed from a set of training data, the diagnostic test parameters are complete. In some embodiments, a biological sample is run in one or more assays to produce the relevant quantitative biomarker levels used for classification. The measured biomarker levels are used as input for the classification method that outputs a classification and an optional score for the sample that reflects the confidence of the class assignment.

[00231] In some embodiments, a biological sample is optionally diluted and run in a multiplexed aptamer assay, and data is assessed as follows. First, the data from the assay are

optionally normalized and calibrated, and the resulting biomarker levels are used as input to a Bayes classification scheme. Second, the log-likelihood ratio is computed for each measured biomarker individually and then summed to produce a final classification score, which is also referred to as a diagnostic score. The resulting assignment as well as the overall classification score can be reported. In some embodiments, the individual log-likelihood risk factors computed for each biomarker level can be reported as well.

Kits

[00232] Any combination of the biomarkers described herein can be detected using a suitable kit, such as for use in performing the methods disclosed herein. Furthermore, any kit can contain one or more detectable labels as described herein, such as a fluorescent moiety, etc.

[00233] In some embodiments, a kit includes (a) one or more capture reagents (such as, for example, at least one aptamer or antibody) for detecting one or more biomarkers in a biological sample, and optionally (b) one or more software or computer program products for predicting whether the individual from whom the biological sample was obtained has NAFLD, steatosis, and/or NASH (such as stage 1, 2, 3, or 4 NASH, or stage 2, 3, or 4 NASH). Alternatively, rather than one or more computer program products, one or more instructions for manually performing the above steps by a human can be provided.

[00234] In some embodiments, a kit comprises a solid support, a capture reagent, and a signal generating material. The kit can also include instructions for using the devices and reagents, handling the sample, and analyzing the data. Further the kit may be used with a computer system or software to analyze and report the result of the analysis of the biological sample.

[00235] The kits can also contain one or more reagents (e.g., solubilization buffers, detergents, washes, or buffers) for processing a biological sample. Any of the kits described herein can also include, e.g., buffers, blocking agents, mass spectrometry matrix materials, antibody capture agents, positive control samples, negative control samples, software and information such as protocols, guidance and reference data.

[00236] In some embodiments, kits are provided for the analysis of NAFLD and/or NASH, wherein the kits comprise PCR primers for one or more biomarkers described herein. In some embodiments, a kit may further include instructions for use and correlation of the biomarkers with NAFLD and/or NASH prognosis. In some embodiments, a kit may include a DNA array containing the complement of one or more of the biomarkers described herein, reagents, and/or enzymes for amplifying or isolating sample DNA. The kits may include reagents for real-time PCR, for example, TaqMan probes and/or primers, and enzymes.

[00237] For example, a kit can comprise (a) reagents comprising at least one capture reagent for determining the level of one or more biomarkers in a test sample, and optionally (b) one or more algorithms or computer programs for performing the steps of comparing the amount of each biomarker quantified in the test sample to one or more predetermined cutoffs. In some embodiments, an algorithm or computer program assigns a score for each biomarker quantified based on said comparison and, in some embodiments, combines the assigned scores for each biomarker quantified to obtain a total score. Further, in some embodiments, an algorithm or computer program compares the total score with a predetermined score, and uses the comparison to determine whether the individual has NAFLD, steatosis and/or NASH. Alternatively, rather than one or more algorithms or computer programs, one or more instructions for manually performing the above steps by a human can be provided.

Computer Methods and Software

[00238] Once a biomarker or biomarker panel is selected, a method for assessing NAFLD in an individual may comprise the following: 1) collect or otherwise obtain a biological sample; 2) perform an analytical method to detect and measure the biomarker or biomarkers in the panel in the biological sample; and 3) report the results of the biomarker levels. In some embodiments, the results of the biomarker levels are reported qualitatively rather than quantitatively, such as, for example, a proposed diagnosis (“NAFLD,” “steatosis,” “NASH,” “NASH stage 2, 3 or 4,” etc.) or simply a positive / negative result where “positive” and “negative” are defined. In some embodiments, a method for assessing NAFLD in an individual may comprise the following: 1) collect or otherwise obtain a biological sample; 2) perform an analytical method to detect and measure the biomarker or biomarkers in the panel in the biological sample; 3) perform any data normalization or standardization; 4) calculate each biomarker level; and 5) report the results of the biomarker levels. In some embodiments, the biomarker levels are combined in some way and a single value for the combined biomarker levels is reported. In this approach, in some embodiments, the reported value may be a single number determined from the sum of all the biomarker calculations that is compared to a pre-set threshold value that is an indication of the presence or absence of disease. Or the diagnostic score may be a series of bars that each represent a biomarker value and the pattern of the responses may be compared to a pre-set pattern for determination of the presence or absence of disease.

[00239] At least some embodiments of the methods described herein can be implemented with the use of a computer. An example of a computer system 100 is shown in Figure 9. With reference to Figure 9, system 100 is shown comprised of hardware elements that are electrically

coupled via bus 108, including a processor 101, input device 102, output device 103, storage device 104, computer-readable storage media reader 105a, communications system 106 processing acceleration (e.g., DSP or special-purpose processors) 107 and memory 109. Computer-readable storage media reader 105a is further coupled to computer-readable storage media 105b, the combination comprehensively representing remote, local, fixed and/or removable storage devices plus storage media, memory, etc. for temporarily and/or more permanently containing computer-readable information, which can include storage device 104, memory 109 and/or any other such accessible system 100 resource. System 100 also comprises software elements (shown as being currently located within working memory 191) including an operating system 192 and other code 193, such as programs, data and the like.

[00240] With respect to Figure 9, system 100 has extensive flexibility and configurability. Thus, for example, a single architecture might be utilized to implement one or more servers that can be further configured in accordance with currently desirable protocols, protocol variations, extensions, etc. However, it will be apparent to those skilled in the art that embodiments may well be utilized in accordance with more specific application requirements. For example, one or more system elements might be implemented as sub-elements within a system 100 component (e.g., within communications system 106). Customized hardware might also be utilized and/or particular elements might be implemented in hardware, software or both. Further, while connection to other computing devices such as network input/output devices (not shown) may be employed, it is to be understood that wired, wireless, modem, and/or other connection or connections to other computing devices might also be utilized.

[00241] In one aspect, the system can comprise a database containing features of biomarkers characteristic of NAFLD and/or NASH. The biomarker data (or biomarker information) can be utilized as an input to the computer for use as part of a computer implemented method. The biomarker data can include the data as described herein.

[00242] In one aspect, the system further comprises one or more devices for providing input data to the one or more processors.

[00243] The system further comprises a memory for storing a data set of ranked data elements.

[00244] In another aspect, the device for providing input data comprises a detector for detecting the characteristic of the data element, e.g., such as a mass spectrometer or gene chip reader.

[00245] The system additionally may comprise a database management system. User requests or queries can be formatted in an appropriate language understood by the database

management system that processes the query to extract the relevant information from the database of training sets.

[00246] The system may be connectable to a network to which a network server and one or more clients are connected. The network may be a local area network (LAN) or a wide area network (WAN), as is known in the art. Preferably, the server includes the hardware necessary for running computer program products (e.g., software) to access database data for processing user requests.

[00247] The system may include an operating system (e.g., UNIX[®] or Linux) for executing instructions from a database management system. In one aspect, the operating system can operate on a global communications network, such as the internet, and utilize a global communications network server to connect to such a network.

[00248] The system may include one or more devices that comprise a graphical display interface comprising interface elements such as buttons, pull down menus, scroll bars, fields for entering text, and the like as are routinely found in graphical user interfaces known in the art. Requests entered on a user interface can be transmitted to an application program in the system for formatting to search for relevant information in one or more of the system databases. Requests or queries entered by a user may be constructed in any suitable database language.

[00249] The graphical user interface may be generated by a graphical user interface code as part of the operating system and can be used to input data and/or to display inputted data. The result of processed data can be displayed in the interface, printed on a printer in communication with the system, saved in a memory device, and/or transmitted over the network or can be provided in the form of the computer readable medium.

[00250] The system can be in communication with an input device for providing data regarding data elements to the system (e.g., expression values). In one aspect, the input device can include a gene expression profiling system including, e.g., a mass spectrometer, gene chip or array reader, and the like.

[00251] The methods and apparatus for analyzing biomarker information according to various embodiments may be implemented in any suitable manner, for example, using a computer program operating on a computer system. A conventional computer system comprising a processor and a random access memory, such as a remotely-accessible application server, network server, personal computer or workstation may be used. Additional computer system components may include memory devices or information storage systems, such as a mass storage system and a user interface, for example a conventional monitor, keyboard and tracking device. The computer system may be a stand-alone system or part of a network of computers including a server and one or more databases.

[00252] The biomarker analysis system can provide functions and operations to complete data analysis, such as data gathering, processing, analysis, reporting and/or diagnosis. For example, in one embodiment, the computer system can execute the computer program that may receive, store, search, analyze, and report information relating to the biomarkers. The computer program may comprise multiple modules performing various functions or operations, such as a processing module for processing raw data and generating supplemental data and an analysis module for analyzing raw data and supplemental data to generate a disease status and/or diagnosis. Identifying NAFLD, steatosis, and/or NASH may comprise generating or collecting any other information, including additional biomedical information, regarding the condition of the individual relative to the disease, identifying whether further tests may be desirable, or otherwise evaluating the health status of the individual.

[00253] Some embodiments described herein can be implemented so as to include a computer program product. A computer program product may include a computer readable medium having computer readable program code embodied in the medium for causing an application program to execute on a computer with a database.

[00254] As used herein, a “computer program product” refers to an organized set of instructions in the form of natural or programming language statements that are contained on a physical media of any nature (e.g., written, electronic, magnetic, optical or otherwise) and that may be used with a computer or other automated data processing system. Such programming language statements, when executed by a computer or data processing system, cause the computer or data processing system to act in accordance with the particular content of the statements. Computer program products include without limitation: programs in source and object code and/or test or data libraries embedded in a computer readable medium.

Furthermore, the computer program product that enables a computer system or data processing equipment device to act in pre-selected ways may be provided in a number of forms, including, but not limited to, original source code, assembly code, object code, machine language, encrypted or compressed versions of the foregoing and any and all equivalents.

[00255] In one aspect, a computer program product is provided for indicating whether an individual has NAFLD, whether an individual has steatosis, and/or whether an individual has NASH (such as stage 1, 2, 3, or 4 NASH, or stage 2, 3, or 4 NASH). The computer program product includes a computer readable medium embodying program code executable by a processor of a computing device or system, the program code comprising: code that retrieves data attributed to a biological sample from an individual, wherein the data comprises biomarker levels that correspond to one or more of the biomarkers described herein, and code that executes

a classification method that indicates the NAFLD, steatosis, and/or NASH status of the individual as a function of the biomarker levels.

[00256] While various embodiments have been described as methods or apparatuses, it should be understood that embodiments can be implemented through code coupled with a computer, e.g., code resident on a computer or accessible by the computer. For example, software and databases could be utilized to implement many of the methods discussed above. Thus, in addition to embodiments accomplished by hardware, it is also noted that these embodiments can be accomplished through the use of an article of manufacture comprised of a computer usable medium having a computer readable program code embodied therein, which causes the enablement of the functions disclosed in this description. Therefore, it is desired that embodiments also be considered protected by this patent in their program code means as well. Furthermore, the embodiments may be embodied as code stored in a computer-readable memory of virtually any kind including, without limitation, RAM, ROM, magnetic media, optical media, or magneto-optical media. Even more generally, the embodiments could be implemented in software, or in hardware, or any combination thereof including, but not limited to, software running on a general purpose processor, microcode, programmable logic arrays (PLAs), or application-specific integrated circuits (ASICs).

[00257] It is also envisioned that embodiments could be accomplished as computer signals embodied in a carrier wave, as well as signals (e.g., electrical and optical) propagated through a transmission medium. Thus, the various types of information discussed above could be formatted in a structure, such as a data structure, and transmitted as an electrical signal through a transmission medium or stored on a computer readable medium.

Methods of Treatment

[00258] In some embodiments, following a determination that a subject has NAFLD, steatosis, or NASH, the subject undergoes a therapeutic regimen to delay or prevent worsening of the disease. Nonlimiting exemplary therapeutic regimens for NAFLD, steatosis, and/or NASH include weight loss, blood sugar control, and alcohol avoidance. In some embodiments, a subject is given a therapeutic agent, such as pioglitazone, vitamin E, and/or metformin. *See, e.g., Sanyal et al., 2010, NEJM, 362: 1675-1685.* In some embodiments, a subject undergoes gastric bypass (or similar) surgery, for example, in order to accelerate weight loss.

[00259] In some embodiments, methods of monitoring NAFLD are provided. In some embodiments, the present methods of determining whether a subject has NAFLD are carried out at a time 0. In some embodiments, the method is carried out again at a time 1, and optionally, a time 2, and optionally, a time 3, etc., in order to monitor the progression of the NAFLD in the

subject. In some embodiments, different biomarkers are used at different time points, depending on the current state of the individual's disease and/or depending on the rate at which the disease is believed or predicted to progress.

Other Methods

[00260] In some embodiments, the biomarkers and methods described herein are used to determine a medical insurance premium and/or a life insurance premium. In some embodiments, the results of the methods described herein are used to determine a medical insurance premium and/or a life insurance premium. In some such instances, an organization that provides medical insurance or life insurance requests or otherwise obtains information concerning a subject's NAFLD or NASH status and uses that information to determine an appropriate medical insurance or life insurance premium for the subject. In some embodiments, the test is requested by, and paid for by, the organization that provides medical insurance or life insurance.

[00261] In some embodiments, the biomarkers and methods described herein are used to predict and/or manage the utilization of medical resources. In some such embodiments, the methods are not carried out for the purpose of such prediction, but the information obtained from the method is used in such a prediction and/or management of the utilization of medical resources. For example, a testing facility or hospital may assemble information from the present methods for many subjects in order to predict and/or manage the utilization of medical resources at a particular facility or in a particular geographic area.

EXAMPLES

[00262] The following examples are provided for illustrative purposes only and are not intended to limit the scope of the application as defined by the appended claims. Routine molecular biology techniques described in the following examples can be carried out as described in standard laboratory manuals, such as Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 3rd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (2001).

Example 1. NAFLD Study Subjects

[00263] The samples used for identifying biomarkers were from Geisinger Health. Serum samples were collected and liver biopsies were performed on 576 obese patients before they underwent bariatric surgery for weight loss.

[00264] Samples were collected in red top serum tubes and processed per protocol; briefly, a sample was allowed to clot for 30 minutes at room temperature, and then centrifuged at 1300xg for 10 minutes and the top layer was removed and stored at -80°C. Samples were thawed once for aliquoting and once for the assay.

[00265] In order to identify biomarkers that will distinguish subjects with NAFLD from normal obese subjects, and biomarkers that will distinguish subjects with NASH from subjects with steatosis in the liver, the study subjects were divided into normal, three levels of liver steatosis (mild, moderate, and severe steatosis), and four stages of NASH according to the liver biopsy results, using the Brunt classification method (Brunt et al., 2007, *Modern Pathol.*, 20: S40-S48). The groups were subclassified as shown in Table 1.

Table 1: Subclassification of steatosis and NASH stage groups

Group	Steatosis	Inflammation	Ballooning	Fibrosis
Obese controls	0	0	0	0
Mild steatosis	1	0 or 1	0	0
Moderate steatosis	2	0, 1 or 2	0	0
Severe steatosis	3	0, 1 or 2	0	0
NASH stage 1	1, 2 or 3	0, 1 or 2	1	0 or 1
NASH stage 2	1, 2 or 3	0, 1 or 2	2	2
NASH stage 3 (bridging)	1, 2 or 3	0, 1 or 2	2	3
NASH stage 4 (cirrhosis)	1, 2 or 3	0, 1 or 2	2	4

Subject Demographics

[00266] Certain characteristics for the individuals in each of the groups discussed above are shown in Table 2.

Table 2: Subject demographics

Group	# Female	# Male	Total	# Blinded	Age at biopsy, mean years	BMI, mean kg/m ²	LDL, mean mg/dl	% with Diabetes
Control	111	14	125	41	44.59	46.8	107.86	28 (22.4%)
Mild Steatosis	44	7	51	16	45.75	46.6	112.12	15 (29.4%)
Moderate Steatosis	25	7	32	10	44.5	44.77	103.29	12 (37.5%)
Severe Steatosis	45	9	54	17	47.11	47.75	101.11	23 (42.6%)
NASH Stage 1	93	20	113	37	46.69	47.29	103.37	58(51.3%)
NASH Stage 2	27	11	38	12	48.52	48.9	109.74	22 (57.9%)
NASH Stage 3	12	8	20	0	50.05	46.27	101.06	17(85%)
NASH Stage 4	6	4	10	0	48.7	47.22	101.9	5 (50%)
Total	363	80	443					

[00267] As shown in Table 2, age, body mass index, and LDL levels were determined for the subjects, and found to be balanced across all groups.

Example 2. Multiplex Aptamer Assay for Biomarker Identification

[00268] The sample quality of the normal, NAFLD, and NASH samples in the groups mentioned above were assessed by comparing distributions of biomarkers associated with sample handling, such as shear, cell lysis, and complement activation in the cases and controls. The sample quality was good, and there was no case control bias.

[00269] A multiplex aptamer assay was used to analyze the samples and controls to identify biomarkers predictive of NAFLD and NASH. The multiplexed analysis used in this experiment included aptamers to detect 1129 proteins in blood from small sample volumes (~65 μ l of serum or plasma), with low limits of detection (1 pM median), ~7 logs of dynamic range, and ~5% median coefficient of variation. The multiplex aptamer assay is described, e.g., in Gold et al. (2010) Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery. PLoS ONE 5(12): e15004; and U.S. Publication Nos: 2012/0101002 and 2012/0077695.

[00270] Stability Selection takes many subsets of half the data and performs biomarker selection using the lasso classifier, which is a regularized logistic regression model. See, e.g., Meinshausen et al., 2010, *J. Royal Statistical Soc: Series B (Statistical Methodology)*, 72: 417-473. The selection path for a single biomarker is the proportion of these subsets for which that biomarker was selected by the lasso model over a range of lambda. Lambda is a tuning parameter which determines how many biomarkers are selected by the lasso. The maximum selection probability over a range of lambda values is the ultimate metric used to select a set of biomarkers.

[00271] Candidate biomarkers were identified by stability selection, which were then used to generate the random forest classifier model. See, e.g., Shi et al., *J. Comput. Graph. Stat.* 15(1): 118-138 (2006). Briefly, a random forest predictor is an ensemble of individual classification tree predictors. See, e.g., Breiman, *Machine Learning*, 45(1): 5-32 (2001). For each observation, each individual tree votes for one class and the forest predicts the class that has the plurality of votes. The user specifies the number of randomly selected variables (mtry) to be searched through for the best split at each node. The Gini index is used as the splitting criterion. See, e.g., Breiman et al., *Classification and Regression Trees*, Chapman and Hall, New York, 1984. The largest tree possible is grown and is not pruned. The root node of each tree in the forest contains a bootstrap sample from the original data as the training set. The observations that are not in the training set, roughly 1/3 of the original data set, are referred to as out-of-bag (OOB) observations. One can arrive at OOB predictions as follows: for a case in the original data, predict the outcome by plurality vote involving only those trees that did not contain the case in their corresponding bootstrap sample. By contrasting these OOB predictions with the

training set outcomes, one can arrive at an estimate of the prediction error rate, which is referred to as the OOB error rate.

[00272] Univariate analysis was performed using the non-parametric Kolmogorov-Smirnov test (KS statistics), which quantifies the distance between the cumulative distribution function of each aptamer for two reference distributions designated case (mild, moderate and severe steatosis and/or NASH 1-4) and control (normal obese). The performance of the random forest classifier is dependent upon the number and quality of the biomarkers used to construct and train the classifier. A single biomarker will perform in accordance with its KS-distance and its PCA (principal component analysis) value as exemplified herein. If a classifier performance metric is defined as the sum of the sensitivity (fraction of true positives, f_{TP}) and specificity (one minus the fraction of false positives, $1 - f_{FP}$), a perfect classifier will have a score of two and a random classifier, on average, will have a score of one. Using the definition of the KS-distance, that value x^* which maximizes the difference in the cdf (cumulative distribution function) functions can be found by solving

$$\frac{\partial KS}{\partial x} = \frac{\partial(cdf_c(x) - cdf_d(x))}{\partial x} = 0$$

for x which leads to $p(x^* | c) = p(x^* | d)$, i.e., the KS distance occurs where the class-dependent pdfs (probability density functions) cross. Substituting this value of x^* into the expression for the KS-distance yields the following definition for KS

$$\begin{aligned} KS &= cdf_c(x^*) - cdf_d(x^*) \\ &= \int_{-\infty}^{x^*} p(x|c)dx - \int_{-\infty}^{x^*} p(x|d)dx \\ &= 1 - \int_{x^*}^{\infty} p(x|c)dx - \int_{-\infty}^{x^*} p(x|d)dx \\ &= 1 - f_{FP} - f_{FN}, \end{aligned}$$

the KS distance is one minus the total fraction of errors using a test with a cut-off at x^* , essentially a single analyte Bayesian classifier. Since we define a score of $sensitivity + specificity = 2 - f_{FP} - f_{FN}$, combining the above definition of the KS-distance we see that $sensitivity + specificity = 1 + KS$. We select biomarkers with a statistic that is inherently suited for building classifiers.

[00273] The addition of subsequent biomarkers with good KS distances (>0.3 , for example) will, in general, improve the classification performance if the subsequently added biomarkers are independent of the first biomarker. Using the sensitivity plus specificity as a classifier score, many high scoring classifiers may be generated.

A. Steatosis Classifier

[00274] Based on the subject classifications, we assumed that all steatosis groups as well as NASH stages 1-4 have fat in the liver cells. A classifier (steatosis, or fat in the liver) was developed by comparing obese normal subjects to all NAFLD subjects.

[00275] Markers chosen by stability selection (see Figure 1) were supplied to a random forest algorithm to generate a model. The resulting ROC curve is provided (see below).

[00276] A ROC curve for a nine marker classifier for NAFLD (steatosis) is shown in Figure 2. The area under the curve (AUC) was 0.90 ± 0.03 . The sensitivity was 92% and the specificity was 63%, with a cutoff of 0.5.

[00277] The probability score, i.e. $\text{Prob}(\text{Steatosis})$, from the model of each classifier was plotted for each individual across all groups to assess whether it could be used as a severity/monitoring model in addition to the binary decision on which it was constructed (Figure 3). The plot shows a clear discrimination between no steatosis and steatosis and probability vote increases with the level of steatosis. NASH subjects at all stages have severe steatosis.

[00278] Figure 4 shows the cumulative distribution functions (CDFs) for the 9 biomarkers in the classifier.

[00279] Table 3 shows the biomarkers in the 9-marker classifier. Table 3 also provides an alternate name for certain biomarkers, the gene name, and the UniProt accession number for each biomarker, and whether the biomarker is present at higher or lower levels in the NAFLD population, as compared to the normal population.

Table 3: Nine biomarker classifier for NAFLD

Biomarker/Aliases	Gene Name	UniProt	Biomarker level higher / lower in all NAFLD population
Aminoacylase-1	ACY1	Q03154	Higher
Sex hormone-binding globulin	SHBG	P04278	Lower
Cathepsin Z, Cathepsin P, Cathepsin X	CTSZ	Q9UBR2	Higher
c-met, Hepatocyte growth factor receptor, Met proto-oncogene	MET	P08581	Lower

tyrosine kinase			
Gelsolin	GSN	P06396	Lower
Galectin-3 binding protein, Lectin galactoside-binding soluble 3-binding protein	LGALS3BP	Q08380	Higher
Tissue-type plasminogen activator, tPA	PLAT	P00750	Higher
Neural cell adhesion molecule L1-like protein	CHL1	O00533	Lower
Antithrombin III	SERPINC1	P01008	Lower

[00280] Figure 3 shows box plots for the nine biomarker classifier in each of the subject groups (from left to right: normal, mild steatosis, moderate steatosis, severe steatosis, NASH1, NASH2, NASH3, NASH4). The black line within each box represents the median (or 50th percentile) of the data points, and the box itself represents the inter-quartile range (IQR), the area encompassing data points from the 25th to 75th percentile. The whiskers extend to cover data points within 1.5 x IQR of the top and bottom of the box.

B. NASH (Fibrosis) Classifier

[00281] All subjects with NASH have some form of inflammation and ballooning associated with fibrosis. We therefore compared all steatosis groups with NASH stages 2, 3 and 4. To ensure identification of true fibrosis biomarkers, the NASH stage 1 group was excluded.

[00282] Markers chosen by stability selection (Figure 5) were supplied to a random forest algorithm to generate a model. The resulting ROC is provided below.

[00283] A ROC curve for the four marker classifier for NASH stages 2, 3, and 4 (fibrosis) is shown in Figure 6. The area under the curve (AUC) was 0.82 +/- 0.07, with a sensitivity of 62% and a specificity of 92% at a cutoff of 0.5.

[00284] The probability score, i.e. Prob(Steatosis), from the model of each classifier was plotted for each individual across all groups to assess whether it could be used as a severity/monitoring model in addition to the binary decision on which it was constructed (Figure 7). The plot shows a clear discrimination between no steatosis and steatosis and probability vote increases with the level of steatosis. NASH subjects at all stages have severe steatosis.

[00285] Table 4 shows the biomarkers in the 4-marker classifier. Table 4 also provides an alternate name for certain biomarkers, the gene name, and the UniProt accession number for

each biomarker, and whether the biomarker is present at higher or lower levels in the NASH 2, 3, and 4 populations, as compared to all NAFLD populations.

Table 4: Four biomarker classifier for NASH stages 2, 3, and 4 versus steatosis (NAFLD)

Biomarker/Aliases	Gene Name	UniProt	Biomarker level higher / lower in fibrosis (NASH) population
Complement C7	C7	P10643	Higher
Collectin Kidney 1	COLEC11	Q9BWP8	Higher
Peptidylprolyl isomerase D	PPID	Q08752	Lower
Insulin-like growth factor-binding protein 3	IGFBP3	P17936	Lower

[00286] Figure 7 shows box plots for the four biomarker classifier in each of the subject groups (from left to right: normal, mild steatosis, moderate steatosis, severe steatosis, NASH1, NASH2, NASH3, NASH4). The black line within each box represents the median (or 50th percentile) of the data points, and the box itself represents the inter-quartile range (IQR), the area encompassing data points from the 25th to 75th percentile. The whiskers extend to cover data points within 1.5 x IQR of the top and bottom of the box.

[00287] Figure 8 shows the CDFs for the 4 biomarkers in the classifier.

Example 3. Additional Biomarkers and Classifiers for NAFLD and/or NASH

[00288] Stability Selection takes many subsets of half the data and performs biomarker selection using the lasso classifier, which is a regularized logistic regression model. See, e.g., Meinshausen et al., 2010, *J. Royal Statistical Soc: Series B (Statistical Methodology)*, 72: 417-473. The selection path for a single biomarker is the proportion of these subsets for which that biomarker was selected by the lasso model over a range of lambda. Lambda is a tuning parameter which determines how many biomarkers are selected by the lasso. The maximum selection probability over a range of lambda values is the ultimate metric used to select a set of biomarkers.

[00289] Using the stability selection method, additional classifiers were defined to distinguish various groups of individuals. The classifiers (including the classifiers discussed above) are shown in Table 5. Markers from comparisons 2 and 5 were used to build a random forest classifier for steatosis (NAFLD) and fibrosis (NASH), as discussed above.

Table 5. Classifiers obtained using stability selection

	Comparison	Sensitivity	Specificity	Markers
1	Control versus NASH stage 1 to 4	0.8641304	0.8196721	ACY1, SHBG, LGALS3BP, SIGLEC7, CTSZ, MET, GSN

2	Control versus (All steatosis + NASH stage 1-4)	0.8635015	0.7452830	ACY1, SHBG, CTSZ, MET, GSN, LGALS3BP, PLAT, CHL1, SERPINC1
3	Control versus All steatosis	0.7664234	0.7440000	ACY1, SHBG, SIGLEC14
4	All steatosis versus NASH 1	0.4901961	0.5743243	TOP1, SIGLEC14
5	All steatosis versus NASH stage 2-4	0.7543860	0.8310811	C7, COLEC11, PPID, IGFBP3
6	All steatosis versus NASH stage 1-4	0.6734694	0.5983607	SIGLEC14, AIMP1, TOP1, COLEC11, CA6, STX1A

*All Steatosis: mild, moderate and severe steatosis

[00290] Comparison 1 in Table 5 shows a 7-marker classifier that distinguishes control subjects from NASH stages 1 to 4 with 86.4% sensitivity and 82% specificity. Comparison 3 shows a 3-marker classifier that distinguishes control subjects versus all steatosis (mild, moderate, and severe) with 76.6% sensitivity and 74.4 % specificity.

[00291] Further information on the biomarkers listed in Table 5 that are not in Tables 3 and 4, above, is shown in Table 6.

Table 6: Additional biomarkers for NAFLD and/or NASH

Biomarker/Aliases	Gene Name	UniProt	Biomarker level higher / lower in NASH versus steatosis versus obese controls
Sialic acid-binding Ig-like lectin 7	SIGLEC 7	Q9Y286	Higher
Siglec-14	SIGLEC14	Q08ET2	Higher
Topoisomerase I	TOP1	P11387	Lower
Endothelial-Monocyte Activating Polypeptide 2 (EMAP-2)	AIMP1	Q12904	Lower
Carbonic anhydrase 6	CA6	Q16623	Lower
Syntaxin 1A	STX1A	Q9Y286	Lower

[00292] The top 25 biomarkers by univariate KS distance for the control group versus NASH stages 1 to 4 are shown in Table 7. These biomarkers, and combinations of these biomarkers, can be used to separate control subjects (such as obese subjects) from subjects with NASH and/or to separate control subjects from subjects with steatosis.

Table 7: Top 25 biomarkers

Biomarker	Signed ks distance	UniProt	Biomarker level higher / lower in NASH versus obese controls
ACY1	0.61843	Q03154	Higher
THBS2	0.48071	P35442	Higher
LGALS3BP	0.44946	Q08380	Higher
KYNU	0.44146	Q16719	Higher
COLEC11	0.43708	Q9BWP8	Higher
CTSZ	0.42166	Q9UBR2	Higher
IL19	0.41688	Q9UHD0	Higher
POR	0.41021	P16435	Higher
INS	0.40888	P01308	Higher
SHBG	-0.39253	P04278	Lower
GPT	0.37459	Q9H3H5	Higher
GNS	0.37136	P15586	Higher
RET	0.37043	P07949	Higher
AFM	0.36986	P43652	Higher
SELE	0.36239	P16581	Higher
CD163	0.36146	Q86VB7	Higher
ENPP7	0.35518	Q6UWV6	Higher
IGFBP7	0.35063	Q16270	Higher
GSN	-0.34851	P06396	Lower
SIGLEC7	0.34564	Q9Y286	Higher
LAMA1.LAMB1.LAMC1	0.33401	P25391 P07942 P11047	Higher
IL18R1	0.31973	Q13478	Higher
FN1	0.31898	P02751	Higher
TGFBI	0.31823	Q15582	Higher
AKR1A1	0.31421	P14550	Higher

Example 4: Exemplary Biomarker Detection Using Aptamers

[00293] An exemplary method of detecting one or more biomarkers in a sample is described, e.g., in Kraemer et al., *PLoS One* 6(10): e26332, and is described below. Three different methods of quantification: microarray-based hybridization, a Luminex bead-based method, and qPCR, are described.

Reagents

[00294] HEPES, NaCl, KCl, EDTA, EGTA, MgCl₂ and Tween-20 may be purchased, e.g., from Fisher Biosciences. Dextran sulfate sodium salt (DxSO₄), nominally 8000 molecular weight, may be purchased, e.g., from AIC and is dialyzed against deionized water for at least 20 hours with one exchange. KOD EX DNA polymerase may be purchased, e.g., from VWR. Tetramethylammonium chloride and CAPSO may be purchased, e.g., from Sigma-Aldrich and streptavidin-phycoerythrin (SAPE) may be purchased, e.g., from Moss Inc. 4-(2-Aminoethyl)-

benzenesulfonylfluoride hydrochloride (AEBSF) may be purchased, e.g., from Gold Biotechnology. Streptavidin-coated 96-well plates may be purchased, e.g., from Thermo Scientific (Pierce Streptavidin Coated Plates HBC, clear, 96-well, product number 15500 or 15501). NHS-PEO4-biotin may be purchased, e.g., from Thermo Scientific (EZ-Link NHS-PEO4-Biotin, product number 21329), dissolved in anhydrous DMSO, and may be stored frozen in single-use aliquots. IL-8, MIP-4, Lipocalin-2, RANTES, MMP-7, and MMP-9 may be purchased, e.g., from R&D Systems. Resistin and MCP-1 may be purchased, e.g., from PeproTech, and tPA may be purchased, e.g., from VWR.

Nucleic acids

[00295] Conventional (including amine- and biotin-substituted) oligodeoxynucleotides may be purchased, e.g., from Integrated DNA Technologies (IDT). Z-Block is a single-stranded oligodeoxynucleotide of sequence 5'-(AC-BnBn)₇-AC-3', where Bn indicates a benzyl-substituted deoxyuridine residue. Z-block may be synthesized using conventional phosphoramidite chemistry. Aptamer capture reagents may also be synthesized by conventional phosphoramidite chemistry, and may be purified, for example, on a 21.5×75 mm PRP-3 column, operating at 80°C on a Waters Autopurification 2767 system (or Waters 600 series semi-automated system), using, for example, a timberline TL-600 or TL-150 heater and a gradient of triethylammonium bicarbonate (TEAB) / ACN to elute product. Detection is performed at 260 nm and fractions are collected across the main peak prior to pooling best fractions.

Buffers

[00296] Buffer SB18 is composed of 40 mM HEPES, 101 mM NaCl, 5 mM KCl, 5 mM MgCl₂, and 0.05% (v/v) Tween 20 adjusted to pH 7.5 with NaOH. Buffer SB17 is SB18 supplemented with 1 mM trisodium EDTA. Buffer PB1 is composed of 10 mM HEPES, 101 mM NaCl, 5 mM KCl, 5 mM MgCl₂, 1 mM trisodium EDTA and 0.05% (v/v) Tween-20 adjusted to pH 7.5 with NaOH. CAPSO elution buffer consists of 100 mM CAPSO pH 10.0 and 1 M NaCl. Neutralization buffer contains of 500 mM HEPES, 500 mM HCl, and 0.05% (v/v) Tween-20. Agilent Hybridization Buffer is a proprietary formulation that is supplied as part of a kit (Oligo aCGH/ChIP-on-chip Hybridization Kit). Agilent Wash Buffer 1 is a proprietary formulation (Oligo aCGH/ChIP-on-chip Wash Buffer 1, Agilent). Agilent Wash Buffer 2 is a proprietary formulation (Oligo aCGH/ChIP-on-chip Wash Buffer 2, Agilent). TMAC hybridization solution consists of 4.5 M tetramethylammonium chloride, 6 mM trisodium EDTA, 75 mM Tris-HCl (pH 8.0), and 0.15% (v/v) Sarkosyl. KOD buffer (10-fold concentrated) consists of 1200 mM Tris-HCl, 15 mM MgSO₄, 100 mM KCl, 60 mM (NH₄)₂SO₄, 1% v/v Triton-X 100 and 1 mg/mL BSA.

Sample preparation

[00297] Serum (stored at -80°C in 100 μL aliquots) is thawed in a 25°C water bath for 10 minutes, then stored on ice prior to sample dilution. Samples are mixed by gentle vortexing for 8 seconds. A 6% serum sample solution is prepared by dilution into $0.94\times$ SB17 supplemented with 0.6 mM MgCl_2 , 1 mM trisodium EGTA, 0.8 mM AEBSF, and 2 μM Z-Block. A portion of the 6% serum stock solution is diluted 10-fold in SB17 to create a 0.6% serum stock. 6% and 0.6% stocks are used, in some embodiments, to detect high- and low-abundance analytes, respectively.

Capture reagent (aptamer) and streptavidin plate preparation

[00298] Aptamers are grouped into 2 mixes according to the relative abundance of their cognate analytes (or biomarkers). Stock concentrations are 4 nM for each aptamer, and the final concentration of each aptamer is 0.5 nM. Aptamer stock mixes are diluted 4-fold in SB17 buffer, heated to 95°C for 5 min and cooled to 37°C over a 15 minute period prior to use. This denaturation-renaturation cycle is intended to normalize aptamer conformer distributions and thus ensure reproducible aptamer activity in spite of variable histories. Streptavidin plates are washed twice with 150 μL buffer PB1 prior to use.

Equilibration and plate capture

[00299] Heat-cooled $2\times$ Aptamer mixes (55 μL) are combined with an equal volume of 6% or 0.6% serum dilutions, producing equilibration mixes containing 3% and 0.3% serum. The plates are sealed with a Silicone Sealing Mat (Axymat Silicone sealing mat, VWR) and incubated for 1.5 h at 37°C . Equilibration mixes are then transferred to the wells of a washed 96-well streptavidin plate and further incubated on an Eppendorf Thermomixer set at 37°C , with shaking at 800 rpm, for two hours.

Manual Assay

[00300] Unless otherwise specified, liquid is removed by dumping, followed by two taps onto layered paper towels. Wash volumes are 150 μL and all shaking incubations are done on an Eppendorf Thermomixer set at 25°C , 800 rpm. Equilibration mixes are removed by pipetting, and plates are washed twice for 1 minute with buffer PB1 supplemented with 1 mM dextran sulfate and 500 μM biotin, then 4 times for 15 seconds with buffer PB1. A freshly made solution of 1 mM NHS-PEO4-biotin in buffer PB1 (150 μL /well) is added, and plates are incubated for 5 minutes with shaking. The NHS-biotin solution is removed, and plates washed 3 times with buffer PB1 supplemented with 20 mM glycine, and 3 times with buffer PB1. Eighty-five μL of buffer PB1 supplemented with 1 mM DxSO_4 is then added to each well, and plates are irradiated under a BlackRay UV lamp (nominal wavelength 365 nm) at a distance of 5 cm for 20 minutes with shaking. Samples are transferred to a fresh, washed streptavidin-coated plate, or an

unused well of the existing washed streptavidin plate, combining high and low sample dilution mixtures into a single well. Samples are incubated at room temperature with shaking for 10 minutes. Unadsorbed material is removed and the plates washed 8 times for 15 seconds each with buffer PB1 supplemented with 30% glycerol. Plates are then washed once with buffer PB1. Aptamers are eluted for 5 minutes at room temperature with 100 μ L CAPSO elution buffer. 90 μ L of the eluate is transferred to a 96-well HybAid plate and 10 μ L neutralization buffer is added.

Semi-Automated Assay

[00301] Streptavidin plates bearing adsorbed equilibration mixes are placed on the deck of a BioTek EL406 plate washer, which is programmed to perform the following steps: unadsorbed material is removed by aspiration, and wells are washed 4 times with 300 μ L of buffer PB1 supplemented with 1 mM dextran sulfate and 500 μ M biotin. Wells are then washed 3 times with 300 μ L buffer PB1. One hundred fifty μ L of a freshly prepared (from a 100 mM stock in DMSO) solution of 1 mM NHS-PEO4-biotin in buffer PB1 is added. Plates are incubated for 5 minutes with shaking. Liquid is aspirated, and wells are washed 8 times with 300 μ L buffer PB1 supplemented with 10 mM glycine. One hundred μ L of buffer PB1 supplemented with 1 mM dextran sulfate are added. After these automated steps, plates are removed from the plate washer and placed on a thermoshaker mounted under a UV light source (BlackRay, nominal wavelength 365 nm) at a distance of 5 cm for 20 minutes. The thermoshaker is set at 800 rpm and 25°C. After 20 minutes irradiation, samples are manually transferred to a fresh, washed streptavidin plate (or to an unused well of the existing washed plate). High-abundance (3% serum+3% aptamer mix) and low-abundance reaction mixes (0.3% serum+0.3% aptamer mix) are combined into a single well at this point. This “Catch-2” plate is placed on the deck of BioTek EL406 plate washer, which is programmed to perform the following steps: the plate is incubated for 10 minutes with shaking. Liquid is aspirated, and wells are washed 21 times with 300 μ L buffer PB1 supplemented with 30% glycerol. Wells are washed 5 times with 300 μ L buffer PB1, and the final wash is aspirated. One hundred μ L CAPSO elution buffer are added, and aptamers are eluted for 5 minutes with shaking. Following these automated steps, the plate is then removed from the deck of the plate washer, and 90 μ L aliquots of the samples are transferred manually to the wells of a HybAid 96-well plate that contains 10 μ L neutralization buffer.

Hybridization to custom Agilent 8 \times 15k microarrays

[00302] 24 μ L of the neutralized eluate is transferred to a new 96-well plate and 6 μ L of 10 \times Agilent Block (Oligo aCGH/ChIP-on-chip Hybridization Kit, Large Volume, Agilent 5188–5380), containing a set of hybridization controls composed of 10 Cy3 aptamers is added to each

well. Thirty μL $2\times$ Agilent Hybridization buffer is added to each sample and mixed. Forty μL of the resulting hybridization solution is manually pipetted into each “well” of the hybridization gasket slide (Hybridization Gasket Slide, 8-microarray per slide format, Agilent). Custom Agilent microarray slides, bearing 10 probes per array complementary to 40 nucleotide random region of each aptamer with a $20\times$ dT linker, are placed onto the gasket slides according to the manufacturers' protocol. The assembly (Hybridization Chamber Kit – SureHyb-enabled, Agilent) is clamped and incubated for 19 hours at 60°C while rotating at 20 rpm.

Post Hybridization Washing

[00303] Approximately 400 mL Agilent Wash Buffer 1 is placed into each of two separate glass staining dishes. Slides (no more than two at a time) are disassembled and separated while submerged in Wash Buffer 1, then transferred to a slide rack in a second staining dish also containing Wash Buffer 1. Slides are incubated for an additional 5 minutes in Wash Buffer 1 with stirring. Slides are transferred to Wash Buffer 2 pre-equilibrated to 37°C and incubated for 5 minutes with stirring. Slides are transferred to a fourth staining dish containing acetonitrile, and incubated for 5 minutes with stirring.

Microarray Imaging

[00304] Microarray slides are imaged with an Agilent G2565CA Microarray Scanner System, using the Cy3-channel at $5\ \mu\text{m}$ resolution at 100% PMT setting, and the XRD option enabled at 0.05. The resulting TIFF images are processed using Agilent feature extraction software version 10.5.1.1 with the GE1_105_Dec08 protocol. Primary Agilent data is available as Supplementary Information (Figure S6).

Luminex probe design

[00305] Probes immobilized to beads have 40 deoxynucleotides complementary to the 3' end of the 40 nucleotide random region of the target aptamer. The aptamer complementary region is coupled to Luminex Microspheres through a hexaethyleneglycol (HEG) linker bearing a 5' amino terminus. Biotinylated detection deoxyoligonucleotides comprise 17–21 deoxynucleotides complementary to the 5' primer region of target aptamers. Biotin moieties are appended to the 3' ends of detection oligos.

Coupling of probes to Luminex Microspheres

[00306] Probes are coupled to Luminex Microplex Microspheres essentially per the manufacturer's instructions, but with the following modifications: amino-terminal oligonucleotide amounts are 0.08 nMol per 2.5×10^6 microspheres, and the second EDC addition is $5\ \mu\text{L}$ at 10 mg/mL. Coupling reactions are performed in an Eppendorf ThermoShaker set at 25°C and 600 rpm.

Microsphere hybridization

[00307] Microsphere stock solutions (about 40000 microspheres/ μL) are vortexed and sonicated in a Health Sonics ultrasonic cleaner (Model: T1.9C) for 60 seconds to suspend the microspheres. Suspended microspheres are diluted to 2000 microspheres per reaction in $1.5\times$ TMAC hybridization solutions and mixed by vortexing and sonication. Thirty-three μL per reaction of the bead mixture are transferred into a 96-well HybAid plate. Seven μL of 15 nM biotinylated detection oligonucleotide stock in $1\times$ TE buffer are added to each reaction and mixed. Ten μL of neutralized assay sample are added and the plate is sealed with a silicon cap mat seal. The plate is first incubated at 96°C for 5 minutes and incubated at 50°C without agitation overnight in a conventional hybridization oven. A filter plate (Dura pore, Millipore part number MSBVN1250, 1.2 μm pore size) is prewetted with 75 μL $1\times$ TMAC hybridization solution supplemented with 0.5% (w/v) BSA. The entire sample volume from the hybridization reaction is transferred to the filter plate. The hybridization plate is rinsed with 75 μL $1\times$ TMAC hybridization solution containing 0.5% BSA and any remaining material is transferred to the filter plate. Samples are filtered under slow vacuum, with 150 μL buffer evacuated over about 8 seconds. The filter plate is washed once with 75 μL $1\times$ TMAC hybridization solution containing 0.5% BSA and the microspheres in the filter plate are resuspended in 75 μL $1\times$ TMAC hybridization solution containing 0.5% BSA. The filter plate is protected from light and incubated on an Eppendorf Thermalmixer R for 5 minutes at 1000 rpm. The filter plate is then washed once with 75 μL $1\times$ TMAC hybridization solution containing 0.5% BSA. 75 μL of 10 $\mu\text{g}/\text{mL}$ streptavidin phycoerythrin (SAPE-100, MOSS, Inc.) in $1\times$ TMAC hybridization solution is added to each reaction and incubated on Eppendorf Thermalmixer R at 25°C at 1000 rpm for 60 minutes. The filter plate is washed twice with 75 μL $1\times$ TMAC hybridization solution containing 0.5% BSA and the microspheres in the filter plate are resuspended in 75 μL $1\times$ TMAC hybridization solution containing 0.5% BSA. The filter plate is then incubated protected from light on an Eppendorf Thermalmixer R for 5 minutes, 1000 rpm. The filter plate is then washed once with 75 μL $1\times$ TMAC hybridization solution containing 0.5% BSA. Microspheres are resuspended in 75 μL $1\times$ TMAC hybridization solution supplemented with 0.5% BSA, and analyzed on a Luminex 100 instrument running Xponent 3.0 software. At least 100 microspheres are counted per bead type, under high PMT calibration and a doublet discriminator setting of 7500 to 18000.

qPCR read-out

[00308] Standard curves for qPCR are prepared in water ranging from 108 to 102 copies with 10-fold dilutions and a no-template control. Neutralized assay samples are diluted 40-fold into diH₂O. The qPCR master mix is prepared at $2\times$ final concentration ($2\times$ KOD buffer, 400

µM dNTP mix, 400 nM forward and reverse primer mix, 2× SYBR Green I and 0.5 U KOD EX). Ten µL of 2× qPCR master mix is added to 10 µL of diluted assay sample. qPCR is run on a BioRad MyIQ iCycler with 2 minutes at 96°C followed by 40 cycles of 96°C for 5 seconds and 72°C for 30 seconds.

Example 5. Further NAFLD and NASH Analysis

[00309] The data from the multiplex aptamer assay described in Example 2 for the samples described in Example 1 were subjected to a further analysis, using a logistic regression model.

[00310] Stability Selection takes many subsets of half the data and performs biomarker selection using the lasso classifier, which is a regularized logistic regression model. *See, e.g.,* Meinshausen et al., 2010, *J. Royal Statistical Soc: Series B (Statistical Methodology)*, 72: 417-473. The selection path for a single biomarker is the proportion of these subsets for which that biomarker was selected by the lasso model over a range of lambda. Lambda is a tuning parameter, which determines how many biomarkers are selected by the lasso. The maximum selection probability over a range of lambda values is the ultimate metric used to select a set of biomarkers.

C. Steatosis Classifier

[00311] Based on the subject classifications, we assumed that all steatosis groups as well as NASH stages 1-4 have fat in the liver cells. A classifier (steatosis, or fat in the liver) was developed by comparing obese normal subjects to all NAFLD and NASH subjects.

[00312] Markers were fit with logistic regression models to generate classifiers.

[00313] Table 8 shows the biomarkers in the 8-marker steatosis (NAFLD) classifier. Table 8 also shows the logistic regression coefficients for the model and the 95% confidence interval for the coefficient estimate. The 8-marker classifier contains all of the markers of the 9-marker classifier shown in Table 3, except for PLAT.

Table 8: Eight biomarker classifier for NAFLD

Biomarker	Biomarker level higher / lower in all NAFLD population	Coefficient	Low 95% confidence interval	High 95% confidence interval
Intercept		23.682	0.0205235	48.665007
ACY1	Higher	2.205	1.479981	3.028281
SHBG	Lower	-1.219	-1.96066	-0.52774
CTSZ	Higher	3.070	1.607459	4.636245
MET	Lower	-1.900	-3.84342	-0.01765
GSN	Lower	-2.014	-4.08462	0.024845

LGALS3BP	Higher	1.814	0.58276	3.132223
CHL1	Lower	-2.491	-4.46361	-0.59133
SERPINC1	Lower	-1.502	-2.96705	-0.13184

[00314] Figure 12 shows box plots for the 8 marker classifier for each set of steatosis and NASH subjects. The black line within each box represents the median (or 50th percentile) of the data points, and the box itself represents the inter-quartile range (IQR), the area encompassing data points from the 25th to 75th percentile. The whiskers extend to cover data points within 1.5 x IQR of the top and bottom of the box. The plot shows a clear discrimination between no steatosis and steatosis and probability vote increases with the level of steatosis. NASH subjects at all stages have severe steatosis.

D. NASH (Fibrosis) Classifier

[00315] All subjects with NASH have some form of inflammation and ballooning associated with fibrosis. For this analysis, we compared the mild and moderate steatosis groups to NASH stages 2, 3 and 4. To ensure identification of true fibrosis biomarkers, the NASH stage 1 group was excluded. Subjects with severe steatosis were omitted in this analysis because biopsy sampling in those subjects could have missed some fibrosis.

[00316] Markers were fit with logistic regression models to generate classifiers to generate a model.

[00317] Table 9 shows the biomarkers in the 8-marker fibrosis (NASH) classifier. Table 9 also shows the logistic regression coefficients for the model and the 95% confidence interval for the coefficient estimate. The 8-marker classifier contains all of the markers of the 4-marker classifier shown in Table 4, plus four additional markers.

Table 9: Eight biomarker classifier for NASH stages 2, 3, and 4 versus mild to moderate steatosis (NAFLD)

Biomarker/Aliases	Biomarker level higher / lower in fibrosis (NASH) population	Coefficient	Low 95% confidence interval	High 95% confidence interval
Intercept		-58.307	-117.01013	-8.491203
C7	Higher	2.711339	0.016014	5.569299
COLEC11	Higher	0.578295	-1.01116	2.184399
PPID	Lower	-1.47222	-3.09367	0.024429
IGFBP3	Lower	-1.88591	-4.25566	0.245891
GPC5	Lower	-2.24248	-3.99262	-0.74934
HIPK3	Higher	1.176491	0.286007	2.806758
IGFBP7	Higher	4.363192	1.274937	8.250915
IL3RA	Higher	3.106253	0.455772	6.208888

[00318] Figure 13 shows box plots for the 8 biomarker fibrosis classifier in each of the subject groups (from left to right: normal, mild steatosis, moderate steatosis, severe steatosis, NASH1, NASH2, NASH3, NASH4). The black line within each box represents the median (or 50th percentile) of the data points, and the box itself represents the inter-quartile range (IQR), the area encompassing data points from the 25th to 75th percentile. The whiskers extend to cover data points within 1.5 x IQR of the top and bottom of the box.

[00319] The four additional biomarkers in the fibrosis classifier in Table 9 are shown in Table 10, along with alternate names, gene names, and the UniProt accession number ofr each biomarker.

Table 10: Additional biomarkers in fibrosis 8 biomarker classifier

Biomarker/Aliases	Gene Name	UniProt
Glypican-5	GPC5	<u>Q8N158</u>
Homeodomain-interacting protein kinase 3	HIPK3	<u>Q9H422</u>
Insulin-like growth factor-binding protein 7	IGFBP7	<u>Q16270</u>
Interleukin-3 receptor alpha	IL3RA	<u>P26951</u>

[00320] Figure 14 shows the cumulative distribution functions for the four additional markers in the eight-marker classifier for fibrosis.

Example 6. Unblinding of Blinded Samples

[00321] As shown in Table 2, a set of samples in each of the control, mild steatosis, moderate steatosis, severe steatosis, NASH stage 1, and NASH stage 2 were blinded. The probability that each of the blinded samples was from a subject with steatosis was determined using the 8-marker classifier shown in Table 8. Figure 15 shows box plots for the blinded samples after unblinding, according to their actual sample group.

[00322] Figure 16 shows the 8-marker steatosis classifier performance for the discovery set and for the blinded validation set. The upper curve is the ROC curve for the discovery set, which has an area-under-curve (AUC) of 0.927 ± 0.03 and a sensitivity of 92.8% and specificity of 73.3% at a cutoff of 0.5. The lower curve is the ROC curve for the blinded validation set, which as an AUC of 0.889 ± 0.06 and a sensitivity of 88% and a specificity of 65.8% at a cutoff of 0.5.

[00323] Table 10 shows the performance of the 8 marker steatosis classifier for the blinded validation set for identifying a subject as positive or negative for steatosis.

Table 10: Performance of 8 marker steatosis classifier for blinded validation set

Truth/Test	Neg.	Pos.	Total
Neg.	27	14	41
Pos.	11	81	92
Total	38	95	133

[00324] The probability that each of the blinded samples was from a subject with fibrosis was determined using the 8-marker classifier shown in Table 9. Figure 17 shows box plots for the blinded samples after unblinding, according to their actual sample group.

[00325] Figure 18 shows the 8-marker fibrosis classifier performance for the discovery set and for two different blinded validation sets. The second validation set includes the first validation set plus the normal group (individuals negative for disease). Because the model was not trained with the normal group, it is naïve to those samples, which may reveal false positives. The upper curve (red) is the ROC curve for the discovery set (control (mild+moderate steatosis) versus NASH grades 2, 3, and 4), which has an area-under-curve (AUC) of 0.929 ± 0.04 and a sensitivity of 78.8% and specificity of 89.9% at a cutoff of 0.5. The middle curve (blue) is the ROC curve for the first blinded validation set, which has an AUC of 0.885 ± 0.11 and a sensitivity of 66.7% and a specificity of 84.6% at a cutoff of 0.5. The lower curve (cyan) is the ROC curve for the second blinded validation set, which has an AUC of 0.891 ± 0.08 and a sensitivity of 66.7% and a specificity of 89.5% at a cutoff of 0.5.

[00326] Tables 11 and 12 shows the performance of the 8 marker fibrosis classifier for the two blinded validation sets for identifying subjects as positive or negative for fibrosis.

Table 11: Performance of 8 marker fibrosis classifier for first blinded validation set

Truth/Test	Neg.	Pos.	Total
Neg.	22	4	26
Pos.	4	8	12
Total	26	12	38

Table 12: Performance of 8 marker fibrosis classifier for second blinded validation set

Truth/Test	Neg.	Pos.	Total
Neg.	60	7	67
Pos.	4	8	12
Total	64	15	79

[00327] Figure 19 shows sensitivity and specificity distributions of 2500 bootstrap iterations of the 20% hold-out verification set, using (A) the 8-marker steatosis classifier and (B) the 8-marker fibrosis classifier. Empirical 95% confidence intervals are shown, as well as the training and validation estimates, both of which are within the 95% confidence intervals.

Example 7. Performance of Classifier in Pediatric Subjects

[00328] Ninety serum samples from children were obtained from the Pediatric Gastroenterology and Nutrition Department of the Medical College of Wisconsin. The subjects contributing samples fell into four groups: non-obese controls (N=45), obese with normal liver function tests (N=20), obese with elevated liver function tests (N=7), and subjects diagnosed with NASH (N=18). The samples were tested using the 8-marker steatosis classifier shown in Table 8 and the 8-marker fibrosis classifier shown in Table 9.

[00329] The probability that each of the pediatric samples was from a subject with steatosis was determined using the 8-marker classifier shown in Table 8. Figure 20 shows box plots for the pediatric samples according to their actual sample group. The steatosis classifier accurately identified pediatric subjects with NASH.

[00330] Unlike the steatosis classifier, the 8-marker fibrosis classifier did not effectively identify pediatric subjects with fibrosis in this experiment. (Data not shown.)

Example 8. Biomarker Discovery for Developing Biomarker Panels for Steatosis, Lobular Inflammation, Hepatocyte Ballooning and Fibrosis

[00331] A total of 297 adult serum samples were analyzed. These samples are from three NASH CRN cohorts: NAFLD Database (n=81), PIVENS trial (n=80), and DB2 (n=136). The NAFLD and DB2 collections were established to study NAFLD and NASH natural history. The PIVENS trial (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis) was conducted by the NASH CRN to investigate treatments in non-diabetic NASH patients. All samples were collected pre-treatment, and have baseline liver biopsy results obtained within 6 months of serum collection. Table 13 and Figure 21 show the distribution of histological and NAFLD activity score (NAS scores) from the baseline liver biopsy. NAS is a histological scoring system for non-alcoholic fatty liver disease (NAFLD), described, for example, in Kleiner et al., *Hepatology* 41(6):1313-21 (2005). It is based on four categories of liver involvement, including steatosis, lobular inflammation, hepatocyte ballooning, and fibrosis. Steatosis is scored from 0 to 3 and is based on the percentage of surface area involved in steatosis. Lobular inflammation is scored from 0 to 3 and is based on the number of foci per 200x field. Hepatocyte ballooning is scored from 0 to 2 and is based on the prevalence of ballooned hepatocytes (e.g., none, rare, or many). Fibrosis is scored from 0 to 4 and is based on the extent and location of fibrosis, up to cirrhosis (scored 4).

[00332] Table 13: Baseline Liver Biopsy Histology

Category	Sample Counts (n)				Total
	0	1	2	3	
Steatosis	44	81	102	70	297
Lobular Inflammation	9	215	56	17	297
Hepatocyte Ballooning	172	43	82	NA	297
Fibrosis*	147	21/18/12	61	37	296

*Fibrosis score missing for one sample

[00333] Biomarker levels were compared to the NASH diagnosis (NASH Dx) provided by the NASH CRN investigators (nashdx field in the data dictionary). A positive NASH diagnosis (diagnosis code =2) was recorded for 123 study participants. These samples were compared to the 174 samples from individuals with either no NAFLD (diagnosis code 99, n=31) or NAFLD, not NASH (diagnosis code 0, n=143).

Identifying Candidate Biomarkers

[00334] The Jonckheere–Terpstra Test (JT-test) was applied to identify candidate biomarkers of the individual histological components of NASH (steatosis, lobular inflammation, hepatocyte ballooning and fibrosis), the NAS score, and NASH Dx. The JT test is a rank-based nonparametric test that can be used to determine if there is a statistically significant trend between an ordinal independent variable (histology score from low to high) and a continuous dependent variable (SOMAscan protein measurement). In addition to the SOMAscan proteomic measurements, 20 continuous clinical variables were included as potential biomarkers in this analysis.

[00335] After correcting for multiple comparisons, the number of significant markers (based on a Bonferroni corrected p-value of < 0.01) ranged from 27 to 132, depending on the histological component (Table 14). Box plots for the top 6 proteins in each category are shown in Figure 22-27. The only clinical variable in the top 6 biomarkers is AST (labeled clin.ast in the figures).

Table 14: Number of Significant Proteins by JT-Test, Bonferroni corrected p <0.01

Category	Number of Proteins
Steatosis	27
Inflammation	48
Ballooning	104
Fibrosis	132
NAS	96
NASH Dx	86

[00336] As shown in Figure 22, one or more of biomarkers ACY1, KYNU, ITGA1/ITGB1, POR, HSP90AA1/HSP90AB1, and CSF1R may be used to determine the likelihood that a subject has steatosis.

[00337] As shown in Figure 23, one or more of biomarkers ACY1, THBS2, COLEC11, ITGA1/ITGB1, and POR may be used to determine the likelihood that a subject has lobular inflammation. In some embodiments, clinical AST levels may be considered as well.

[00338] As shown in Figure 24, one or more of biomarkers ACY1, COLEC11, THBS2, ITGA1/ITGB1, and HSP90AA1/HSP90AB1 may be used to determine the likelihood that a subject has hepatocyte ballooning. In some embodiments, clinical AST levels may be considered as well.

[00339] As shown in Figure 25, one or more of biomarkers C7, COLEC11, THBS2, ITGA1/ITGB1, HSP90AA1/HSP90AB1, and DCN may be used to determine the likelihood that a subject has fibrosis.

[00340] There is an overlap in the highest ranking serum proteins across categories. Disease severity in different histological categories may be related. For example, a patient with a hepatocyte ballooning score of 2 is likely to also have fibrosis. There are 10 unique proteins among the 6 highest ranking markers by histological category (Table 15).

Table 15: Overlap of the Highest Ranked Proteins in Each Histological Category

GENE ID	Protein (UniProt ID)	Steatosis	Inflammation	Ballooning	Fibrosis	TOTAL
ACY1	Aminoacylase 1 (Q03154)	+	+	+	-	3
C7	Complement component 7 (P10643)	-	-	-	+	1
COLEC11	Collectin (Q9BWP8)	-	+	+	+	3
CSF1R	Colony stimulating factor 1 receptor (P07333)	+	-	-	-	1
DCN	Decorin (P07585)	-	-	-	+	1
HSP90AA1/HSP90AB1	Heat shock protein 90kDa alpha/beta (P07900/P08238)	+	-	+	+	3
ITGA1/ITGB1	Integrin, alpha 1/beta 1 (P56199/P05556)	+	+	+	+	4
KYNU	Kynureninase (Q16719)	+	-	-	-	1
POR	P450 cytochrome oxidoreductase (P16435)	+	+	-	-	2
THBS2	Thrombospondin 2 (P35442)	-	+	+	+	3

[00341] In addition to the biomarkers listed in Table 15, clinical AST levels formed part of the top six markers for lobular inflammation and hepatocyte ballooning. Clinical AST levels are determined using routine blood tests known in the art.

[00342] A broader view of the overlapping and unique serum markers is shown in Figure 28, where all of the significant (Bonferroni corrected $p < 0.01$) proteins in each category are compared. This analysis demonstrates that models can be built that either capture multiple aspects of NASH biology, or are specific to one component.

[00343] While the pilot models were built from samples representing the extremes (e.g. steatosis 0 vs 3, ballooning 0 vs 2, and fibrosis 0 vs 3), the 10x-cross-validated performance AUCs (0.97 ± 0.02 and 0.94 ± 0.07) demonstrates that the model performs across all samples.

Example 9. Further Development of Biomarker Panels for Steatosis, Lobular Inflammation, Hepatocyte Ballooning and Fibrosis

[00344] Biomarker discovery began with univariate KS-distances distinguishing disease from control followed by stability selection and JT-tests for monotonic behavior among disease stage severity. A summary of each of the analysis filtering steps is provided below. Once the final candidate list has been reduced to the most parsimonious set of markers within one standard error from the “best” model (via cost function from Feature Selection), the final set of features were used to fit a model for each liver disease component.

[00345] Briefly, dimensionality reduction and candidate filtering followed the process below:

- 1) **KS-analysis:** KS-distances > 0.4 and KS-distance associated FDR < 0.05 (5%) **OR**
- 2) **Stability selection:** analytes with a maximum selection probability (proportion of entries in the model) greater than 0.45, 0.45, 0.5, 0.5, and 0.5 for each of steatosis, lobular inflammation, ballooning, fibrosis, and NASHdx respectively **AND**
- 3) **JT-analysis:** JT-test associated FDR < 0.05 (5%)
- 4) **Control analytes:** negative control analytes such as HybControls, Spuriomers, and NonHuman targets were removed
- 5) **Site markers:** markers that distinguish samples from different sites or studies were removed from potential candidates in each component list
- 6) **Spin Stability:** Analytes with Time to Spin Stability score (Bayesian models from the sample handling experiment) in the lower 33 percentile (%ile) were removed
- 7) **Reproducibility:** analytes determined to have a coefficient of variance (%CV) greater than 15% during the version 3 assay reproducibility study were removed
- 8) **Gaussian distribution:** a visual inspection of the distribution split by clinical group (disease vs control) for Gaussian approximation was performed and analytes with non-Gaussian, bimodal, or vastly differing variance structures among the clinical groups were removed.

[00346] Following the above analysis, candidate markers for each liver disease component were identified. Table 16 shows the final candidates for each histological category identified in this further analysis.

Table 16: Overlap of the Highest Ranked Proteins in Each Histological Category

GENE ID	Protein (UniProt ID)	Steatosis	Inflammation	Ballooning	Fibrosis
ACY1	Aminoacylase 1 (Q03154)	+	+	+	+
C7	Complement component 7 (P10643)			+	+
COLEC11	Collectin (Q9BWP8)		+	+	+
CSF1R	Colony stimulating factor 1 receptor (P07333)		+		+
DCN	Decorin (P07585)				+
ITGA1/ITGB1	Integrin, alpha 1/beta 1 (P56199/P05556)	+	+	+	+
KYNU	Kynureninase (Q16719)	+	+		+
POR	P450 cytochrome oxidoreductase (P16435)	+	+	+	+
THBS2	Thrombospondin 2 (P35442)	+	+	+	+
FCGR3B	Low affinity immunoglobulin gamma Fc region receptor III-B (O75015.2)		+		
LGALS3BP	Galectin-3-binding protein (Q08380.1)			+	
SERPINC1	Antithrombin-III (P01008.1)			+	
IGFBP7	Insulin-like growth factor-binding protein 7 (Q16270.1)				+
PIK3CA/PIK3R1	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform / Phosphatidylinositol 3-kinase regulatory subunit alpha (P42336.2/ P27986.2)				+
NAGK	N-acetyl-D-glucosamine kinase (Q9UJ70.4)				+
DDC	Aromatic-L-amino-acid decarboxylase (P20711.2)				+
SERPINA7	Thyroxine-binding globulin (P05543.2)				+

[00347] Final models were built using a combination of feature selection using an AUC and/or sensitivity + specificity cost function and the minimal set of features resulting in similar performance (peak -1se). Figures 29 to 32 show the search progress of the feature selection algorithm. Using AUC as the cost (i.e. performance) metric, features/biomarkers are sequentially added according to which *additional* marker results in the largest performance increase. The points within the boxplots (left) represent specific run/fold combinations of the search algorithm. The right panel shows the same data with 95% confidence intervals based on the mean AUC by feature. The red point/box represents the model with peak AUC and the dark and light green represent 1 and 2 standard errors from the peak respectively. One standard error from the peak is generally considered the “best” performing, most parsimonious (i.e. least complex) model.

[00348] Based on the feature selection results, the following markers were selected for the models for the respective condition.

- Steatosis: ACY1
- Lobular inflammation: COLEC11, CSF1R
- Hepatocyte ballooning: ITGA1/ITGB1, COLEC11, SERPINC1, LGALS3BP
- Fibrosis: C7, THBS2, KYNU, SERPINA7.

Example 10. NIH Adult NASH Model

[00349] The specification of naïve Bayes models was generated during the discovery phase of the initial NIH data for adults in each of the following disease conditions: steatosis, lobular inflammation, ballooning, and fibrosis. The full naïve Bayes model parameters are shown below along with a description of how to calculate normalized posterior probabilities (and class predictions) given an unknown sample with \log_{10} (RFU)-transformed analyte measurements for each feature.

[00350] Naive Bayes models contain $2pk + k$ parameters, where k is the number of classes, p is the number of features/proteins; a mean (μ) and standard deviation (σ) for each protein \times class combination, plus the class-specific prior, which was determined by the training class prevalence (i.e., an *uninformative* prior). Naive Bayes models assume Gaussian densities and are calculated via the probability density function (PDF) given class-specific parameters μ and σ :

$$f(x | \mu_k, \sigma_k) = \frac{1}{\sqrt{2\pi\sigma_k^2}} \exp\left(\frac{-(x - \mu_k)^2}{2\sigma_k^2}\right), \quad (1)$$

[00351] Using this equation (1), an unknown sample with p \log_{10} -transformed (RFU) protein measurements ($\vec{x} = x_1, \dots, x_p$) and $k = 2$ classes (disease and control), can be classified via equation (2):

$$P(k | \vec{x}) = \left[\prod_{i=1}^p \frac{1}{\sqrt{2\pi\sigma_{ik}^2}} \exp\left(\frac{-(x_i - \mu_{ik})^2}{2\sigma_{ik}^2}\right) \right] \times P(k), \quad (2)$$

[00352] Normalized posterior probabilities (Pr) were obtained by calculating the class-specific proportion of the total density, for example:

$$Pr(\text{control} | \text{proteins}) = \frac{P(\text{control} | \text{proteins})}{P(\text{control} | \text{proteins}) + P(\text{disease} | \text{proteins})},$$

$$Pr(\text{disease} | \text{proteins}) = \frac{P(\text{disease} | \text{proteins})}{P(\text{control} | \text{proteins}) + P(\text{disease} | \text{proteins})},$$

and the class prediction was made by a decision cutoff determined according to the maximal perpendicular distance of the ROC curve to the unit line.

[00353] Table 17 provides mapping between gene identifiers and protein names used in the analysis.

Table 17: Mapping of gene identifiers and protein names

GENE Name	Protein Name
ACY1.3343.1.4	Aminoacylase-1
COLEC11.4430.44.3	Collectin-11
CSF1R.2638.12.2	Macrophage colony-stimulating factor 1 receptor
ITGA1.ITGB1.3503.4.2	Integrin alpha-I: beta-1 complex
SERPINC1.3344.60.4	Antithrombin-III
LGALS3BP.5000.52.1	Galectin-3-binding protein
C7.2888.49.2	Complement component C7
THBS2.3339.33.1	Thrombospondin-2
KYNU.4559.64.2	Kynureninase
SERPINA7.2706.69.2	Thyroxine-binding globulin

Steatosis Naïve Bayes Model

```
Robust Naive Bayes Classifier for Discrete Predictors

Call:
robust.naiveBayes.default(x = log.data, y = dataset$Response)

A-priori probabilities:
dataset$Response
  control steatosis
  0.14815  0.85185

Conditional densities:
                ACY1.3343.1.4
control_mu      3.82550
steatosis_mu    4.18191
control_sigma   0.23774
steatosis_sigma 0.28751
```

[00354] To classify an unknown sample having protein RFU measurements: $x_1 = \log_{10}(\text{ACY } 1.3343.1.4)$, the following was calculated:

$$P(\textit{steatosis} | x_1) = \frac{1}{\sqrt{2\pi(0.28751)^2}} \exp\left(\frac{-(x_1 - (4.18191))^2}{2(0.28751)^2}\right) \times 0.85185$$

$$P(\textit{control} | x_1) = \frac{1}{\sqrt{2\pi(0.23774)^2}} \exp\left(\frac{-(x_1 - (3.8255))^2}{2(0.23774)^2}\right) \times 0.14815$$

$$Pr(\textit{steatosis}) = \frac{P(\textit{steatosis} | x_1)}{P(\textit{steatosis} | x_1) + P(\textit{control} | x_1)}$$

where the decision threshold (cutoff) for the steatosis class is $Pr(\textit{steatosis}) > 0.86153$.

Lobular Inflammation Naive Bayes Model

Robust Naive Bayes Classifier for Discrete Predictors

Call:

```
robust.naiveBayes.default(x = log.data, y = dataset$Response)
```

A-priori probabilities:

```
dataset$Response
  control lobinflam
  0.75421  0.24579
```

Conditional densities:

```
                COLEC11.4430.44.3 CSF1R.2638.12.2
control_mu      3.73389             2.71638
lobinflam_mu    4.00075             2.83843
control_sigma   0.17571             0.10198
lobinflam_sigma 0.25238             0.09696
```

[00355] To classify an unknown sample having protein RFU measurements: $x_1 = \log_{10}(\textit{COLEC11.4430.44.3})$, and $x_2 = \log_{10}(\textit{CSF1R.2638.12.2})$, the following was calculated:

$$\begin{aligned}
 P(\text{lobinflam} \mid x_1, x_2) &= \frac{1}{\sqrt{2\pi(0.25238)^2}} \exp\left(\frac{-(x_1 - (4.00075))^2}{2(0.25238)^2}\right) \times \\
 &\quad \frac{1}{\sqrt{2\pi(0.09696)^2}} \exp\left(\frac{-(x_2 - (2.83843))^2}{2(0.09696)^2}\right) \times 0.24579 \\
 P(\text{control} \mid x_1, x_2) &= \frac{1}{\sqrt{2\pi(0.17571)^2}} \exp\left(\frac{-(x_1 - (3.73389))^2}{2(0.17571)^2}\right) \times \\
 &\quad \frac{1}{\sqrt{2\pi(0.10198)^2}} \exp\left(\frac{-(x_2 - (2.71638))^2}{2(0.10198)^2}\right) \times 0.75421 \\
 Pr(\text{lobinflam}) &= \frac{P(\text{lobinflam} \mid x_1, x_2)}{P(\text{lobinflam} \mid x_1, x_2) + P(\text{control} \mid x_1, x_2)}
 \end{aligned}$$

where the decision threshold (cutoff) for the lobular inflammation class is $Pr(\text{lobinflam}) > 0.22539$.

Ballooning Naive Bayes Model

Robust Naive Bayes Classifier for Discrete Predictors

Call:

```
robust.naiveBayes.default(x = log.data, y = dataset$Response)
```

A-priori probabilities:

```
dataset$Response
  control ballooning
  0.57912  0.42088
```

Conditional densities:

```

ITGA1.ITGB1.3503.4.2 COLEC11.4430.44.3 SERPINC1.3344.60.4 LGALS3BP.5000.52.1
control_mu          3.01777          3.70799          4.720919         3.05050
ballooning_mu       3.29517          3.95049          4.863504         3.15268
control_sigma       0.17479          0.15080          0.094992         0.13341
ballooning_sigma    0.27017          0.26956          0.087817         0.13401

```

[00356] To classify an unknown sample having protein RFU measurements: $x_1 = \log_{10}(\text{ITGA1.ITGB1.3503.4.2})$, $x_2 = \log_{10}(\text{COLEC11.4430.44.3})$, $x_3 = \log_{10}(\text{SERPINC1.3344.60.4})$, and $x_4 = \log_{10}(\text{LGALS3BP.5000.52.1})$, the following was calculated:

$$\begin{aligned}
 P(\text{ballooning} \mid x_1, \dots, x_4) &= \frac{1}{\sqrt{2\pi(0.27017)^2}} \exp\left(\frac{-(x_1 - (3.29517))^2}{2(0.27017)^2}\right) \times \\
 &\frac{1}{\sqrt{2\pi(0.28856)^2}} \exp\left(\frac{-(x_2 - (3.95848))^2}{2(0.28856)^2}\right) \times \\
 &\frac{1}{\sqrt{2\pi(0.08782)^2}} \exp\left(\frac{-(x_3 - (4.6635))^2}{2(0.08782)^2}\right) \times \\
 &\frac{1}{\sqrt{2\pi(0.13401)^2}} \exp\left(\frac{-(x_4 - (3.15268))^2}{2(0.13401)^2}\right) \times 0.42088 \\
 P(\text{control} \mid x_1, \dots, x_4) &= \frac{1}{\sqrt{2\pi(0.17479)^2}} \exp\left(\frac{-(x_1 - (3.01777))^2}{2(0.17479)^2}\right) \times \\
 &\frac{1}{\sqrt{2\pi(0.1508)^2}} \exp\left(\frac{-(x_2 - (3.70799))^2}{2(0.1508)^2}\right) \times \\
 &\frac{1}{\sqrt{2\pi(0.09499)^2}} \exp\left(\frac{-(x_3 - (4.72082))^2}{2(0.09499)^2}\right) \times \\
 &\frac{1}{\sqrt{2\pi(0.13341)^2}} \exp\left(\frac{-(x_4 - (3.05858))^2}{2(0.13341)^2}\right) \times 0.57912 \\
 Pr(\text{ballooning}) &= \frac{P(\text{ballooning} \mid x_1, \dots, x_4)}{P(\text{ballooning} \mid x_1, \dots, x_4) + P(\text{control} \mid x_1, \dots, x_4)}
 \end{aligned}$$

where the decision threshold (cutoff) for the ballooning class is $Pr(\text{ballooning}) > 0.3151$.

Fibrosis Naive Bayes Model

```

Robust Naive Bayes Classifier for Discrete Predictors

Call:
robust.naiveBayes.default(x = log.data, y = dataset$Response)

A-priori probabilities:
dataset$Response
 control fibrosis
 0.66892  0.33108

Conditional densities:
      C7.2888.49.2 THBS2.3339.33.1 KYNU.4559.64.2 SERPINA7.2706.69.2
control_mu      3.414743          3.0136          3.20911          4.731746
fibrosis_mu     3.564544          3.3116          3.45495          4.772775
control_sigma   0.089359          0.1451          0.17464          0.088306
fibrosis_sigma  0.138501          0.2366          0.25642          0.056368
    
```

[00357] To classify an unknown sample having protein RFU measurements: $x_1 = \log_{10}(C7.2888.49.2)$, $x_2 = \log_{10}(THBS2.3339.33.1)$, $x_3 = \log_{10}(KY NU.4559.64.2)$, and $x_4 = \log_{10}(SERPINA7.2706.69.2)$, the following was calculated:

$$\begin{aligned}
 P(\textit{fibrosis} \mid x_1, \dots, x_4) &= \frac{1}{\sqrt{2\pi(0.1385)^2}} \exp\left(\frac{-(x_1 - (3.56454))^2}{2(0.1385)^2}\right) \times \\
 &\quad \frac{1}{\sqrt{2\pi(0.2366)^2}} \exp\left(\frac{-(x_2 - (3.3116))^2}{2(0.2366)^2}\right) \times \\
 &\quad \frac{1}{\sqrt{2\pi(0.25642)^2}} \exp\left(\frac{-(x_3 - (3.45485))^2}{2(0.25642)^2}\right) \times \\
 &\quad \frac{1}{\sqrt{2\pi(0.05637)^2}} \exp\left(\frac{-(x_4 - (4.77277))^2}{2(0.05637)^2}\right) \times 0.33108 \\
 P(\textit{control} \mid x_1, \dots, x_4) &= \frac{1}{\sqrt{2\pi(0.08936)^2}} \exp\left(\frac{-(x_1 - (3.41474))^2}{2(0.08936)^2}\right) \times \\
 &\quad \frac{1}{\sqrt{2\pi(0.1451)^2}} \exp\left(\frac{-(x_2 - (3.01358))^2}{2(0.1451)^2}\right) \times \\
 &\quad \frac{1}{\sqrt{2\pi(0.17464)^2}} \exp\left(\frac{-(x_3 - (3.20911))^2}{2(0.17464)^2}\right) \times \\
 &\quad \frac{1}{\sqrt{2\pi(0.05831)^2}} \exp\left(\frac{-(x_4 - (4.73175))^2}{2(0.05831)^2}\right) \times 0.66892 \\
 Pr(\textit{fibrosis}) &= \frac{P(\textit{fibrosis} \mid x_1, \dots, x_4)}{P(\textit{fibrosis} \mid x_1, \dots, x_4) + P(\textit{control} \mid x_1, \dots, x_4)}
 \end{aligned}$$

where the decision threshold (cutoff) for the fibrosis class is $Pr(\textit{fibrosis}) > 0.31707$.

Example 11. Naive Bayes Classifiers

[00358] The general goal is to use a probabilistic modeling framework to predict the class of an unknown sample. Such mathematical models, or classifiers, are based on training data and are built (i.e. model fitting) in order to make class predictions about the unknown sample. For this purpose, Bayes' Theorem can be generalized to the form:

$$\textit{Posterior Probability} = \frac{\textit{Likelihood}(\textit{data}) \times \textit{Prior}}{\textit{Evidence}} \tag{1}$$

and then written in terms of probabilities,

$$P(\textit{outcome} \mid \textit{data}) = \frac{P(\textit{data} \mid \textit{outcome}) \times P(\textit{outcome})}{P(\textit{data})} \tag{2}$$

where the term $P(\textit{data})$ is a normalizing constant that is independent of the outcome, and is often ignored if *relative* posteriors are desired over *absolute* posteriors. Equation (2) then simplifies to,

$$P(\textit{outcome} \mid \textit{data}) \propto P(\textit{data} \mid \textit{outcome}) \times P(\textit{outcome}) \tag{3}$$

Naïve Bayes in Practice

[00359] Consider an example where proteomic measurements, assumed to have Gaussian (i.e. Normal) distributions, are taken from an individual and the posterior probability of interest is whether that individual belongs to one of k possible outcomes/classes. For example, if there are $k = 2$ possible classes, disease or control (i.e. a *binary* classifier), this can be re-written as:

$$\begin{aligned} P(\text{control} \mid \text{protein RFU}) &= P(\text{protein RFU} \mid \text{control}) \times P(\text{control}), \\ P(\text{disease} \mid \text{protein RFU}) &= P(\text{protein RFU} \mid \text{disease}) \times P(\text{disease}). \end{aligned}$$

[00360] If there are p proteins that are all naively assumed to be independent, one can multiply their individual probabilities to produce a cumulative probability. For the disease posterior this gives:

$$\begin{aligned} P(\text{control} \mid \text{protein RFUs}) &= P(\text{prot}_1 \mid \text{control}) \times P(\text{prot}_2 \mid \text{control}) \times \dots \times P(\text{prot}_p \mid \text{control}) \times \\ &= P(\text{control}), \\ P(\text{disease} \mid \text{protein RFUs}) &= P(\text{prot}_1 \mid \text{disease}) \times P(\text{prot}_2 \mid \text{disease}) \times \dots \times P(\text{prot}_p \mid \text{disease}) \times \\ &= P(\text{disease}). \end{aligned}$$

[00361] Naive Bayes models contain $2pk + k$ parameters, where k is the number of classes, p is the number of features/proteins; a mean (μ) and standard deviation (σ) for each protein \times class combination, plus the class-specific prior, which is often determined by the training class proportions (i.e. an *uninformative* prior). Naïve Bayes models assume Gaussian densities and are calculated via the probability density function (PDF) given class-specific parameters μ and σ :

$$f(x \mid \mu_k, \sigma_k) = \frac{1}{\sqrt{2\pi\sigma_k^2}} \exp\left(\frac{-(x - \mu_k)^2}{2\sigma_k^2}\right), \quad (4)$$

[00362] To classify an unknown sample with p protein measurements ($\vec{x} = x_1, \dots, x_p$) and k classes, calculate the following:

$$P(k \mid \vec{x}) = \left[\prod_{i=1}^p \frac{1}{\sqrt{2\pi\sigma_{ik}^2}} \exp\left(\frac{-(x_i - \mu_{ik})^2}{2\sigma_{ik}^2}\right) \right] \times P(k), \quad (5)$$

[00363] The result of equation (5) in this Example gives a probability *density* for each class, which is not constrained on the interval [0, 1]. Normalized posterior probabilities (Pr) are obtained by calculating the class-specific proportion of the total density,

$$Pr(k = j \mid \vec{x}) = \frac{P(j \mid \vec{x})}{\sum_{i=1}^k P(i \mid \vec{x})} \quad (6)$$

Example calculation

[00364] Consider a $k = 2$ class (disease vs. control) and $p = 2$ biomarker/feature example, with $2pk + k = 10$ parameters:

Table 18: A 2 marker/protein naive Bayes model. Subscripts for control/disease.

Model Parameters	Control	Disease
Training Samples	224	73
Protein 1 ($\hat{\mu}_c, \hat{\mu}_d$)	3.73389	4.00075
Protein 1 ($\hat{\sigma}_c, \hat{\sigma}_d$)	0.17571	0.25238
Protein 2 ($\hat{\mu}_c, \hat{\mu}_d$)	2.71638	2.83843
Protein 2 ($\hat{\sigma}_c, \hat{\sigma}_d$)	0.10198	0.09696

Table 19: 5 unknown samples with 2 protein measurements (RFU) each (log₁₀-transform → Gaussian).

Sample	Prot1	Prot1 (log ₁₀)	Prot2	Prot2 (log ₁₀)
1	6208.8	3.79301	397.5	2.59934
2	2917.2	3.46497	504.8	2.70312
3	5856.7	3.76765	526.3	2.72123
4	12510.8	4.09729	712.9	2.85303
5	11929.3	4.07661	697.8	2.84373

[00365] For unknown **Sample 1** above, the naive Bayes posterior conditional probability densities are calculated using equation (5) of this Example as follows:

Control posterior density:

$$\begin{aligned}
 P(\text{control} \mid x_1 = 3.79301, x_2 = 2.59934) &= P(x_1 = 3.79301 \mid \text{control}) \times \\
 &P(x_2 = 2.59934 \mid \text{control}) \times \\
 &P(\text{control}) \\
 &= P(x_1 = 3.79301 \mid \mu_c = 3.73389, \sigma_c = 0.17571) \times \\
 &P(x_2 = 2.59934 \mid \mu_c = 2.71638, \sigma_c = 0.10198) \times \\
 &(224 / (224 + 73)) \\
 &= 2.14546 \times 2.02464 \times 0.75421 \\
 &= 3.27613
 \end{aligned}$$

Disease posterior density:

$$\begin{aligned}
 P(\text{disease} \mid x_1 = 3.79301, x_2 = 2.59934) &= P(x_1 = 3.79301 \mid \text{disease}) \times \\
 &P(x_2 = 2.59934 \mid \text{disease}) \times \\
 &P(\text{disease}) \\
 &= P(x_1 = 3.79301 \mid \mu_d = 4.00075, \sigma_d = 0.25238) \times \\
 &P(x_2 = 2.59934 \mid \mu_d = 2.83843, \sigma_d = 0.09696) \times \\
 &(73 / (224 + 73)) \\
 &= 1.1265 \times 0.19677 \times 0.24579 \\
 &= 0.05448
 \end{aligned}$$

[00366] Normalized posterior probabilities: From equation (6) of this Example, the relative proportion of each density is:

$$Pr(\text{control} | \vec{x}) = \frac{3.27613}{0.05448 + 3.27613} = 0.98364$$

$$Pr(\text{disease} | \vec{x}) = \frac{0.05448}{0.05448 + 3.27613} = 0.01636$$

[00367] Figure 33A/B depict the class-specific probability densities (disease vs. control) from the training data and the vertical dashed line shows the measurement values of Sample 1 for proteins 1 and 2 respectively. Figure 34A/B depict the bivariate plots of the 2 proteins, where B shows the decision boundary between disease and control with the positions of the 5 unknown samples identified with an X.

Table 20: Normalized posterior probabilities for 5 unknown samples. The disease class prediction is based on a decision cutoff of $Pr(\text{disease}) > 0.5$ (see also Figs. 34A-34B).

Sample	Pr(control)	Pr(disease)	Class Prediction
1	0.98364	0.01636	control
2	0.97012	0.02988	control
3	0.92891	0.07109	control
4	0.17962	0.82038	disease
5	0.23105	0.76895	disease

[00368] The foregoing embodiments and examples are intended only as examples. No particular embodiment, example, or element of a particular embodiment or example is to be construed as a critical, required, or essential element or feature of any of the claims. Various alterations, modifications, substitutions, and other variations can be made to the disclosed embodiments without departing from the scope of the present application, which is defined by the appended claims. The specification, including the figures and examples, is to be regarded in an illustrative manner, rather than a restrictive one, and all such modifications and substitutions are intended to be included within the scope of the application. Steps recited in any of the method or process claims may be executed in any feasible order and are not limited to an order presented in any of the embodiments, the examples, or the claims. Further, in any of the aforementioned methods, one or more specifically listed biomarkers can be specifically excluded either as an individual biomarker or as a biomarker from any panel.

CLAIMS

1. A method of determining whether a subject has non-alcoholic fatty liver disease (NAFLD), comprising forming a biomarker panel having N biomarker proteins from the biomarker proteins listed in Table 15 and Table 16, and detecting the level of each of the N biomarker proteins of the panel in a sample from the subject, wherein N is at least 5.
2. The method of claim 1, wherein N is 5 to 10, or N is 6 to 10, or N is 7 to 10, or N is 8 to 10, or N is 9 to 10, or N is at least 6, or N is at least 7, or N is at least 8, or N is at least 9, or N is 5, or N is 6, or N is 7, or N is 8, or N is 9, or N is 10.
3. A method of determining whether a subject has non-alcoholic fatty liver disease (NAFLD), comprising detecting the level of ITGA1/ITGB1 in a sample from the subject, wherein a level of ITGA1/ITGB1 that is higher than a control level indicates that the subject has NAFLD.
4. A method of determining whether a subject has non-alcoholic fatty liver disease (NAFLD), comprising detecting the level of HSP90AA1/HSP90AB1 in a sample from the subject, wherein a level of HSP90AA1/HSP90AB1 that is higher than a control level indicates that the subject has NAFLD.
5. A method of determining whether a subject has non-alcoholic fatty liver disease (NAFLD), comprising detecting the levels of ITGA1/ITGB1 and HSP90AA1/HSP90AB1 in a sample from the subject, wherein a level of ITGA1/ITGB1 and/or a level of HSP90AA1/HSP90AB1 that is higher than a control level indicates that the subject has NAFLD.
6. The method of any one of claims 3 to 5, further comprising detecting the level of at least one, at least two, at least three, at least four, at least five, at least six, or at least seven biomarkers selected from ACY1, C7, COLEC11, CSF1R, DCN, KYNU, POR and THBS2, in a sample from the subject, wherein a level of at least one biomarker selected from ACY1, C7, COLEC11, CSF1R, DCN, KYNU, POR and THBS2 that is higher than a control level of the respective biomarker, indicates that the subject has NAFLD.
7. The method of any one of claims 3 to 6, wherein the method comprises detecting the levels of ITGA1/ITGB1, HSP90AA1/HSP90AB1, ACY1, COLEC11, and THBS2.
8. The method of any one of claims 3 to 7, wherein the method comprises determining the AST level in the subject, wherein an elevated AST level indicates the subject has NAFLD.

9. A method of determining whether a subject has non-alcoholic fatty liver disease (NAFLD), comprising detecting the level of at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or eleven biomarkers selected from ACY1, C7, COLEC11, CSF1R, DCN, HSP90AA1/HSP90AB1, ITGA1/ITGB1, KYNU, POR, FCGR3B, LGALS3BP, SERPINC1, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and THBS2, in a sample from the subject, wherein a level of at least one biomarker selected from ACY1, C7, COLEC11, CSF1R, DCN, HSP90AA1/HSP90AB1, ITGA1/ITGB1, KYNU, POR, FCGR3B, LGALS3BP, SERPINC1, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and THBS2 that is higher than a control level of the respective biomarker, indicates that the subject has NAFLD.

10. The method of claim 9, wherein the method comprises detecting the level of HSP90AA1/HSP90AB1 or ITGA1/ITGB1, or both HSP90AA1/HSP90AB1 and ITGA1/ITGB1.

11. The method of any one of the preceding claims, wherein the method comprises determining whether a subject has steatosis, lobular inflammation, hepatocyte ballooning, and/or fibrosis.

12. The method of claim 11, wherein the steatosis is mild, moderate, or severe steatosis.

13. The method of any one of claims 1 to 12, wherein the method comprises determining whether a subject has non-alcoholic steatohepatitis (NASH).

14. The method of claim 13, wherein the NASH is stage 1, 2, 3, or 4 NASH.

15. A method of determining whether a subject has steatosis, comprising providing a biomarker panel comprising at least one, at least two, at least three, at least four, at least five or six, biomarkers selected from ACY1, KYNU, ITGA1/ITGB1, POR, HSP90AA1/HSP90AB1, THBS2, and CSF1R; detecting the level of the biomarkers in a sample from the subject to give biomarker values that correspond to the biomarkers in the biomarker panel in order to determine whether the subject has steatosis or determine the likelihood that the subject has steatosis.

16. A method of determining whether a subject has steatosis, comprising detecting at least one, at least two, at least three, at least four, at least five or six, biomarkers selected from ACY1, KYNU, ITGA1/ITGB1, POR, HSP90AA1/HSP90AB1, THBS2, and CSF1R, in a sample from the subject in order to determine whether the subject has steatosis or determine the likelihood that the subject has steatosis.

17. The method of claim 15 or claim 16, wherein the method comprises detecting ACY1, KNYU and at least one, at least two, at least three or four additional biomarkers selected from ITGA1/ITGB1, POR, HSP90AA1/HSP90AB1, THBS2, and CSF1R.

18. The method of any one of claims 15 to 17, wherein the method comprises detecting ACY1, KNYU and at least one, at least two, at least three or four additional marker selected from ITGA1/ITGB1, POR, HSP90AA1/HSP90AB1 and CSF1R.

19. The method of any one of claims 15 to 18, wherein the method comprises detecting at least one biomarker selected from ITGA1/ITGB1, HSP90AA1/HSP90AB1, THBS2, and CSF1R.

20. The method of any one of claims 15 to 18, wherein the method comprises detecting ACY1.

21. A method of determining whether a subject has lobular inflammation, comprising providing a biomarker panel comprising at least one, at least two, at least three, at least four or five, biomarkers selected from ACY1, THBS2, COLEC11, ITGA1/ITGB1, CSF1R, KYNU, FCGR3B, and POR; detecting the level of the biomarkers in a sample from the subject to give biomarker values that correspond to the biomarkers in the biomarker panel in order to determine whether the subject has lobular inflammation or determine the likelihood that the subject has lobular inflammation.

22. A method of determining whether a subject has lobular inflammation, comprising detecting at least one, at least two, at least three, at least four or five, biomarkers selected from ACY1, THBS2, COLEC11, ITGA1/ITGB1, CSF1R, KYNU, FCGR3B, and POR, in a sample from the subject in order to determine whether the subject has lobular inflammation or determine the likelihood that the subject has lobular inflammation.

23. The method of claim 21 or claim 22, wherein the method comprises detecting ACY1, THBS2, COLEC11 and at least one or two additional biomarker selected from ITGA1/ITGB1, CSF1R, KYNU, FCGR3B, and POR.

24. The method of any one of claims 21 to 23, comprising detecting ACY1, THBS2, COLEC11 and at least one or two additional biomarker selected from ITGA1/ITGB1, CSF1R, KYNU, FCGR3B, and POR.

25. The method of any one of claims 21 to 24, comprising detecting ITGA1/ITGB1.

26. The method of any one of claims 21 to 25, wherein the method comprises detecting COLEC11 and CSF1R.

27. A method of determining whether a subject has hepatocyte ballooning, comprising providing a biomarker panel comprising at least one, at least two, at least three, at least four or five, biomarkers selected from ACY1, COLEC11, THBS2, ITGA1/ITGB1, SERPINC1, C7, POR, LGALS3BP, and HSP90AA1/HSP90AB1; detecting the level of the biomarkers in a sample from the subject to give biomarker values that correspond to the biomarkers in the biomarker panel in order to determine whether the subject has hepatocyte ballooning or determine the likelihood that the subject has hepatocyte ballooning.

28. A method of determining whether a subject has hepatocyte ballooning, comprising detecting at least one, at least two, at least three, at least four or five, biomarkers selected from ACY1, COLEC11, THBS2, ITGA1/ITGB1, SERPINC1, C7, POR, LGALS3BP, and HSP90AA1/HSP90AB1, in a sample from the subject in order to determine whether the subject has hepatocyte ballooning or determine the likelihood that the subject has hepatocyte ballooning.

29. The method of claim 27 or claim 28, wherein the method comprises detecting ACY1, COLEC11, THBS2 and at least one or two additional biomarker selected from ITGA1/ITGB1 and HSP90AA1/HSP90AB1.

30. The method of any one of claims 27 to 29, comprising detecting ACY1, COLEC11, THBS2 and at least one or two additional biomarker selected from ITGA1/ITGB1 and HSP90AA1/HSP90AB1.

31. The method of any one of claims 27 to 30, wherein the method comprises detecting ITGA1/ITGB1, COLEC11, SERPINC1, and LGALS3BP.

32. A method of determining whether a subject has fibrosis, comprising providing a biomarker panel comprising at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, or fourteen biomarkers selected from C7, COLEC11, THBS2, ITGA1/ITGB1, HSP90AA1/HSP90AB1, ACY1, CSF1R, KYNU, POR, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and DCN; detecting the level of the biomarkers in a sample from the subject to give biomarker values that correspond to the biomarkers in the biomarker panel in order to determine whether the subject has fibrosis or determine the likelihood that the subject has fibrosis.

33. A method of determining whether a subject has fibrosis, comprising detecting at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, or fourteen biomarkers selected from C7, COLEC11, THBS2, ITGA1/ITGB1,

HSP90AA1/HSP90AB1, ACY1, CSF1R, KYNU, POR, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and DCN, in a sample from the subject in order to determine whether the subject has fibrosis or determine the likelihood that the subject has fibrosis.

34. The method of claim 32 or claim 33, wherein the biomarker panel comprises C7, COLEC11, THBS2 and at least one, at least two or three additional biomarker selected from ITGA1/ITGB1, HSP90AA1/HSP90AB1 and DCN.

35. The method of any one of claims 32 to 34, comprising detecting C7, COLEC11, THBS2 and at least one, at least two or three additional biomarker selected from ITGA1/ITGB1, HSP90AA1/HSP90AB1 and DCN.

36. The method of any one of claims 32 to 35, wherein the method comprises detecting C7, THBS2, KYNU, and SERPINA7.

37. The method of any one of the preceding claims, wherein the subject is at risk of developing NAFLD.

38. The method of any one of the preceding claims, wherein the subject is at risk of developing steatosis, lobular inflammation, hepatocyte ballooning and/or fibrosis.

39. The method of any one of the preceding claims, wherein the subject is at risk of developing NASH.

40. The method of any one of the preceding claims, wherein the subject is obese.

41. The method of any one of the preceding claims, wherein each biomarker is a protein biomarker.

42. The method of any one of the preceding claims, wherein the method comprises contacting biomarkers of the sample from the subject with a set of biomarker capture reagents, wherein each biomarker capture reagent of the set of biomarker capture reagents specifically binds to a different biomarker being detected.

43. The method of claim 42, wherein each biomarker capture reagent is an antibody or an aptamer.

44. The method of claim 43, wherein each biomarker capture reagent is an aptamer.

45. The method of claim 44, wherein at least one aptamer is a slow off-rate aptamer.

46. The method of claim 45, wherein at least one slow off-rate aptamer comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least 10 nucleotides with modifications.

47. The method of claim 45 or claim 46, wherein each slow off-rate aptamer binds to its target protein with an off rate ($t_{1/2}$) of ≥ 30 minutes, ≥ 60 minutes, ≥ 90 minutes, ≥ 120 minutes, ≥ 150 minutes, ≥ 180 minutes, ≥ 210 minutes, or ≥ 240 minutes.

48. The method of any one of the preceding claims, wherein the sample is a blood sample.

49. The method of claim 48, wherein the sample is selected from a serum sample and a plasma sample.

50. The method of any one of the preceding claims, wherein if the subject has NAFLD or NASH, the subject is recommended a regimen selected from weight loss, blood sugar control, and alcohol avoidance.

51. The method of any one of the preceding claims, wherein if the subject has NAFLD or NASH, the subject is recommended for gastric bypass surgery.

52. The method of any one of the preceding claims, wherein if the subject has NAFLD or NASH, the subject is prescribed at least one therapeutic agent selected from pioglitazone, vitamin E, and metformin.

53. The method of any one of the preceding claims, wherein the method comprises determining whether a subject has NAFLD or NASH for the purpose of determining a medical insurance premium or life insurance premium.


54. The method of any one of the preceding claims, wherein the method further comprises determining a medical insurance premium or life insurance premium.

55. The method of any one of the preceding claims, wherein the method further comprises using information resulting from the method to predict and/or manage the utilization of medical resources.

56. The method of any one of the preceding claims, wherein the method comprises detection ITGA1 and/or ITGB1 and/or a complex of ITGA1 and ITGB1.

57. The method of any one of the preceding claims, wherein the method comprises detecting HSP90AA1 and/or HSP90AB1.

1/48



	Target
A	ACY1
B	SHBG
C	CTSZ
D	MET
E	GSN
F	LGALS3BP
G	PLAT
H	CHL1
I	SERPINC1

Fig. 1

2/48




Fig. 2




Fig. 3

4/48




Fig. 4




Fig. 4 (cont.)




Fig. 4 (cont.)

7/48




Fig. 4 (cont.)

8/48





Fig. 4 (cont.)

9/48



	Target
A	C7
B	COLEC11
C	PPID
D	IGFBP3

Fig. 5

10/48




Fig. 6

11/48

4 Marker Random Forest Classifier:
Vote by Class




Fig. 7

12/48




Fig. 8




Fig. 8 (cont.)

14/48




Fig. 9

15/48





Fig. 10



Base = Uridine (U) or Cytidine (C) (attachment is to the 5-position)

Z = R plus (CH₂)_n connecting group, where n=0-3




Fig. 11

17/48




Fig. 11 (cont.)




Fig. 12

19/48




Fig. 13

20/48




Fig. 14




Fig. 14 (cont.)




Fig. 15

23/48




Fig. 16




Fig. 17

25/48

Fibrosis Model Performance




Fig. 18

26/48





Fig. 19A

27/48





Fig. 19B




Fig. 20

29/48




Fig. 21

30/48




Fig. 22

31/48




Fig. 22 (cont.)

32/48




Fig. 23

33/48




Fig. 23 (cont.)

34/48




Fig. 24

35/48




Fig. 24 (cont.)

36/48




Fig. 25

37/48




Fig. 25 (cont.)

38/48




Fig. 26

39/48




Fig. 26 (cont.)

40/48




Fig. 27

41/48




Fig. 27 (cont.)

42/48

Protein Intersections: Up/Down Trends

Top Analytes by Bonferroni < 0.01 cutoff




Fig. 28

steatosis

Forward Stepwise Model Search
Runs: 25 – Folds: 5




Fig. 29

lobular inflammation

Forward Stepwise Model Search
Runs: 25 -- Folds: 5




Fig. 30

ballooning

Forward Stepwise Model Search
Runs: 25 – Folds: 5






Fig. 31

fibrosis

Forward Stepwise Model Search
Runs: 25 – Folds: 5



46/48

Fig. 32

47/48




Fig. 33B

Fig. 33A





Fig. 34B

Fig. 34A

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/016798

A. CLASSIFICATION OF SUBJECT MATTER
INV. G01N33/68
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
G01N
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, WPI Data, CHEM ABS Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2014/150198 A2 (SOMALOGIC INC [US]) 25 September 2014 (2014-09-25) tables 7-10	1,2, 11-14, 37-55
Y	----- WASCO WRUCK ET AL: "Multi-omic profiles of human non-alcoholic fatty liver disease tissue highlight heterogenic phenotypes", SCIENTIFIC DATA, vol. 2, 8 December 2015 (2015-12-08), page 150068, XP055355763, ISSN: 2052-4436, DOI: 10.1038/sdata.2015.68 page 4; figures 1,2; table 2 ----- -/--	1,2, 11-14, 37-55

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search 23 March 2017	Date of mailing of the international search report 19/05/2017
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Pinheiro Vieira, E

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/016798

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KATSUTOSHI TOKUSHIGE ET AL: "Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease", JOURNAL OF GASTROENTEROLOGY, vol. 48, no. 12, 13 March 2013 (2013-03-13), pages 1392-1400, XP055123172, ISSN: 0944-1174, DOI: 10.1007/s00535-013-0766-5 figures 1-3; table 2 -----	1,2, 11-14, 37-55
X	CYNTHIA A. MOYLAN ET AL: "Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease", HEPATOLOGY, vol. 59, no. 2, 13 December 2013 (2013-12-13), pages 471-482, XP055143275, ISSN: 0270-9139, DOI: 10.1002/hep.26661 figure 1; table 3 -----	1,2, 11-14, 37-55

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2017/016798

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1, 2(completely); 11-14, 37-55(partially)

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1, 2(completely); 11-14, 37-55(partially)

A method of determining whether a subject has non-alcoholic fatty liver disease (NAFLD), comprising forming a biomarker panel having N biomarker proteins from the list in table 15 and table 16 and detecting the level of the biomarker proteins of the panel in a sample, wherein N is at least 5.

2. claims: 3(completely); 6-14, 37-57(partially)

A method of determining whether a subject has non-alcoholic fatty liver disease (NAFLD), comprising detecting the level of ITGA1/ITGB1 in a sample.

3. claims: 4(completely); 6-14, 37-57(partially)

A method of determining whether a subject has non-alcoholic fatty liver disease (NAFLD), comprising detecting the level of HSP90AA1/HSP90AB1 in a sample.

4. claims: 5(completely); 6-14, 37-57(partially)

A method of determining whether a subject has non-alcoholic fatty liver disease (NAFLD), comprising detecting the level of ITGA1/ITGB1 and HSP90AA1/HSP90AB1 in a sample.

- 5-20. claims: 9, 11-14, 37-57(all partially)

A method of determining whether a subject has non-alcoholic fatty liver disease (NAFLD), comprising detecting the level of at least one biomarker selected from ACY1, C7, COLEC11, CSF1R, DCN, KYNU, POR, FCGR3B, LGALS3BP, SERPINC1, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and THBS2 (each biomarker corresponds to a further invention) in a sample and comparing the same to a control level of the respective biomarkers. Further combinations of 2 to 11 biomarkers can be made with the first biomarker of each invention.

21. claims: 15-20(completely); 37-57(partially)

A method of determining whether a subject has steatosis, comprising providing a biomarker panel comprising at least one, at least two, at least three, at least four, at least five or six, biomarkers selected from ACY1, KYNU, ITGA1/ITGB1, POR, HSP90AA1/HSP90AB1, THBS2, and CSF1R.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

22. claims: 21-26(completely); 37-57(partially)

Method of determining whether a subject has lobular inflammation, comprising providing a biomarker panel comprising at least one, at least two, at least three, at least four or five, biomarkers selected from ACY1, THBS2, COLEC11, ITGA1/ITGB1, CSF1R, KYNU, FCGR3B, and POR.

23. claims: 27-31(completely); 37-57(partially)

A method of determining whether a subject has hepatocyte ballooning, comprising providing a biomarker panel comprising at least one, at least two, at least three, at least four or five, biomarkers selected from ACY1, COLEC11, THBS2, ITGA1/ITGB1, SERPINC1, C7, POR, LGALS3BP, and HSP90AA1/HSP90AB1.

24. claims: 32-36(completely); 37-57(partially)

A method of determining whether a subject has fibrosis, comprising providing a biomarker panel comprising at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, or fourteen biomarkers selected from C7, COLEC11, THBS2, ITGA1/ITGB1, HSP90AA1/HSP90AB1, ACY1, CSF1R, KYNU, POR, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and DCN.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2017/016798

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2014150198 A2	25-09-2014	CN 105143887 A	09-12-2015
		EP 2972386 A2	20-01-2016
		HK 1220251 A1	28-04-2017
		US 2014303018 A1	09-10-2014
		WO 2014150198 A2	25-09-2014
